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Abstract 
The emergence of P. falciparum resistant to current front-line artemisinin combination 
therapies underscores the urgent demand for new candidate molecules for a single exposure 
radical cure and prophylaxis drug. Developing a suitable candidate component that is both 
potent and effects a rapid rate of kill to replace artemisinins requires a new and innovative in 
vitro screening assays to support discovery. A standard Bioluminescence Relative Rate of Kill 
(BRRoK) assay to quickly triage rapid cytocidal antimalarial compounds in vitro has been 
developed. Recognizing limitations in the BRRoK assay necessitated a subsequent 
development of a modified-BRRoK assay. This mBRRoK assay explores a compound’s RoK 
and potency together in a fixed-concentration assay format more amenable to a high throughput 
screening of a large compound libraries.  
Proof-of-principle for the mBRRoK assay was developed using the Medicine for Malaria 
Venture (MMV) Malaria Box compounds for which BRRoK data was available. A subsequent 
validation of mBRRoK was carried out using the MMV Pathogen Box open source discovery 
library. Potential new leads were identified, of a particular interest are novel PfeEF2 inhibitors 
(MMV634140 and MMV667494) that show a rapid initial relative rate of kill. These 
compounds are suggested for further optimization and characterization.  
The mBRRoK assay was adapted, miniaturized and optimized for high throughput screening of 
12,514 TCAMS library. The results demonstrated that this assay is simple, sensitive (81% true 
discovery rate), reliable and robust with Z´ value of 0.74-0.98 and S/B ratio of 160 to 475. 
Predicted fast-acting hits were selected and confirmed using the standard BRRoK assay in both 
the original Dd2luc reporter strain, but also in a new NF54luc (chloroquine-sensitive) strain. The 
results demonstrated the utility of mBRRoK assay not only for rapid screening of potent and 
fast-acting compound, but also to study drug-resistance profiles across different parasite strains. 
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The mBRRoK assay offers significant opportunities during early stage of antimalarial drug 
discovery and development to triage compound sets through understanding potency and initial 
rate of kill, but is also an assay system amenable to adaptations such as assays in artemisinin 
resistant reporter strains and the study of stage-specific action.  
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1 CHAPTER 1: Introduction  
1.1 Epidemiology of malaria 
Malaria is a protozoan disease that is endemic in the tropics and sub-tropics. The disease is 
caused by an apicomplexan obligate parasite belonging to the genus Plasmodium. Six species 
of Plasmodium cause human malaria: P. falciparum, P. vivax, P. ovale curtisi, P. ovale 
wallikeri, P. malariae and P. knowlesi. Of these, the most prevalent species are the P. vivax and 
P. falciparum that are responsible for the majority of the cases of malaria globally (WHO, 
2018). About 228 million malaria cases (range between 206-258 million) and 405,000 death, 
of which 67% (272,000) of the mortality occurred in children under 5 years of age (WHO, 
2019). P. falciparum is the most virulent and widely studied species. The majority of global 
malaria death are attributed to P. falciparum infection mostly in the WHO African region 
(WHO, 2019). After this, P. vivax is responsible for the majority of cases found in the Southeast 
Asia and South America. P. vivax is not prevalent in Africa because of the lack of Duffy antigen 
erythrocyte receptor that is essential for the parasite to invade erythrocytes (Guerra et al., 2006). 
However, there is growing evidence of P. vivax infection in all regions of Africa (Twohig et 
al., 2019). P. falciparum and P. vivax malaria often occur together in some regions, except in 
some areas in Southeast Asia, for instance South Korea where only P. vivax is found (Howes 
et al., 2016). P. vivax has a characteristic clinical feature of causing relapsing malaria and this 
is attributed to the persistence of a dormant liver form (hypnozoite) which can become 
reactivated later after the initial infection. These hypnozoites can persist in the liver for up to 
two years after the initial inoculation of sporozoites into the blood stream by the mosquito 
vector (Imwong et al., 2007). Presently, primaquine and tafenoquine (8-aminoquinoline) are 
the drug of choice to prevent relapse by killing the dormant liver forms that result from P. vivax 
infection. However, these drugs can cause haemolytic anaemia in glucose-6-phosphate 
dehydrogenase (G6PD) deficient patients. P. ovale curtisi and P. ovale wallikeri and P. 
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malariae are morphologically indistinguishable sympatric species.  P. ovale curtisi and P. ovale 
wallikeri cases are underestimated with seriousness of the disease resembling that of 
uncomplicated P. vivax malaria. P. knowlesi is a zoonotic infection in Southeast Asia, and can 
also cause severe malaria (Singh et al., 2004). 
1.2 The current status of global malaria  
There has been a significant reduction in the global malaria incidence rate (figure 1.1) between 
2010 (71%) and 2018 (57%) (WHO, 2019). This substantial reduction has been attributed to 
the intensive deployment of insecticide-treated bed nets (ITN), indoor residual spraying and 
effective use of Artemisinin-based combination therapies (ACT). However, in 2018, the WHO 
reported that data from 2015-2017 shows that the significant progress achieved in the last 
decade in reducing global malaria is stagnant (Figure 1.2) (WHO, 2018). The likely contributing 
factors to the stall in progress were highlighted as threats to malaria control in the WHO’s 
Global Technical Strategy for Malaria 2016-2030 (WHO, 2018). Among these, is resistance to 
the current first line drug for the treatment of uncomplicated malaria (ACTs). Since 2008 when 
artemisinin treatment failure was reported in the Greater Mekong Sub-region (Noedl et al., 2008 
and Dondorp et al., 2009), collective efforts towards malaria eradication have seen major 
setbacks in the P. falciparum malaria-endemic area (WHO, 2017). In addition, mosquito 
resistance to pyrethroids, frequently used in the insecticide-treated nets (ITNs) and indoor 
residual spraying of home, is becoming rampant in malaria-endemic areas (WHO, 2017; Alonso 
and Noor, 2017). To further buttress this point, the WHO reported that 552 million ITNs were 
delivered worldwide and 83% of this total were distributed in sub-Saharan Africa between 2015 
and 2017 (WHO, 2018). Although the level of intervention is high, there is a coverage gap that 
is another major challenge in malaria control (Alonso and Noor, 2017). 
3 
 
 
Figure 1.1: 2018 Global malaria case incidence rate by country 
The key show the malaria incidence rate on country basis. The countries indicated in white 
have eradicated malaria while those in brown still have significant number of malaria cases 
Source: WHO, (2019)  
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Another likely contributing factor is the level of malaria funding which has remained 
unchanged since 2010 (Alonso and Noor, 2017). The available fund for malaria control was 
only 41% of what was recommended to be the annual need in order to meet the targets stated 
in the WHO’s Global Technical Strategy for Malaria 2016-2030 (WHO, 2017).  Most of the 
malaria high-burden countries that rely almost entirely on international donor support also 
report more malaria cases in 2016 than in 2014 (Alonso and Noor, 2017). In view of the above 
points, the present malaria control status will be a challenge to achieving the targets set in the 
WHO’s Global Technical Strategy for Malaria 2016-2030. 
 
Figure 1.2  Global malaria cases between 2010 and 2017 
The incidence of malaria has steadily decreased from 2010 until 2015.  However, there has 
been a stall in this progress between 2015 and 2017 leading to reduced trend in global malaria 
control. Source: (WHO, 2018) 
 
Considering the current status of global malaria control, there is an urgent need to change the 
course of how the disease can be effectively managed in the countries with the highest burden. 
In response to this, the WHO and Roll Back Malaria Partnership have brought about a country-
led approach that is termed “high burden to high impact” (WHO, 2018). This call has made the 
work of Ministries of Health in the affected countries to be synergized more closely to share 
best practice in order to reverse the current downward trend in malaria control (WHO, 2018). 
According to the WHO (2018) Global Malaria Report, the “high burden to high impact” call is 
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anchored on four major pillars. First, the call to galvanize both national and international 
commitment into actions that will reduce malaria death. Second, the strategic use of information 
to maximize the effective deployment of control measures for optimum benefit. Third, the 
establishment of best global guidance, policies and strategies that is acceptable to all malaria-
endemic nations. And fourth, the execution of a well harmonized national malaria response that 
involves other areas such as environment, education and agriculture.  The malaria-endemic 
communities are optimistic that if a “high burden to high impact” response is globally 
implemented there should be a move to malaria control progress being back on the previous 
downward track (WHO, 2018). 
1.3 Transmission of the human malaria parasite 
Human malaria parasites are naturally transmitted by the female Anopheles mosquitoes of 
which there are about 430 species out of which  30-40 species transmit the disease in human 
(Figure 1.3) (CDC, 2016). Female Anopheles mosquitoes are anthropophilic blood feeders and 
the blood meal is used for their egg production. Three main factors determine the capability of 
Anopheles mosquitoes to transmit malaria parasites: innate susceptibility, host preference, and 
duration of its life span (CDC, 2016). Female Anopheles mosquitoes that are good vectors of 
malaria parasites are typically nocturnal endophagic feeders and these can be successfully 
targeted through the use of insecticide-treated bed nets (ITNs), mosquito window screen nets 
or indoor residual spraying of insecticides (CDC, 2016) . However, some are exophagic feeders 
which can be controlled by destroying their breeding habitats. Malaria can also be transmitted 
congenitally. This is the transfer of parasitized erythrocytes from the infected mother either 
transplacentally to the fetus or during labour to the new-born. Another mode of transmission is 
through blood transfusion and the risk of acquiring transfusion malaria is very low CDC (2016). 
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Figure 1.3: Map showing global distribution of the mosquito malaria vectors 
The colour areas in the map show the distribution of Anopheles species that transmit malaria 
parasite across the world (see key). Source: (CDC, 2016) 
 
1.4 Life cycle of Plasmodium species  
Plasmodium species have a complex multistage life-cycle that is similar in all the species that 
infect human with the exception of intra-hepatic development cycles (Figure 1.4). The parasite 
utilizes two independent hosts to complete its life cycle, where asexual development 
(schizogony) predominantly occurs in the human (intermediate host) and the sexual 
development (sporogony) predominantly occurs in the mosquito (definitive host).  
1.4.1 Exo-erythrocytic schizogony 
Human infection with a malaria parasite is initiated when a female Anopheles mosquitoes 
inoculates sporozoites into the dermis while obtaining a blood meal. The sporozoites are rapidly 
transported in the blood circulation to invade the hepatocytes through the transversal process 
(Cowman et al., 2016). This involves penetrating the sinusoidal barrier that is made up of 
fenestrated endothelial cells and macrophage-like Küpffer cells (Tavares et al., 2013). Inside 
the hepatocyte, the sporozoite undergoes repeated mitotic division leading to the production of 
7 
 
daughter merozoites over approximately 6-8 days. The hepatocytes heavily laden with daughter 
merozoites become distended, burst and egress about 40,000 merozoites into the blood 
circulation by budding from merosomes (Sturm et al., 2006). However, in P. vivax and P. ovale, 
some of the parasites persist in the hepatocytes as dormant liver forms (hypnozoites) for a 
period of about two weeks to one year. These hypnozoites can become re-activated resulting in 
a relapsing malaria clinical presentation that is particular to P. vivax and P. ovale infection 
(White, 2011).  
1.4.2 Intraerythrocytic schizogony 
Merozoites in the hepatic circulation invade the red blood cells within two minutes through 
three main steps: pre-invasion, invasion and echinocytosis (Weiss et al., 2015). Parasites invade 
the erythrocytes, degrade the haemoglobin and manipulate the host cell membrane architecture 
to aid its nutrient trafficking in and out of the red blood cells. The parasites undergo different 
developmental changes from rings to trophozoites and then to schizonts within the erythrocytes. 
Inside the erythrocytes the parasites catabolise haemoglobin and modify the host membrane 
including the development of characteristic knob-like projections. These modifications include 
a novel channel through which the parasite transports its nutrient as well as the sequestering of 
toxic haem by-product through a lipid-mediated crystallization into haemozoin.  Merozoites 
inside the erythrocytes undergo repeated mitosis otherwise called schizogony in 48 hours in P. 
falciparum, P.vivax and P. ovale, over 72 hours in P. malariae and over 24 hours in P. knowlesi.  
Schizonts eventually burst to release between 8-32 daughter merozoites into the blood 
circulation depending on the Plasmodium spp. After about three rounds of erythrocytic cycles, 
some of the parasites differentiate into non-dividing male and female gametocyte stages that 
are taken up by female Anopheles mosquitoes while obtaining a blood meal.  
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1.4.3 Sporogony 
The male and female gametocytes develop into microgametes and macrogametes respectively 
inside the mosquitoes’ midgut. The microgametes undergo exflagellation to form eight motile 
flagellated microgametes which fertilize the macrogametes, resulting in the formation of 
zygotes. The zygotes develop to form motile ookinetes that penetrate the mosquito’s gut wall 
and encyst to form an oocyst. The oocyst divides through meiosis to produce thousands of 
haploid sporozoites which are released into the mosquitoes’ salivary gland. When the infected 
mosquitoes obtain a blood meal, these sporozoites are injected into the bloodstream of the 
susceptible host and the life cycle is perpetuated. 
 
Figure 1.4: Life-cycle of human Plasmodium species 
The parasite life cycle is broadly divided into an exo-erythrocytic stage which occurs inside the 
hepatocytes (B); an erythrocytic phase which occurs inside the erythrocytes with (C); 
gametogenesis (D), and the, sporogony predominantly occurring inside mosquito vector (E and 
F). Source: Cowman et al., (2016) 
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1.5 Clinical manifestation of malaria 
The clinical features associated with malaria are related principally to the effects of 
intraerythrocytic cycle of the parasite on the human host. Haemozoin that is released when the 
parasite-infected red blood cells rupture likely act as the predominant trigger for the host 
immune response that results in the characteristic periodic fever. The clinical manifestation of 
malaria can be broadly divided into mild and severe disease. Initial symptoms of malaria are 
non-specific and resemble that of an influenza-like illness and include; headache, fatigue, 
muscle aches, nausea and vomiting (White et al., 2014). These could be followed by a recovery 
which may occur without drug treatment. The clinical manifestation of severe malaria in highly 
endemic regions is usually age-dependent with the signs and symptoms more pronounced in 
children aged under five years. However, in a low endemic region, a wider age group are more 
susceptible to the disease. Other groups of people that are more susceptible to the disease are 
pregnant women and non-immune travellers to the endemic regions. Figure 1.5 illustrates the 
clinical manifestation of severe malaria and its association with the malaria parasite life-cycle. 
1.5.1 Severe anaemia 
This is common among children in the malaria-endemic region and is due to the repeated 
infections that resulted from the increase in splenic clearance of uninfected and infected red 
blood cells which is complicated by inefficient erythropoiesis (Price et al., 2001; Buffet et al; 
2011). 
1.5.2 Cerebral malaria 
This results from serious sequestration of infected red blood cells to the cerebral 
microvasculature which can lead to obstruction of brain vessels. Clinical features of cerebral 
malaria include impaired consciousness, convulsions and long-term neurological abnormalities. 
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Figure 1.5: Relationship between the malaria parasite life-cycle and pathogenesis 
Illustration relating the life cycle of the parasite (left) with the clinical features observed for 
mild and severe malaria (right). Source: Gazzinelli et al., (2014) 
 
1.5.3 Acidosis and hypoglycaemia 
Acidosis occurs as a result of building up of organic acids such as lactic acid which can lead to 
lactic acidosis (Day et al., 2000). Lactic acid is a waste product of anaerobic glycolysis by 
sequestered parasites in the deep tissues and this is aggravated by the lactate produced by the 
Plasmodium spp and inability of hepatic and renal lactate clearance mechanisms to function 
effectively (White et al., 2014).  
Hypoglycaemia and lactic acidosis are related to causing problems most importantly in children 
and expectant mothers (White et al., 2014). Hypoglycaemia occurs as a result of hepatic 
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gluconeogenesis failure and accelerated tissues glucose consumption (Krishna et al., 1994; Day 
et al., 2000) 
1.5.4 Respiratory distress 
Acute respiratory distress syndrome is a serious complication associated with P. falciparum 
infection in expectant mothers; it could also result from P. vivax and P. knowlesi infections 
(Anstey et al., 2007; Daneshvar et al., 2009).  
1.5.5 Renal Impairment and jaundice 
Acute renal failure is a more serious complication of P. falciparum malaria especially in 
children and is seriously linked to jaundice. However, adults who are chronically infected with 
the hepatitis B virus may be predisposed to severe malaria (Barcus et al., 2002). 
1.6 Pathogenesis of severe P. falciparum malaria 
The pathology of severe P. falciparum malaria is strongly linked with the sequestration of 
infected erythrocytes in the deep tissues. This normally has an adverse effect on the related vital 
organs in which the infected erythrocytes sequester (Figure 1.6). Sequestration of P. falciparum 
infected erythrocytes in the brain and placenta causes cerebral and placental malaria 
respectively. Adherence of the infected erythrocytes to the endothelial cells is mediated by the 
parasite variant surface proteins termed Plasmodium falciparum-erythrocyte membrane protein 
-1(PfEMP-1). The parasite expresses and transports the protein out through the parasitophorous 
vacuole and on to the knobs to be display on the external face of the erythrocyte membrane. 
PfEMP-1 is encoded by approximately 60 var genes in two exons; exon 1 codes for the 
polymorphic sequence that forms the extracellular domain while exon 2 codes for the semi-
conserved intracellular domain. The two are joined by a single intron which is highly conserved 
(Kyes et al., 2001). 
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Figure 1.6: Schematic description of pathogenesis of severe P. falciparum malaria 
The figure illustrates the processes involve in the adhesion of malaria parasite ligands, 
Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP-1) to the host receptor in the 
endothelial cell, intercellular adhesion molecule 1 (ICAM1) particularly in the brain. Source: 
Schofield and Grau, (2005). 
 
1.6.1 Adhesion phenotypes in Plasmodium falciparum (PfEMP-1) sequestration 
Adherence of Plasmodium falciparum erythrocytes membrane protein -1(PfEMP-1) to the deep 
tissues is mediated through receptor-ligand interaction. There are three basic types of adhesion 
of infected erythrocytes to the receptor on human cells: cytoadherence to the endothelial cells, 
adherence of infected erythrocytes to uninfected erythrocytes (rosetting) and platelet-mediated 
agglutination (Figure 1.7). In addition, infected erythrocytes also sequestered in the placenta 
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through the receptor termed syncytiotrophoblasts. Human receptors for P. falciparum 
erythrocytes membrane protein-1 (PfEMP-1) are diverse (Table 1.1), because the parasite 
expresses only one ligand but with different domains that mediate various adhesive events. 
 
 
Figure 1.7: Diagramatic representation of cytoadherence and rosetting in the postcapillary 
vasculature 
Plasmodium falciparum-infected erythrocytes (red cells with black dot) adhere to the 
postcapillary endothelial line (green) and to uninfected erythrocytes. Both events lead to 
obstruction of blood flow that can result in severe disease. Source:  Chen et al., (2000) 
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Table 1.1: Human receptors and parasite ligands for the adhesion of PfEMP-1 
Source: Modified from Chen et al., (2000) 
 
1.7 Immune response to malaria parasites infection 
1.7.1 Innate Immune response 
Immune response to malaria parasites can be categorised into innate and adaptive immunity. 
When there is a primary infection, the innate immune response is first activated and the spleen 
is the major centre for this immune protective effect (Buffet et al., 2009; Del Portillo et al., 
2012).  The innate immune response is mediated by the phagocytic activities of the monocytes 
and the macrophages which lowers the risk of developing severe malaria but unable to clear the 
malaria infection. The macrophages in the liver and spleen play a key role in the phagocytic 
removal of malaria parasites (Lee et al., 1986; Deroost et al., 2012; Menezes et al., 2012). 
However, in acute malaria infection, monocytes from the bone marrow coupled with local 
proliferation contribute to the hepatosplenomegaly normally seen in malaria patients (Lee et 
al., 1986; Belyaev et al., 2013). 
1.7.2 Adaptive Immune response 
Acquired immunity to malaria parasite infection entails the activation of humoral and cellular 
immune response (Langhorne et al., 2008, Stevenson and Riley, 2004). Naturally acquired 
Host receptor(s) Receptor location Parasite ligand
HS-like GAGs RBC PfEMP1 (DBL-1α)
CD35 (CR1) RBC PfEMP1 (DBL-1α)
Blood group antigen RBC PfEMP1?
A and B
TSP Serum, endothelium PfEMP1?
CD36 Endothelium, RBC PfEMP1 (CIDR1-α)
ICAM-1 Endothelium PfEMP1 (DBL-2β)
CD31 Endothelium PfEMP1?
VCAM-1 Endothelium ?
E-selectin Endothelium ?
CSA Endothelium PfEMP1 (DBL-3)
IgM and IgG Serum PfEMP1?
EPCR Endothelium, RBC PfEMP1 (CIDR1-α)
15 
 
immunity to malaria has been found to take as long as 10-15 years of repeated parasitic exposure 
to develop (Baird, 1998). The immunity lowers the risk of severe and uncomplicated malaria 
but does not clear the parasitaemia. Antibody-mediated immune response plays a crucial role 
in the reduction of parasitaemia, thereby reducing the clinical symptoms of the disease. 
However, a synergy between monocytes and antibody-response is important in the acquisition 
of protective immunity (Groux and Gysin, 1990).  
T cells play a central role in the clearance of the erythrocytic stage of malaria parasites by 
releasing cytokines that activate other effector cells. CD4+ T cells are basically classified into 
T helper 1 (Th1) and T helper 2 (Th2) cells according to the cytokines they produce. Th1 cells 
produce interleukin (IL)-2, interferon (IFN) γ and tumour necrosis factor (TNF), whereas Th2 
cells produce IL-4, IL-5, IL-6 and IL-10 (Abbas et al., 1996). Th1 cells are responsible for cell-
mediated immunity; they activate macrophages and other cells to produce mediators through 
the release of inflammatory cytokines whereas Th2 cells regulate the humoral immune response 
by activating B cells to produce antibodies. Both Th1 and Th2 cells are involved in protective 
immunity against blood stage malaria and the balance of cytokines produced by these two 
subsets is crucial in determining the outcome of the disease (Wipasa et al., 2002). 
1.8 Diagnosis of Malaria 
Prompt diagnosis of malaria is crucial in the effective control and management of the disease 
in the endemic areas where diagnosis of malaria could be based on the evaluation of clinical 
signs and symptoms or a laboratory-based test. The former means of diagnosis is not always 
reliable as malaria symptoms usually overlap with that of other tropical diseases. In the 
laboratory, malaria is diagnosed using different techniques ranging from gold standard 
microscopic methods to a more sensitive polymerase chain reaction assay. 
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1.8.1 Microscopy 
The conventional means of diagnosing malaria is by microscopic examination of thin and thick 
(species identification) blood films using Giemsa, Wright’s or Field stains (Warhurst and 
Williams, 1996). Light microscopic examination of stained blood film describes the 
parasitaemia, species, and different morphological stages of the malaria parasites (Figure 1.8). 
Although, the technique is simple and inexpensive, it has a limitation of low sensitivity 
(especially at low parasitaemia), being labour intensive, time-consuming and requires a trained 
microscopist particularly for the identification of species accurately at low parasite levels or in 
a mixed infection. 
17 
 
 
Figure 1.8: Photomicrographs of different developmental stages of Plasmodium species 
P. falciparum, P. vivax , P. malariae  and P. ovale . From thin blood smear 
Source: Chotivanich et al., (2007) 
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1.8.2 Quantitative Buffy Coat Technique 
The shortcomings of microscopic diagnosis of malaria parasites led to the development of the 
Quantitative Buffy Coat technique (QBC). The method involves the staining of parasite 
deoxyribonucleic acid in micro-haematocrit tubes with fluorescent dyes such as acridine orange 
and its subsequent detection by fluorescence microscopy or by flow cytometry (Moody, 2002). 
Although the QBC technique is simple, reliable and user-friendly, it has the limitation of 
requiring specialised instrumentation which makes it more expensive than the light microscopy 
coupled with the fact that it is poor at determining parasites species and numbers (Tangpukdee 
et al., 2009). 
1.8.3 Malaria Rapid Diagnostic tests 
Malaria Rapid Diagnostic tests (RDTs) were developed in the mid-1990s (Dietze et al., 1995; 
Makler et al., 1998). They work on the principle of immuno-chromatography whereby a 
chromophore-labelled antibody binds to lysed parasite antigen. This is carried by capillary 
action on a nitrocellulose strip and arrested by a capture antibody giving a colour band on a test 
strip. Immunological RDT techniques are useful in malaria-endemic areas where a large 
proportion of infected people can be readily screened within a short period of time. The most 
available RDTs target P. falciparum histidine-rich protein 2 (PfHRP2) and two enzymes of the 
glycolytic pathway in Plasmodium, namely; lactate dehydrogenase (pLDH) and aldolase (see 
Table 1.2). RDTs extends the benefits of parasite-based diagnosis of malaria beyond the 
technical limitations of light microscopy and offer significant advances in the management of 
malaria in remote endemic areas (Tangpukdee et al., 2009). 
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Table 1.2: Malaria rapid diagnostic tests 
HRP (histidine-rich protein), pLDH (Plasmodium lactate dehydrogenase) 
 Source: Wilson, (2012) 
 
1.8.4 Serological methods 
Serological method for malaria diagnosis is usually based on the principle of detecting 
antibodies against the asexual erythrocytic stage of malaria parasites. Immunofluorescence 
antibody testing (IFA) is a reliable serological technique; although, it is time-consuming but 
with high sensitivity and specificity. The technique is highly reliable and has been documented 
in the literature as the gold standard for malarial serology testing (Doderer et al., 2007).  
1.8.5 Polymerase Chain Reaction 
Recent development in malaria diagnosis have used Polymerase Chain Reaction (PCR)-based 
techniques. These have proven to be one of the most specific and sensitive diagnostic methods, 
particularly in malaria cases with low parasitaemia or mixed infections (Morassin et al., 2002). 
The technique was found out to be more sensitive than QBC and some RDTs (Makler et al., 
1998; Rakotonirina et al., 2008) and has been used to confirm malaria infection, follow-up 
therapeutic response and identification of drug resistance (Chotivanich et al., 2007). 
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1.9 Malaria control strategies 
Two major tools are employed in the control of malaria; entomological and medical. The 
entomological tool relies on the use of insecticide interventions such as the insecticide-treated 
nets (INTs) and indoor residual insecticide sprays (IRSs). Both significantly decrease the daily 
survival rates of the mosquito vector (Enayati and Hemingway, 2010).There is presently no 
effective vaccine against the malaria parasite. The stall in progress reported in malaria control 
over the last few years necessitates the development of new control and elimination tools that 
should include a vaccine. Breaking the cycle of parasite transmission with vaccines will likely 
target three major developmental stages; the pre-erythrocytic, erythrocytic and the gametocytic 
stages. Figure 1.9 illustrates the different approaches that target these three strategic stages of 
the malaria parasites life cycle. 
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Figure 1.9: Vaccine targeting different stages of malaria parasite’s life cycle in clinical 
development. 
Vaccines target majorly target the P. falciparum, few that target the P. vivax are in colour blue 
Source: Draper et al., (2018) 
 
Over 30 P. falciparum malaria vaccines projects are in the pipeline as of 2015 (Figure 1.10). 
The most advanced malaria vaccine project is the RTS,S/AS01 which passed the phase II and 
III clinical trials in 2007 and 2009 respectively (Leach et al., 2011).  The results of phase III 
clinical trial of the vaccine in sub-Saharan African children were published in 2015. The 
findings show that vaccine efficacy decreases rapidly in infants aged 6 to 12 weeks and young 
children 5 to 15 months old. Although the administration of three booster doses after 12 months 
as a follow up decreases malaria cases in young children and infants by 28% and 18% 
respectively (Greenwood and Doumbo, 2016). A setback for RTS,S/AS01 was the failure to 
elicit sterile immunity which would be a hallmark of life-long protection against the parasite. 
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The European Medicines Agency for immunization (EPI) endorsed the use of the vaccine for 
children aged 6 weeks to 17 months in July 2015. Subsequently, an extensive pilot 
implementation to further assess the practicality of administering four doses was recommended 
by WHO. Also, the possibility of the vaccine to decrease childhood mortality and to produce 
supplementary data on safety with regards to its routine use. 
 
Figure 1.10: Worldwide malaria vaccine portfolio as of September 2015 
Source: http://www.who.int/vaccine_research/links/Rainbow/en/index.html 
 
Chemotherapy is highly indispensable towards the goal of malaria eradication in the absence 
of a highly effective vaccine. The role of drugs in malaria control can be divided into those that 
offer an effective treatment of a parasite infection or those that are used as a prophylactic against 
infection in malaria-endemic regions (Greenwood, 2010). Antimalarial agents can be similarly 
categorised based on the stage of the malarial parasite the drug is targeting. Blood 
schizonticides are active against the asexual intraerythrocytic stages of the parasites and tissue 
schizonticides targets the hepatic schizonts thereby preventing erythrocytic invasion. The 
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hypnozoiticides targets the dormant intra-hepatic stages of P. vivax and P. ovale thereby serving 
as anti-relapse therapy. And gametocytocides kill the sexual intraerythrocytic stages of the 
parasites and serve to block the transmission of the parasite. The most commonly used 
antimalarial can be divided into seven principle classes; 4-aminoquinolines (chloroquine, 
amodiaquine), aminoalcohols or aryl alcohols (quinine, mefloquine, halofantrine and 
lumenfantrine), 8-aminoquinolines (primaquine and tafenoquine), artemisinins derivatives 
(artemisinin, artesunate, artemether, and dihydroartemisinin), antifolates (pyrimethamine, 
proguanil and sulfadoxine), naphthoquinone (atovaquone) and antibiotics (doxycycline, 
clindamycin). 
The first antimalarial agent was quinine in the form of an extract from the bark of the cinchona 
tree. This tree is indigenous to the inhabitants of Peru in South America and had been used for 
treating malaria for centuries. The active antimalarial ingredient, quinine, was isolated in 1820 
by two French chemists (Joseph Pelletier and Jean Bienaime Caventou). The drug has a short 
elimination half-life of 8-10 hours and the first case of resistance was reported in 1910 . During 
World War II, the Japanese merchant of Cinchona discontinued its supply to many parts of the 
world (Parkard, 2014). This led to the urgent search for alternative therapy to quinine. 
Chloroquine, the first synthetic antimalarial drug, was developed by a German scientist in 1934 
. The drug was introduced in 1945 , and has an estimated serum half-life of about 60 days. 
However, the parasites are also exposed to a longer period of time when the drug’s plasma 
concentration would be reduced below a therapeutic level, thereby potentially selecting for 
resistant parasites (Stepniewska and White, 2008). Chloroquine resistance was first reported in 
Thailand in 1957, followed by Northern South America in 1960, with resistance spreading to 
Southeast Asia and Papua New Guinea in the 1970s and finally to Africa in the 1980s (Figure 
1.11). 
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Figure 1.11: Map showing the origin and distribution of chloroquine resistance across the 
world.  
Source: Parkard, (2014). 
 
Antifolates drugs, Proguanil and Pyrimethamine, were developed in the 1940s (. Proguanil was 
introduced as an antimalarial agent in 1948  and following the success of proguanil in treating 
malaria, pyrimethamine was later developed and the two drug were used as monotherapy, 
unfortunately giving an opportunity for resistance to develop (Malisa et al., 2011).  The first 
case of resistance to proguanil was reported in 1949, barely a year after its introduction . In 
order to improve the efficacy and curtail the resistance development, sulfones and 
sulphonamides were combined with proguanil or pyrimethamine . Sulfadoxine–Pyrimethamine 
was introduced in 1967 in Thailand and the first case of resistance was reported the same year 
which later spread fast to SouthEast Asia . 
Primaquine (8-aminoquinoline) has been the drug of choice for the treatment of dormant liver 
form of P. vivax infection (Krudsood et al., 2008). The drug was also recommended by WHO 
and approved by FDA as prophylactic agent against P. vivax malaria relapse (Fernando et al., 
2011). However, there have been reports about treatment failure which have been attributed to 
factors such as insufficient dose, improper dosing intervals, risk of reinfection, combination 
with blood schizontocidals and non-adherence to the prescribed dose (Thomas et al., 2016). 
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Recently, FDA has approved the use of tafenoquine (another 8-aminoquinoline) as a 
replacement drug for the radical cure of P. vivax hypnozoites malaria infection (Lacerda et al., 
2019). Tafenoquine was recommended as a single-dose treatment drug, potentially because of 
its longer serum half-life of about 15 days (Llanos-Cuentas et al., 2014; Green et al., 2016). Of 
a note is that both primaquine and tafenoquine cause hemolysis in individual with G6PD 
deficiency, therefore, screening for this phenotype is recommended before commencing the 
drug for treatment (Dern et al., 1981; Rochford et al., 2013; Rueangweerayut et al., 2017). 
The current frontline antimalarial, artemisinin was discovered by the Chinese scientist from the 
sweet wormwood (Artemisia annua) in the 1970s and the chemical structure was published in 
1979. The antimalarial property of artemisinin in the treatment of malaria was fully explored in 
the 1990s. This was a period when an urgent malaria intervention was most needed in Southeast 
Asia, as a result of all the frontline antimalarial fallen to resistance. In the same vein, 
chloroquine and pyrimethamine-resistant strains of P. falciparum are prevalent in Africa 
leading to a rise in childhood death (Fidock et al., 2000, Snow et al., 2001, and Roper et al., 
2004). Artemisinin has the shortest half-life of 0.5-1.4 hours (Bloland, 2001), being a potent 
and fast-acting antimalarial that is capable of reducing parasite biomass by 99.9% within 
48hours. White et al., (1999) recommended the combination of a fast-acting and highly 
efficacious artemisinin with a slowly eliminated drug. This is to reduce resistance development 
and enhance treatment rate. Against this background, the WHO also recommended the 
partnering of artemisinin with a slowly eliminated drug that can clear the residual parasites. 
Artemisinin combination therapies, (ACTs) became a prescribed drug for the treatment of 
uncomplicated malaria globally in 2006 (WHO, 2015). Artemether-lumenfantrine (Coartem, 
Novartis) was the first ACT manufactured that satisfied the global standard of good 
manufacturing practice and was endorsed by the US Food and Drug Administration in April 
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2009 (Premji, 2009). There are now six ACTs approved by WHO for the treatment of malaria 
(Table 1.3), of which resistance against four partner drugs have been reported.  
Resistance to ACTs first appeared in 2008 in Thai-Cambodia, this manifested clinically as a 
delay in parasite clearance time (Dondrop et al., 2009). Some of the factors attributed to the 
treatment failure could be the use of artesunate monotherapy in the region for many years and 
fake or counterfeit drugs (Ashley and Phyo, 2018). In 2014, the molecular marker for 
artemisinin resistance was identified to be a mutation in the Kelch gene on chromosome 13 of 
the parasite genome (Ariey et al., 2014). In other malaria-endemic regions such as India and 
South America, a few artemisinin-resistant parasites have been recorded (Chenet et al., 2016; 
Mishra et al., 2016).  The case of artemisinin resistance is yet to be established in Africa (WHO, 
2018). Meanwhile, triple artemisinin-based combination therapies that will consist of a standard 
dual ACT with another slowly eliminated drug are being assessed clinically as the alternative 
until new drug is available (Maxmen, 2016). 
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Table 1.3: Current ACTs approved for malaria treatment, their targets and resistance 
mechanisms 
Source:Ouji et al.,(2018) 
 
1.10 New candidates in the antimalarial drug pipeline  
Considering the present stalled progress in malaria control over the past two years, new drugs 
are urgently needed. Currently, the pipeline for the discovery of new antimalarial agents is 
robust. There are some 13 candidates presently in the pre-clinical and phase 2 of development. 
Most of these are blood schizonticides proposed for the treatment of uncomplicated P. 
falciparum malaria (Figure 1.12) 
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Figure 1.12: Representation of the targets of the current antimalarial pipeline candidates 
based on their activity against asexual intraerythrocytic parasites.  
Candidates in reds are currently being developed. Source: Ashley and Phyo (2018). 
 
At the forefront of this antimalarial discovery process is a Product Development Partnership 
(PDP) called the Medicine for Malaria Venture (MMV). Presently, the MMV antimalarial 
pipeline contains many promising candidates at different stages of development (translational, 
product development and access) (Figure 1.13) with selected emerging antimalarial in this 
portfolio presented in Table 1.4. Although the antimalarial pipeline is filled with many 
promising candidates, there is currently no novel compound that can be employed in areas 
where ACTs are failing. Hence, the search for new drugs that can replace the existing ones 
continues.  
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Figure 1.13: Global Portfolio of Antimalarial Medicines 
 Source: Adapted from MMV website 
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Table 1.4: Promising antimalarial agents in the MMV portfolio 
Source: Mathews and John, (2018) 
 
1.10 The search for new antimalarial drugs: defining target candidate profiles  
The last decade has seen a resurgence in the discovery and development of antimalarial 
medicines. High throughput phenotypic screening of millions of compounds for antimalarial 
activity coupled with improvement on the existing antimalarial drugs has resulted in the 
generation of new chemo-types. Many of these agents are currently being evaluated in pre-
clinical and early clinical development. Understanding and comparing the relative performance 
of these molecules has led to the defining of ideal target candidate and target product profiles 
for a new antimalarial clinical entity. The target product profile (TPP) is the final product, or 
antimalarial medicine that is anticipated to contain at least two or more active ingredients and 
is defined by how the medicine is intended to be used (Figure 1.14). There are currently two 
TPP; (i) a combination of candidates molecules that have the potential to clear the erythrocytic 
stage infection, block transmission and possess anti-hypnozoitic activities is capable of 
providing post-treatment prophylactic action and is termed a Single Exposure Radical cure and 
Prophylactic (SERCaP) and (ii) a single-exposure chemoprotection medicine (SEC) potentially 
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for use in mass drug administration (Burrows et al., 2017). These TPP anticipate a formulation 
of active compounds that are combined based on their individual properties against the TPP 
targets that are described within target candidate profiles (TCP). The TCPs are tactical targets 
employed to provide guidelines during drug development (Burrows et al., 2017) and the MMV 
have published proposal characteristics of an ideal and minimally acceptable TCP (Burrows et 
al., 2013; Leroy et al., 2014).  
TCP1 – a fast acting molecules to clear the initial erythrocytic stage biomass. 
TCP2- a long duration molecules to complete the clearance of the erythrocytic stage biomass. 
TCP3- (divided into 3a and 3b), 3a is a molecule that can clear the dormant liver stage 
hypnozoite, whilst 3b targets gametocytes to block transmission. 
TCP4- molecules that prevent the population from being infected (chemo-protection) 
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Figure 1.14: MMV Target Candidate profiles (TCP) matched to the two current Target 
Product Profiles (TPP) 
This chart outlines the necessary attributes of a target candidate profile (TCP) under the 
relevant banner of the target product profile (TPP). Source: Burrows et al., (2013) 
 
Consultation between MMV and the wider malaria communities about the potential of the new 
molecules currently in the MMV portfolio has led to a redefinition of the requirement for TPP1 
as well as the role of the TCPs in defining these new clinical entities (Table 1.5 and Figure 
1.15). In broad terms, TPP1 (for patient treatment) has been refined to be a new medicine to 
rapidly decrease the parasite biomass, block transmission and prevent relapse. Whilst TPP2 
(chemo-protection, for example as a prophylactic or in mass drug administration) has been 
updated to include two molecules; one to clear the dormant liver form and the other to clear the 
erythroctytic stage in case of emerging infections (Figure 1.15).   
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Table 1.5: An outline of new TPPs and TCPs for new clinical entity for malaria 
Source: Burrows et al., (2017) 
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Figure 1.15: Interplay between the newly proposed TPPs (centre) and TCPs (left).  
The uses of each TPPs are outlined in the panel to the right, the former TCP 1 and TCP2 have 
been combined to form a new more stringent TCP1, an ideal molecule that kills rapidly and is 
capable of maintaining over the long-term a plasma concentration above the Minimal 
Inhibitory Concentration (MIC) (White et al., 2017). The former TCP2 has been withdrawn. 
This new TCP1 recognises a key limitation of artemisinin - that whilst it has a profoundly rapid 
cytocidal action, it also has a very short serum half-life. Source: Burrows et al., (2017) 
 The former TCP3a now forms the new TCP3 and the former TCP3b is redesigned as TCP5. A 
new TCP, TCP6, has been introduced and this will comprises of molecules that are capable of 
killing the Anopheles mosquitoes that feed on an infected individual. 
 
1.11 The search for new antimalarial drugs: Mass drug screening for new antimalarial 
agents 
Thousands of chemical starting points are now available for further characterisation for hit to 
lead identification. Four research groups: GlaxoSmithKline (GSK, Gamo et al., 2010), St. Jude 
Children’s Research Hospital (Guiguemde et al., 2010), Novartis (Plouffe et al., 2008) and 
Esikits (Avery et al., 2014) have all disclosed the results of the antimalarial phenotypic 
screening of their large/massive chemical libraries (Table 1.6). Access to these data, and open 
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access agreements for sub-library compound sets (see below) are steps introduced to accelerate 
antimalarial drug discovery.  
 
 
Table 1.6: Phenotypic high throughput screening for antimalarial agents 
 
1.11.1 Tres Cantos Antimalarial Compound Set (TCAMS) 
The TCAMS library comprises 13,533 chemical compounds, originally screened by GSK, with 
the objective of serving as the starting point for antimalarial lead identification and 
optimization. The studies that generated this resource was borne out of the observation that 
since 1996 no new antimalarial drug had been developed (Ekland & Fidock, 2008), and 
evidence of emerging resistance to the current front line artemisinins (Andriantsoanirina et al., 
2009; Bonnet et al., 2009; Carrara et al., 2009). Approximately 2 million compounds in the 
chemical library of GSK were screened in 384-well plate format using Lactate Dehydrogenate 
(LDH) assay at a single concentration of 2µM against the P. falciparum 3D7 strain. 19,451 
molecules that inhibited the growth of the parasite by ≥80% were categorised as the primary 
hits. These were re-screened at the same concentration in another two separate experiments 
using the Dd2 malaria parasite strain. 13,533 compounds that inhibited the growth of the 
parasite by more than 80% in at least two of the experiments were considered as the confirmed 
hits which can serve as the antimalarial drug development chemical starting point (Gamo et al., 
2010).   
Also, the confirmed hits were tested for cytotoxicity against human hepatoma HepG2 cells at 
10µM, and only 1,982 of the compounds showed a selective index above the limit of human 
tolerance. The 50% inhibitory concentration (IC50) of most of the compounds were below the 
Organisation Compounds screened Primary hits generated Confirmed hits References
St. Jude Children Research Hospital 309,474 1,300 11,341 Guiguemede et al ., 2010
GlaxoSmithKline 2 million 19,451 13,533 Gamo et al ., 2010
Novartis 1.7 million 17,000 6,549 Meister et al ., 2011
Eskitis 256,263 3,209 1,985 Avery et al ., 2014
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micromolar range and all but one class of antimalarial were detected during the screening 
(Gamo et al., 2010). The full compounds set have been made available to the community 
through Material Transfer Agreements for further characterization and optimization.  
1.11.2  Medicine for Malaria Venture (MMV) - Malaria Box  
The last decade had witnessed the extensive high-throughput screening of large chemical 
libraries leading to the generation of more than 20,000 antimalarial hits (Van Voorhis et al., 
2016). These chemotypes could serve as starting points in the hit-to-lead generation, and also 
have the ability to kill other pathogens because they could share similar biological pathways 
targeted by these compounds (Spangenberg et al., 2013). Against this background, the Medicine 
for Malaria Venture (MMV) had prioritized hits to generate a smaller compound set called 
Malaria Box. This was made freely available for the research community, as a manageable 
resource for drug discovery and assay development purposes. The set contained 400 compounds 
that were active against the asexual blood stage of P. falciparum. 200 compounds were selected 
from the hits, having the rule-of-5-complaint physicochemical properties and termed drug-like 
compounds. While another set of 200 compounds that represent the largest range of structural 
diversity were also selected and named probe-like compounds (Spangenberg et al., 2013) 
(Figure 1.16).  
The open access Malaria Box has been distributed to some 200 researchers across 30 different 
countries throughout the world (van Voorhis et al., 2016). 236 screens have been performed on 
the Malaria Box compounds, and they were found to be active against other pathogens such as 
fungi, bacteria, protozoa, helminths, human cancer cells and the mosquito vector of dengue 
fever (Van Voorhis et al., 2016). In addition, the cytotoxicity test against 73 human cell line 
and developing zebrafish embryo at 10µM and 5µM respectively were carried out (van Voorhis 
et al., 2016). All the tests carried out on malaria box compounds will assist in the selection of 
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compounds for further characterisation and optimization in the drug discovery and development 
programs. 
 
Figure 1.16: Process for selection of the MMV Malaria Box open access compound library 
The schematic reports the process by which MMV prioritized approximately 20,000 hits to 
generate a smaller set of 400 compounds assembled in the Malaria Box. Source: Spangenberg 
et al., (2013) 
1.11.3 Medicine for Malaria Venture - Pathogen Box  
The MMV Pathogen Box comprises of 400 different drug-like compounds that were assembled 
as an open access resource based on the Malaria Box model. Compounds were selected by 
examining and prioritizing chemical molecules from the European Bioinformatics Institute’s 
open access database (ChEMBL17). Also, compounds were donated by the academic and 
pharmaceutical collaborators. This led to the generation of a library containing chemo-types 
that were active against malaria, tuberculosis, and neglected tropical diseases such as 
kinetopastids, cryptosporidiosis, onchocerciasis, lymphatic filariasis, wolbachia, 
schisotosomiasis, trichuriasis, hookworm, toxoplasmosis and dengue. The Pathogen Box also 
contains reference compounds, drugs currently used in the treatment of these diseases  
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1.12 The search for new antimalarial drugs:  the importance of a rapid rate of kill 
Determining the rate of kill of compounds early in the antimalarial drug discovery pipeline is 
important. Clinically, a drug should rapidly reduce parasite biomass. This has the effect of 
reducing the morbidity and mortality of infection. The success of artemisinin is based, in part, 
on this ability. This observation was demonstrated when intravenous artesunate was shown to 
be preferred to quinine in the treatment of severe malaria. In two large multicentre randomised 
malaria controlled trials carried out in Asia (Dondorp et al., 2005), SEAQUAMAT (South East 
Asian Quinine Artesunate Malaria Trial), and in Africa (Dondorp et al., 2010), AQUAMAT 
(African Quinine Artesunate Malaria Trial), artesunate was shown to prevent more death due 
to severe malaria than quinine. This led to an advice that artesunate should become a treatment 
of choice for severe malaria, the success is attributed to rapid killing rate and its action on rings 
stage of malaria parasites.  In addition, fast-acting compounds slow the onset and spread of 
resistance (Corey et al., 2016) with the rapid loss in parasite numbers apparently preventing the 
opportunity for resistance mutants to evolve and become fixed in a parasite population. 
The killing rate of antimalarial drugs is usually estimated in vivo using a severe combined 
immune deficiency (SCID) mouse model or humanised mouse (Le Bihan et al., 2016). This 
approach gives information about the predictive therapeutic index required to completely clear 
the parasites. This is normally estimated using two parameters. The parasite reduction ratio 
(PRR) is the ratio of parasite count at the start of antimalarial treatment divided by the count 
after 48 hours corresponding to one erythrocytic cycle of Plasmodium falciparum growth. The 
second parameter is the parasite clearance time (PCT), and is the time taken to clear 99.9% of 
the parasite load with infections typically no longer detected in the blood film following 
microscopic examination. However, using animal models to clinically evaluate how fast a 
compound works takes a long time and is unsuitable for high throughput screening in the drug 
development process. The challenge is to have a rapid in vitro rate of kill assay that can be used 
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as a filter to select the most efficacious chemo-types during the early process of drug discovery 
and development.  
1.12.1  In vitro Parasite Reduction Ratio (PRR) and Parasite Clearance Time (PCT) 
Assays 
The first in vitro assay that precisely measured the antimalarial killing rate was developed by 
Sanz et al., (2012). The assay measured the speed of action of the antimalarial drug on parasite 
viability as opposed to the traditional techniques that utilized metabolic activities as a surrogate 
for the parasite growth. Importantly, the assay could differentiate between antimalarial agents 
on the basis of their mode of action with drugs having the same rate of kill showing the same 
mode of action.  However, there are issues with the use of the technique in high throughput 
screening of large chemical compounds. Figure 1.17 illustrates how the assay works, briefly, 
asynchronous parasite culture (mostly 80% rings) at 2% haematocrit and 0.5% parasitaemia 
was exposed to test compound at concentration of fold-EC50 value. An aliquot of 10
5 parasite 
culture was removed at 0 hour and every 24 hours for up to 120 hours’ time point. Limiting 
serial dilution was performed on the aliquot in 96 well plate and fresh erythrocytes and culture 
media were added. The parasite culture was maintained for up to 28 days to allow any well with 
viable parasite to resume growth. The parasite growth was monitored using tritriated [3H]-
hypoxanthine incorporation technique and number of viable parasite were estimated. The result 
of the assay takes longer time due to the extensive culturing steps required over 21 to 28 days.  
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Figure 1.17: Diagrammatic representation of the in vitro PRR assay 
The assay was based on limiting serial dilution of drug treated parasite and growth of any 
viable parasite was monitored for up to 28 days. 
Source: Sanz et al., (2012) 
 
1.12.2 In vitro IC50 speed and stage specificity killing rate assay 
Le Manach et al. (2013) developed the second in vitro killing rate assay that was based on the 
modification of a standard [3H] hypoxanthine incorporation technique. The assay utilized two 
approaches; the ‘IC50 speed assay’ and ‘stage specificity’ assay which could not be performed 
independently (figure 1.18). Briefly, the in vitro IC50 speed assay was set up by exposing 
parasite culture to the test compound and incubated for three different time points; 24 hours, 48 
hours and 72 hours. The parasite growth was evaluated by using the tritriated [3H]-hypoxanthine 
assay. Radioactive hypoxanthine was added 24 hours and 48 hours after incubation for the 48 
hours and 72 hours assay respectively. Whereas, [3H]-hypoxanthine was added 16 hours after 
incubation for the 24 hours assay and IC50 values were subsequently determined for five 
benchmark antimalarial; chloroquine, artesunate, atovaquone and pyrimethamine.  
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The stage-specifity assay was carried out by exposing the synchronous culture (early rings and 
schizonts) of NF54 parasite line to 1.6-100 X IC50 of antimalarial compounds in a two-fold 
serial dilution and incubated at 370C for 24 hours. After incubation, the plates were washed 4X 
yielding a greater than 1,000-fold dilution of the antimalarial compounds. Subsequently, 
radioactive hypoxanthine was added and the plates were incubated for another 24 hours before 
either frozen down at -200C or processed. One limitation of this assay is that it takes about four 
to seven days to obtain result. 
 
Figure 1.18: Schematic diagram of “IC50 speed” and “stage-specificity” in vitro assay 
The time points indicate the incubation period, sorbitol treatment, drug exposure, addition of 
hypoxanthine and the final readout are depicted in the diagrammatic representation 
Source: Le Manach et al., (2013) 
 
1.12.3 Reinvasion parasite viability killing rate assay 
 Another in vitro parasite viability fast killing assay that was based on an erythrocyte invasion 
method was developed by Linares et al., (2015). Briefly, asynchronous 3D7 parasite culture 
(≥80% rings) was exposed to 10X IC50 concentration of the antimalarial drug. The plates were 
incubated at 370C for 24 or 48hours. Tested drug was renewed by washing the plate every 24 
hours and adding the same volume of drug. After 24 or 48hours incubation, drug was removed 
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and pre-labelled non-infected erythrocyte was added to the culture and incubated at 370C for 
another 48hours (see figure 1.19 for details). The final incubation will allow viable parasite to 
invade labelled erythrocyte and the new infection was detected by two-colour flow cytometry. 
However, this technique does not readily discriminate between two fast acting drugs such as 
artemisinin and chloroquine. The results require 3 to 4 days to complete and the availability of 
flow cytometer is another limitation.  
 
Figure 1.19:  Schematic Summary of reinvasion parasite viability killing rate assay. 
First, parasite culture was exposed to the antimalarial drug for 24 or 48 hours. Following drug 
removal, the culture was added to pre-labelled erythrocytes to allow re-invasion of viable 
parasites. Two-colour flow cytometry was used to detect new infection and the percentage of 
parasite viability was calculated (see the formula in the schematic diagram)  
Source: Linares et al., (2015) 
1.12.4 Bioluminescence Relative Rate of kill (BRRoK) assay 
The most recent in vitro innovation was a rate of kill assay developed in our laboratory using 
P. falciparum genetically modified to express luciferase (Wong et al., 2011; Hasenkamp et al., 
2013). Hasenkamp et al., (2013) showed that Dd2luc provides the same IC50 data as Sybr Green 
1 assays. This study also showed that luciferase is a more dynamic assay of parasite viability 
due to the rapid turn-over of the luciferase reporter protein. Ullah et al., (2017) showed that loss 
of bioluminescence following drug perturbation correlated with the in vitro PRR and PCT data 
developed for a range of benchmark antimalarials (Sanz et al., 2012) (Figure 1.20). Based on 
this work, Ullah et al.,(2017) then developed the Bioluminescence Relative Rate of Kill 
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(BRRoK) assay. In this study, they showed that effect of the drug on bioluminescence at four 
concentrations of test compound equivalent to the 0.33, 1, 3 and 9 x IC50 and their effect over 
6 hrs. They then showed how these concentration-response data could provide a rank of loss of 
bioluminescence – where adding benchmark drugs allows this surrogate measure of rate of kill 
to be mapped against (relative to) antimalarial compounds with well-described 
pharmacodynamics data. Importantly, and only otherwise available from the in vitro PRR assay 
– the BRRoK assay discriminates between compounds that meet the minimal threshold for rate 
of kill – at least as fast as chloroquine – and those that meet the ideal criteria as faster than 
artemisninins. This innovation provided a rapid (6 hours) assay, compared to the 21-28 days 
for the in vitro PRR assay, that was simple to complete in a multiwall plate with minimal 
processing steps that was robust enough for scale up (Ullah et al., 2017). Table 1.7 provides a 
summary of the relative benefits and issues available in vitro rate of kill assays. 
 
Figure 1.20: Comparing the BRRoK (PC1) with in vitro (PCT) and (b) log PRR of 
antimalarial drugs 
The y-axis shows the zero-meaned PC1 data from Ullah et al., (2017), while the in vitro PCT 
(h) and log PRR data (x-axis of (a) and (b) respectively) are from Sanz et al., (2012). The broken 
lines represent the linear regression. DHA, dihydroartemisinin; PYN, pyronaridine; CQ, 
chloroquine; PPQ, piperaquine; MQ, mefloquine; ATQ, atovaquone. Source: Ullah et al., 
(2017) 
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Table 1.7: Comparison of in vitro assays of antiplasmodial intraerythrocytic killing dynamics 
 
1.13 Addressing the knowledge gap 
Keeping in mind, the shortcomings of the various in vitro rate of kill assays, the BRRoK assay 
suffers from one significant drawback. In the screening of the relative rate of kill of the MMV 
Malaria Box compounds, Ullah et al.,(2017) faced a bottleneck in the assay process in that 
whilst it took 6 hrs to measure the rate of cytocidal action – the EC50 needed to be determined 
for each compound in a standard 48hr standard Sybr Green I potency assay. This requirement 
to use variable concentrations of compounds for a BRRoK assessment significantly limits the 
potential to scale up this in vitro assay format to screen large or even massive chemical libraries 
to prioritise those that potentially meet the TCP1 development criteria. In this thesis I will 
describe an improvement in the BRRoK assay format in the development of a modified BRRoK 
(mBRRoK) assay that uses a much simpler format of only two fixed concentrations of test 
compound. The hypothesis that underpins this approach is explained fully in the introduction 
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to Chapter 3. The overall aim of this study is to provide a simple, robust and rapid in vitro tool 
suitable to screen thousands of compounds to support the drug discovery effort for a new 
SERCaP clinical entity. To achieve this aim, the following targets were addressed in this thesis; 
1. Validate the hypothesis that loss of bioluminescent signal in an mBRRoK assay is 
proportional to potency and rate of kill using a series of benchmark antimalarial 
drugs with known pharmacodynamics properties. 
2. Validate the mBRRoK assay against the BRRoK assay data available for a range of  
MMV Malaria Box compounds – use this data to establish the specificity and 
sensitivity of the mBRRoK assay 
3. Establish the potential of the mBRRoK assay against a new MMV Pathogen Box 
resource to provide novel rate of kill data for an important open access resource. 
4. In collaboration with GSK, utilize the mBRRoK assay to screen the TCAMS library 
to provide a validated short list of novel rapid acting and potent antiplasmodial 
compounds 
This work will then be concluded with a discussion on the perspectives gained from this study 
on the future potential of the assay in the development of potential leads and scaling up to screen 
multimillion compound libraries. 
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2 CHAPTER 2: MATERIALS AND METHODS 
2.1 Materials 
2.1.1 45% glucose solution 
Glucose solution (45% w/v) was prepared by adding 45g of D-glucose to distilled water to a 
total of 100mL. The glucose suspension was dissolved by either placing it in a water bath at 
370C for 30 minutes or with the help of a magnetic stirrer. The solution was vacuum filtered 
(0.45µm pore) and stored as 10mL aliquots at 4oC until use. 
2.1.2 1000X Hypoxanthine solution 
A total of 680mg of hypoxanthine was dissolved in 50mL of 1M sodium hydroxide solution 
(Sigma, UK). The hypoxanthine solution was vacuum filtered (0.45µm pore) and stored as 
0.5mL aliquots at -20oC.  
2.1.3 10% Giemsa solution 
10mL of Giemsa solution (Fluka, UK) was added to 90mL of distilled water. This solution was 
syringe filtered (0.45µm pore) prior to use as a stain. 
2.1.4 5% Albumax 
25g of albumax powder was added to 500 mL of RPMI (Roswell Park Memorial Institute) 1640 
medium (Sigma, UK). The albumax suspension was dissolved by incubating at 370C for up to 
1hr. The solution was vacuum filtered (0.45µm pore) and 40mL aliquots stored at -20oC. 
2.1.5 5% Sorbitol 
5g of D-sorbitol powder (Sigma, UK) was added to a total volume of 100mL of distilled water. 
The solution was vacuum (0.45µm) pore and 15mL aliquots stored at 4oC. 
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2.1.6 10mg/ml Blasticidin S Hydrochloride (BSD) 
5mL of incomplete medium was added to 50mg of Blasticidin S HCl powder (Invitrogen, UK); 
the solution was stored as 0.5mL aliquots at -200C. 125µL of 10mg/ml BSD solution was added 
to complete medium and stored at 4oC for up to 2 weeks. 
2.1.7 WR99210   
A 25mM concentrated stock was prepared by adding 0.05g of WR99210 powder (Jakobus 
Pharmaceutical, USA) to 1mL of DMSO and stored at -200C. A 25µM working solution was 
prepared by a 1:1000 dilution of the 25mM stock into 1mL of incomplete medium and stored 
at 40C. 100µl from the 25µM working solution was added to 500mL of complete medium to 
give the required final concentration of 5nM. 
2.1.8 Glycerol freezing solution  
Glycerol freezing solution was prepared by taking 142.5g of glycerol, 4g sodium lactate, 0.075g 
potassium chloride, 0.311g of disodium phosphate (Na2HPO4) and 0.129g monosodium 
phosphate (NaH2PO4) and adding distilled water to a total volume of 230mL. 10M NaOH was 
used to adjust the pH to 6.8, and the final volume was made up to 250mL with distilled water. 
The glycerol freezing solution was vacuum filtered (0.45µM pore) and stored at 4oC until use. 
2.1.9 Cell culture medium for P. falciparum culture  
Complete growth medium was prepared by supplementing 500ml of RPMI1640 medium with 
18.75mL of 1M HEPES (N-(2-Hydroxyethyl)piperazine-N¹-(2-ethanesulfonic acid)) buffer 
(Sigma, UK), 2mL of 45% glucose solution, 2.5mL of 1M sodium hydroxide solution (Sigma, 
UK), 5mL of 200mM L-Glutamine solution (Sigma, UK), 1.25mL of 10mg/mL Gentamicin 
solution (Sigma, UK), 500µL of 1000X hypoxanthine solution, 20mL of heat-inactivated 
pooled human plasma (National Blood and Transfusion Service, UK), 20mL of 5% albumax-
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II. Incomplete medium lacks the pooled human plasma and albumax components. Depending 
upon the P. falciparum strain, complete media would be supplemented with BSD or WR99210 
for drug selection of the luciferase reporter cassette. 
2.1.10 Malaria Sybr Green 1 Fluorescence (MSF) lysis buffer  
A 10X MSF lysis buffer stock comprises 200mM Tris pH 7.5, 50mM EDTA, 0.08% w/v 
saponin and 0.8% v/v Triton X-100. The 10XMSF stock is stored at room temperature.  A 
1XMSF working solution was prepared by diluting one volume of the 10X MSF stock solution 
in 9 volumes of distilled water. 
2.1.11 Antimalarial compounds  
Antimalarial drugs were purchased from Sigma-Aldrich and dissolved in appropriate solvent 
(Table 2.1). The stock solution were prepared as recommended by the supplier and stored at -
20oC until further use. The MMV Malaria Box compounds were provided by the Medicines for 
Malaria Venture (www.mmv.org) as 20µL of 10mM stock solution in DMSO. Similarly the 
Pathogen Box compounds were provided by the Medicines for Malaria Venture as 10µL of 
10mM stock solution in DMSO. The compounds were diluted to 1mM working concentration 
in 9 volumes of DMSO as recommended by the Medicines for Malaria Venture and stored at -
20oC until use. 
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Table 2.1 Drug stock preparation 
 
Name 
 
Class 
 
Solvent  
Stock  
concentration 
Artemether (ART) Endoperoxide Dimethyl sulfoxide 
(DMSO) 
50mM 
Dihydroartemisinin 
(DHA) 
Endoperoxide Methanol 10mM 
Chloroquine (CQ) 4- aminoquinoline Distilled water 100mM 
Quinine (QN) Aryl-alcohol Ethanol 100mM 
Atovaquone (ATQ) Naphthoquinone  DMSO 20mM 
Pyronaridine (PYN) 4- aminoquinoline Acetic acid 5mM 
Amodiaquine (AQ) 4- aminoquinoline Methanol 10mM 
Mefloquine (MQ) Aryl-alcohol DMSO 10mM 
Piperaquine (PPQ) 4- aminoquinoline Ethanol 10mM 
Doxycycline (DOX) Antibiotics Distilled water 100mM 
Malaria box compounds Varied DMSO 1mM 
Pathogen box compounds Varied DMSO 1mM 
TCAMS compounds  Varied DMSO 1mM 
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2.2 Methods 
2.2.1 Preparation of 50% haematocrit 
Human blood group O Rhesus positive was supplied by the National Blood and Transfusion 
Service (UK).  All work with human materials was carried out according to the provisions of 
the Institution’s Human Tissue Authority (HTA) Licence (#12349). Human blood was passed 
through a leukocyte filter provided with the donation and aliquoted into pre-labelled 50ml tubes 
and stored at 4oC in a HTA-approved refrigerator until use. A 50% haematocrit stock was 
prepared by aspirating the serum with careful removal of any residual buffy coat layer. One 
volume of incomplete medium was added to the red cell pellet and centrifuged at 1520g for 
eight minutes at room temperature.  The supernatant was carefully aspirated and one volume of 
incomplete growth medium was added for subsequent washes and collected by centrifugation. 
After a third wash, the supernatant was carefully aspirated and one volume of incomplete 
growth medium added to make up a 50% haematocrit stock. The 50% haematocrit erythrocytes 
were stored at 4oC for up to two weeks. 
2.2.2 Plasmodium falciparum in continuous culture 
All work in the category III cell culture facility was carried out according to a Code of Practice 
approved by the Health and Safety Executive. Ethical approval for the use of these materials 
for in vitro culture and in vitro assessment of antiplasmodial activity is in place. The genetically-
modified P. falciparum strains used were registered with Keele University Genetic 
Modification Safety Sub-Committee.  
The genetically modified Dd2luc P. falciparum clone (Wong et al., 2011) was typically used 
throughout this study. In this clone, a luciferase reporter gene under the control of a trophozoite 
stage-specific expression cassette has been integrated into chromosome 7 along with a BSD 
drug selectable marker gene. A second genetically modified NF54luc P. falciparum clone 
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(Hmoud, 2019) was provided by a PhD colleague from our laboratory. In this parasite, the same 
trophozoite stage-specific luciferase reporter is present on an episomal plasmid bearing a DHFR 
drug selection marker (selected using the antifolate WR99210) and a rep20 P. falciparum 
telomere associated repeat element (O’Donnell et al., 2002).  
Parasites were continuously cultured in accordance with the method based on that originally 
described by Trager and Jensen (1976) and later modified by Freese et al., (1988). Routine 
culturing of parasites was done at a 2% haematocrit and the growth medium typically changed 
daily together with the preparation of thin blood smear for determination of parasitaemia and 
staging. Cultures were maintained by re-suspending the infected erythrocyte pellet in fresh 
complete medium, fresh uninfected erythrocytes and gassed under 1% oxygen, 3% carbon 
dioxide and 96% nitrogen (BOC, UK) before incubation at 37oC. 
2.2.3  Synchronisation of P. falciparum culture 
P. falciparum culture with predominately early ring stages was synchronised according to the 
method originally described by Lambros and Vanderberg (1979). Packed infected erythrocytes 
were collected by centrifuging the culture suspension at 1520g for five minutes at room 
temperature. The supernatant was carefully aspirated and five volumes of pre-warmed 5% 
sorbitol solution was added and incubated for five minutes at 37oC. The suspension was 
centrifuged at 1520g for five minutes at room temperature, and the supernatant carefully 
aspirated. The infected erythrocytes were re-suspended in fresh complete medium and an 
appropriate volume of uninfected erythrocytes was added. The cultured flask was gassed and 
incubated at 37oC. 
2.2.4 Freezing of P. falciparum culture for long-term storage 
The parasites to be stored should ideally be at parasitaemia of at least 3% and predominantly 
contain ring stage parasites. The parasite culture is collected by centrifugation for 5 minutes at 
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1520g at room temperature. The supernatant was aspirated, leaving about 500µL of media on 
top. The erythrocyte pellet was re-suspended gently in this 500µL of media and the total volume 
used to define one volume. 1.5 volumes of inactivated human plasma was added and mixed 
gently to ensure proper resuspension of the parasite culture. Then 2.5 volumes of glycerolyte 
freezing solution was added dropwise while mixing gently. This parasite 
suspension/glycerolyte solution was then transferred as 1mL aliquots into a labelled cryogenic 
vial (StarLab) and stored in liquid nitrogen for long-term storage. 
2.2.5 Thawing of frozen P. falciparum culture 
A frozen vial of parasite culture was removed from the liquid nitrogen and placed at 37oC to 
thaw. The parasite culture was then transferred from the vial into a 50mL sterile tube and 0.2 
volumes of a 12% NaCl solution was gently added in a dropwise fashion. The tube was 
incubated at room temperature for 5minutes, then, 10 volumes of 1.6% NaCl was slowly added 
whilst continuously gently rotating to mix the tube’s contents. After 5 minutes incubation at 
room temperature, this process was repeated with 10 volumes of 0.9% NaCl in 0.2% glucose. 
The parasite suspension was centrifuged at 850g for 5 minutes at room temperature. The 
supernatant was gently aspirated and the infected erythrocyte pellet cultured as described in 
section 2.2.2. 
2.2.6 Determining parasitaemia and staging of P. falciparum culture by light microscopy 
A thin smear of infected erythrocytes was prepared and fixed with absolute methanol for one 
minute. The slide was dried and then flooded with 10% Giemsa stain for 5 minutes. The stain 
was washed off the slide with water, air dried and one drop of immersion oil was applied before 
imaging under a x100 objective lens. The parasitaemia was estimated by counting the parasites 
in ten fields of infected erythrocytes and the number of erythrocytes per field estimated from 
counts of three fields. The parasitaemia was determined as: 
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(
Mean count of parasites from 10 fields
Mean count of erythrocytes from 3 fields⁄ ) 𝑥100 
 
2.3 Fixed concentration, single time point estimation of relative rate of kill – the 
modified Bioluminescent Relative Rate of Kill (mBRRoK) assay 
2.3.1  Preparation of mastermix 
A thin smear of infected erythrocytes of P. falciparum culture was prepared to check for the 
staging to ensure early trophozoite, 18-24hours post infection, and a parasitaemia of greater that 
2% was available. A mastermix was prepared at 4% HCT, 2% parasitaemia with 7mL of 
mastermix prepared per 96-multiwell plate being assessed.  
2.3.2  96-multiwell plate set up 
The assays were set up in 96 multiwell plates (Sarsted, UK) with 200µL of incomplete medium 
added to the outermost wells to reduce the edge effect resulting from evaporation. 125µL of 
complete medium was dispensed into the wells to which a final 10µM concentration of 
compound is being prepared. 100µL was added to the adjacent wells that, after dilution, will 
have a final 2µM concentration of compound as well as the control wells (no compound) 
(Figure 2.1). 2.5µL of 1mM compound solution was added to the 10µM wells and mixed by 
repeated pipetting. 25µL was transferred into the adjacent wells to provide a final 2µM of 
compound, mixed by repeated pipetting and finally discarding 25µL, creating a 1/5 dilution. 
Two positive control columns were set up on each plate, these had no compound inhibitor and 
represent 100% growth achieved in the absence of an inhibitor. 2.5µL of DMSO (to create a 
2.25% solvent control) was added to the first positive column for a 10µM compound control 
and mixed by repeated pipetting. 25µL was moved to the second positive column for 2µM 
control (0.45% DMSO solvent control), mixed and 25µL was discarded. 100µL of mastermix 
was added to all the test wells and mixed by pipetting. The plate was incubated for 6 hours at 
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37oC in a gassed chamber. Each compound was tested in duplicate on each plate, with three 
biological repeats providing a total of n=6 samples for each compound at each concentration. 
 
Figure 2.1:  Schematic representation of the assay plate set up for modified bioluminescent 
relative rate of kill (mBRRoK) assay using fixed concentrations 
The outermost wells (light brown) represent incomplete medium used to minimise edge effects 
from evaporation. Up to thirteen compounds were tested on each plate in duplicate at two 
concentrations (dark red). Controls representing no compounds but with DMSO content 
reflective of the carrier solvent for 10µM compound (2.2% DMSO, orange) and 2µM compound 
(0.45% DMSO, yellow) were provided as untreated controls. 
 
2.3.3 Determination of luciferase signal 
A single-step lysis protocol was carried out as described by Hasenkamp et al., (2012). In brief, 
after six hours of incubation, 40µl of cultured parasites were transferred from each well onto a 
white 96 multiwell plate (Greiner, UK) containing 10µl of 5X passive lysis buffer (Promega, 
UK). The well contents was homogenised by gentle shaking and 50µl of luminogenic substrate 
(Promega, UK) added to the lysed parasites. The resulting bioluminescence signal, in relative 
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light units, was measured for two seconds on a Glomax Multi Detection System (Promega, 
UK).  
2.3.4  Data analysis 
The relative light unit data was exported into an Excel sheet using the InstinctTM software 
(Promega). The mean of the 2.2% and 0.45% DMSO controls were used to define 100% of the 
relative signal (no compound control) for the 10µM and 2µM compound treated wells, 
respectively. The mean and standard deviation of n=6 relative signals were plotted in GraphPad 
Prism v5.0 (GraphPad Software, Inc., San Diego, CA, USA). 
2.4  Determination of 50% inhibitory concentration (IC50) 
This protocols was carried out based on a protocol that originally described by Smilkstein et 
al., (2004) and revised as described below. 
2.4.1  Preparation of mastermix 
The same procedure was used as described in the section 2.3.1 except that the final mastermix 
was at a 1% trophozoite parasitaemia. The protocol used is to prepare a serial two-fold dilution 
series.  
2.4.2  96 multiwell plate set up 
The same 200µL of incomplete medium was added to the outermost wells to reduce edge 
effects. 200µL of complete medium was added to the compound loading wells in column 2 
(Figure 2.2).  The compound dilution wells (columns 3 to 10) each contained 100µL of 
complete medium. Two types of controls were set up on each assay plate in column 11. The top 
three wells contained 100µL of complete medium with no compound and represent the 
normalised 100% growth in the absence of an inhibitor (positive control). The bottom three 
wells contain 100µL of complete medium with a supra-lethal dose of 10µM chloroquine to 
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represent a total kill with 0% relative growth (negative control). Appropriate volumes of test 
compound were added to the loading wells and mixed by repeated pipetting. 100µL of this mix 
was then moved across the dilution wells before 100µLis discarded to provide a two-fold serial 
dilutions of the compound of interest. 100µL of mastermix was added to all wells and the 
multiwall plate incubated for 48 hours at 37oC in a gassed box. 
 
Figure 2.2 Schematic representation of 96 multiwell plate set up to determine a 50% 
inhibitory concentration  
The outermost wells (light brown) represent incomplete medium. Two compounds were tested 
on each plate with the leftmost column (column 2, dark red) represents the loading wells (n=3 
for each compound). The next wells (columns 3 to10, orange) represent the dilution wells. The 
rightmost column (column 11); yellow wells represent the positive control (no drug, 100% 
relative growth) and light blue wells represent the negative control (10µM CQ, 0% relative 
growth) 
2.4.3 Sybr Green I fluorescence assay 
Sybr Green I (x5000, Invitrogen) was diluted into 1X Malaria Sybr Green I Flourescence (MSF) 
lysis buffer (20mM Tris HCl, 5mM EDTA, 0.008% Saponin and 0.08% Triton X100). 100µL 
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of the MSF buffer-dye suspension was added to the corresponding well on a black 96 multiwell 
plate (Greiner, UK). To these, 100µL of the malaria parasite culture was added and mixed by 
repeated pipetting. The multiwell plate was incubated at room temperature in the dark for one 
hour before the fluorescence signal (in relative fluorescence units, RFU) was measured using a 
Glomax MultiMax (Promega, UK) fitted to use the blue fluorescent module (excitation 490nm: 
emission 510-570nm). 
2.4.4 Data analysis 
Fluorescent signal data was exported into an Excel spreadsheet using the InstinctTM software 
(Promega). This data was converted to a normalised % growth using the formula below: 
(
(∑signalof interest − ∑β
(∑α − ∑β⁄ ) 𝑥100 
Signal of interest in the mean of n=9 wells exposed to the same concentration of compound 
α are the 100% growth controls using n=9 wells with no inhibitor added 
β are the 0% growth controls using n=9 wells with 10µM CQ supralethal dose 
The mean values from three biological repeats, each of three technical repeats provide the n=9 
samples used here. The means and their standard deviation were plotted against log10-
transformed compound concentration using Graphpad Prism v5.0 (GraphPad Software, Inc., 
San Diego, CA, USA). A log concentration-normalised response regression analysis was 
performed to estimate the IC50 and provide the reported 95% confidence interval. 
2.5 Bioluminescence Relative Rate of Kill (BRRoK) assay 
The assay was carried out according to the protocol originally described by Ullah et al., (2017) 
with revisions as described below. 
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2.5.1  Preparation of mastermix 
A 4% HCT and 2% trophozoite stage mastermix was prepared as described in section 2.3.1. 
2.5.2  96 multiwell plate set up 
The assays were set up in 96 multwell plates (Sarsted, UK) with 200µL of incomplete medium 
added to the outermost wells to minimize edge effects (Figure 2.3). 150µL of complete medium 
was added to the compound loading wells (columns 2 and 7) and 100µL of complete medium 
was added to the three adjacent compound-dilution wells. A volume of drug/compound 
corresponding to 9xIC50 of each compound was added to the loading wells on each plate. The 
content in the loading wells was mixed by repeated pipetting and 50µL moved across the 
dilution wells with mixing and finally discarded to produce a 3-fold dilution. 100µL of 
mastermix was added to all the wells (thus diluting the compounds to produce 9x, 3x, 1x and 
0.33xIC50 over the four wells). Six wells without any drug served as the 100% normalised 
growth (positive) control. The plate was incubated at 37oC for 6 hours in a gassed box. 
2.5.3 Determination of luciferase signal 
This was carried out  as described in section 2.3.3 
2.5.4 Data analysis 
This was carried out as detailed in the section 2.3.4 except that with only one (positive) control 
was used to calculate the signal of interest as a proportion of the untreated control. 
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Figure 2.3 Assay plate set-up for Bioluminescence Relative Rate of Kill (BRRoK) 
determination 
The outermost (light brown) wells contain 200µL of incomplete medium. Compound loading 
wells (final 9xEC50) are indicated in dark red with the plate setup allowing up to 4 compounds 
to be evaluated. The dilution wells are indicated in orange (providing a 3 fold dilution series). 
The positive (yellow) wells contain no compound, with all bioluminescent signals measured 
determined as a percentage of their mean RLU count. 
 
 
2.6 A modified Bioluminescence Relative Rate of Kill (mBRRoK) assay adapted for 
high-throughput screening of the Tres Cantos Antimalarial Compound set 
2.6.1 Preparation of master mix 
A mastermix was prepared according to the protocol detailed in the section 2.3.1 except that 
the total volume was based on the requirement for 7.7mL per plate (based on 20µl per test well 
on a 384 multiwell plate). 
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2.6.2 384 well plate set up 
The assay was set up in 384 well plates (Sarsted) that were pre-loaded by GlaxoSmithKline 
(GSK, Tres Cantos, Spain) with 0.02µl or 0.04µl of 10mM and 1mM fixed concentrations of 
the TCAMs compounds (figure 2.4)  respectively (separate plate for each fixed concentration 
). Upon resuspension in 20µl of parasite culture, this provides for either a 10µM or a 2µM fixed 
concentration in that well. 20µl of 2%HCT was dispensed into the first eight wells (negative 
control i.e. 0% growth) of column 6 (blank), while 20µl of the master mix (positive control i.e. 
100% growth) was added to the remaining eight wells. 10µM and 2µM fixed concentration of 
four known antimalarial (dihyroartemisinin, chloroquine, mefloquine, and atovaquone) were 
added in triplicates to column 18 (blank). Then, 20µl of master mix was added to the remaining 
wells containing the test compound and antimalarial. The plates were gently mixed and 
incubated at 37oC in gassed modular chamber for six hours.  
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Figure 2.4: Assay plate set-up for modified Bioluminescence Relative Rate of Kill 
determination. 
Red indicates 2% parasite culture added to all the wells except the first 8 wells in column 6 
(pink) where 2%HCT was added as negative control (0% growth). The remaining 8 wells in 
column 6 contained 2% parasite culture without drug (100% growth). 
2.6.3 Luciferase assay 
A single lysis procedure described by Hasenkamp et al., (2012) was used throughout. After six 
hours of incubating the assay plates, 5X passive lysis buffer (Promega) and luciferase substrate 
(Promega) were reconstituted in ratio of 1 to 2 respectively. An equal volume (20µl) of the 
reconstituted reagent was added to the culture in each wells using a repeating dispenser 
(Sarsted, UK) and gently mixed. The luciferase signal was measured in relative light units on a 
Glomax Multi Detection System (Promega, UK).  
2.6.4 Data analysis 
Data generated was exported into an excel sheet using the Instinct software (Promega). The 
mean of the eight wells with only master mix (positive control) was used to define 100% of 
signal (no compound) for the 10µM and 2µM compound treated plates. The one data point for 
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each fixed concentration were plotted in Graphpad prism V 5.0 (GraphPad Software, Inc. San 
Diego, CA, USA). 
Principle component analysis (PCA) of the subsequent confirmatory BRRoK data using both 
Dd2luc and NF54luc strains was performed by Dr. Raman Sharma, LSTM. PCA was performed 
on the 0.3x, 1x, 3x and 9xIC50 variables for the 6 hrs bioluminescence assay endpoints using 
the KNIME analytics platform to reduce the dimensionality of these data set, allowing the 
concentration rate relationship to be captured in one parameter. Correlation of the PC1 
components with relative bioluminescence data, with accompanying statistical analyses, was 
carried out using GraphPad Prism v5.0. 
2.6.5 Assessment of mBRRoK assay quality parameters 
20µl each of non-infected erythrocytes (negative signal control) and parasite-infected 
erythrocytes (positive signal control), were added to the first 8 wells and last 8 wells of column 
6 respectively on each assay plate. The data generated were used to calculate the metrics for 
assessing the quality of high throughput assays such as the Z` score, % maximum and minimum 
coeffeicient of  variation (%CVmax and %CVmin) and the signal/background (S/B) ratio as 
described by Zhang et al., (1999). The Z` was calculated by using the formula: Z` = 1  [(3σ (+) 
+ 3σ (-)) / µ (+) - µ (-)], in which σ (+) and µ (+) are the mean and standard deviation of positive 
signal control respectively, while σ (-) and µ (-) are the mean and standard deviation of negative 
signal control respectively. %CVmax was evaluated: 100x [σ (+) / µ (+)] and %CVmin: 100x [σ (-) / 
µ (-)]. The S/B was calculated: σ (+) / σ (-). 
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3 CHAPTER 3: Validation of a modified Bioluminescence Relative rate of       
Kill (mBRRoK) assay 
3.1 Introduction 
Rate of kill is an important pharmacodynamics property of antimalarial compounds that is 
typically evaluated at the preclinical and phase IIa of clinical trials. Determining this parameter 
early in the drug development process offers the opportunity to reduce the attrition rate later in 
the 10-15 years of discovery and clinical trials (Tamimi and Ellis, 2009). Towards this aim, 
Ullah et al., (2017) developed and validated a rapid in vitro bioluminescence-based rate of kill 
assay (BRRoK) that allows the determination of the initial cytocidal effect of antimalarial 
agents within six hours. The assay utilizes a genetically modified parasite clone (Dd2luc) that 
expresses a strong luciferase signal under the control of Pfpcna flanking sequence during the 
S-phase of the trophozoite stage (Wong et al., 2011). Expression of this strong luciferase signal 
at trophozoite stage has been attributed to the temporal control of Pfpcna 5´ and 3´flanking 
sequences on the luciferase reporter gene (Hasenkamp et al., 2012). The Dd2luc parasite was 
generated using the bxb1integrase system (Wu et al., 1995) where the luciferase reporter, 
flanked by Pfpcna 5´ and 3´ un-transcribed regulatory sequences, was inserted into 
chromosome 7 of P. falciparum. 
Earlier work in Horrocks’ laboratory has demonstrated the optimization of a bioluminescence 
assay on a 96 wells plate format. Hasenkamp et al., (2013) showed a proof of principle that 
cytocidal action of antimalarial drugs could be measured in the Dd2luc parasite strain through 
the loss of luciferase signal following drug exposure. The loss of luciferase signal was both 
concentration and time dependent and has been attributed to luciferase being an unstable 
reporter with a half-life of approximately 1.5 hr in P. falciparum (Hasenkamp et al., 2013). 
Building on this, Ullah et al., (2017) developed and validated a microplate-based 
bioluminescence relative rate of kill (BRRoK) assay to determine the initial rate of kill of 
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benchmark antimalarial drugs. Briefly, the relative concentration-dependent effect of six WHO-
approved antimalarial drugs were initially compared by using fold changes in EC50 
concentrations. Dd2luc parasites were exposed to equal concentrations of drug that corresponds 
to a range of 81-0.33x EC50 using 3-fold dilution in a microtiter plate and incubated for six 
hours. The residual bioluminescence signal was read, normalized against the untreated control, 
and plotted against the drug concentrations (Figure 3.1). The result shows that all the drugs, 
except atovaquone, attain their initial maximal rate of kill at a concentration that corresponds 
to >9x EC50. This observation agrees with the findings of Sanz et al., (2012) who had earlier 
reported that cytocidal drugs reach their optimum killing rate at a concentration of 10xEC50. 
The killing rate of drugs were ranked as artemisinin>chloroquine>4-methanol 
quinolines>atovaquone which is in agreement with what has been reported in vivo and in vitro 
about their relative ranking order (White et al., 1997; Pukrittayakamee et al., 2000 
(Bahamontes-Rosa et al., 2012; Le Manach et al., 2013). 
Subsequently, Ullah et al., (2017) used the BRRoK assay to determine the initial cytocidal 
effects of 372 compounds of the MMV Malaria box after measuring their EC50 values. The 
Dd2luc parasite was exposed to fold-EC50 concentrations (0.33x to 9x) of the compounds. Loss 
of bioluminescence signal for these compounds in concentration and time dependent manner 
was used to compare against those for a panel of benchmark antimalarial dugs. The BRRoK 
assay provided a relative ranking order and not a true rate of kill, although these data are ranked 
with benchmarks for which the true rate of kill has been determined.  This ranking also aligns 
with the description of minimal essential and ideal criteria for a TCP1 candidate molecule in 
the future SERCaP drug defined by MMV (Burrows et al., 2013). As such, the BRRoK assay 
provides a fast and simple way of exploring the immediate cytocidal rate of kill effect of these 
compounds.  
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Figure 3.1: Concentration-dependent bioluminescence signal loss following fold EC50 of 
benchmark antimalarial drugs perturbation 
Mean fraction of residual bioluminescence signal normalized against an untreated control after 
6 hours of exposure to fold-IC50 of the antimalarial drugs (RLU±stdev (n=6)). ATQ, 
atovaquone; MQ; mefloquine; QN, quinine; PPQ,piperaquine; CQ,chloroquine;DHA, 
dihydroartemisinin. (Source: Ullah et al., 2017). 
 
Moving forward, a Principle Component Analysis (PCA) was performed on the BRRoK data 
for four equipotent concentrations at 3 and 6 hrs endpoints to reduce the dimensionality to a 
single value that can be easily explore and managed. The concentration rate relationship was 
compressed into a new variables called principle components. The first principle component 
(PC1), accounted for majority of the variance (89%) in the 6 hour dataset. Subsequently, the 
percentage of explained variance reduced across the second principle component (PC2), third 
principle component (PC3) and fourth principle component (PC4) (Table 3.1). The PC1 was 
used to rank the initial cytocidal effect of 372 MMV Malaria Box compounds (figure 3.2), with 
smaller value indicating a faster acting compound, that is the lower the PC1 values, the greater 
the cytocidal effect. Consequently, the ranking of initial cytocidal activities of the MMV 
compounds was informed by comparison against the initial cytocidal effect determined for the 
known antimalarial drugs. This provides a surrogate information with regards to immediate 
66 
 
cytocidal effects of MMV compounds. Using the PC1 value estimated from BRRoK data, 53 
MMV compounds were shown to exert an initial rate of kill at least as fast as chloroquine, of 
these, 17 compounds were shown to be at least as good as  dihydroartemisinin. 
Table 3.1: Estimated variance in the principle components of BRRoK data derived after 3 
and 6hrs of compound exposure 
Source: (Ullah, 2016 PhD thesis) 
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Figure 3.2: Scatter plot of BRRoK (PC1) against IC50 values of 372 MMV Malaria Box 
compounds and 7 known antimalarial drugs. 
The Malaria Box compounds are indicated as pink squares and blue circles for drug-like and 
probe-like respectively. Benchmark antimalarial drugs are represented with black diamonds. 
The continuous and broken horizontal lines indicated the ideal (for dihydroartemisinin) and 
minimal (for chloroquine) thresholds respectively, as reported by BRRoK assay for TCP1 
candidates. ATQ, atovaquone; CQ; chloroquine; DHA, dihydroartemisinin; MQ, mefloquine; 
PPQ, piperaquine; PYN, pyronaridine; QN, quinine. (Source, Ullah et al., 2017).  
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Moreover, Ullah et al., (2019) provided a proof-of-principle that the Rok of antimalarial 
compounds is linked to their mechanism of action. This was demonstrated by comparing the 
BRRoK data with the predicted mode of action for the MMV compounds. This resulted in a 
relative ranking of PfATP4 > parasite haemoglobin catabolism > DHFR-TS > DHODH > bc1 
complex targets, in order of fast to slow RoK. Also, MMV compounds were clustered together 
based on their related core scaffold and compared against the BRRoK data and revealed that 
compounds with similar chemical structures, and therefore likely targets, clustered together. 
This analyses showed an intrinsic rapid cytocidal action for the diamino-glycerols and 2- 
(aminomethyl) phenol and slow action for the 8-hydroxyquinolines, 2-phenylbenzimidazole 
and triazolopyrimidines scaffolds (Ullah et al., 2019).  
The BRRoK assay is a valuable tool to support drug discovery due to its ease of use, it can be 
readily scaled for high-throughput screening, and it is rapid, robust and offers an ability to 
differentiate between minimal and ideal TCP1 candidates. However, there are limitations in the 
use of this assay. Firstly, is the need to use genetically modified parasite (GM) lines that express 
the luciferase reporter gene. However, in Horrocks’ laboratory, there is now access to another 
GM parasite line that express the luciferase, under the control of Pfpcna flanking sequences, in 
the more drug-sensitive NF54 line (Hmoud, 2019). The second limitation is that the temporal 
(trophozoite) expression of luciferase GM parasites, with poor levels of reporter expression in 
rings and schizonts stages. However, this could readily be addressed in transgenic parasites line 
using a new reporter construct with a luciferase flanked by regulatory sequences that will afford 
temporal expression at all/other erythrocytic stages. The third limitation which is a major 
setback of the BRRoK assay is the need to know the EC50 values. This data takes a longer time 
(48hrs) to measure than the BRRoK assay (6hrs), and may not be available for large compound 
sets or the P. falciparum clone being investigated. This limits the utilization of the assay for 
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high throughput screening of large compound set such as TCAMS library – a gap that is 
addressed in this thesis. 
Developing a much higher throughput assay to identify rapid acting compounds is key to 
quickly triage thousands of antimalarial hits currently available to malaria community. In 
addition, the assay should incorporate a second property of potency in the triage process for 
rapid acting compounds. Ideally, bringing these two properties (potency and rate of kill) 
together can be achieved using fixed concentrations – offering a much simpler assay set-up at 
the same time. There is an understanding that the loss of bioluminescence when parasites are 
exposed to a concentration of compound relates to both the potency of compounds (in terms of 
access or binding to target) and RoK (intrinsic due to mechanism of action). Potency is 
expressed as EC50 and more importantly as the multiples of which are achieved in fixed 
concentrations (i.e. the more potent a compound, the more fold EC50 achieved at a fixed 
concentration).  Sanz et al., (2012) and Ullah et al., (2017) reported that maximal in vitro RoK 
is achieved at 10x and 9x EC50, respectively.  
An ideal criteria for potency for a compound of interest set here as less than 200nM, with 10x 
EC50 will be equivalent to 2µM. A minimum criteria was set at 1µM maximum potency, with 
10x EC50 will be equivalent to 10µM. Therefore, two fixed concentration of 2µM and 10µM 
were employed here to screen for rapid and potent antimalarial compounds. The assay is now 
termed the modified Bioluminescence Relative Rate of kill (mBRRoK) as it utilizes two fixed 
concentrations of test compounds against the trophozoites stage of P. falciparum for six hours.  
To support the development and validation of the mBRRoK assay, I provide here; 
1. proof-of-principle in the use of fixed concentration assays of benchmark antimalarial (known 
potency and RoK determined using a range of in vitro RoK assays) to demonstrate the 
application of the mBRRoK assay. 
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2. validate the mBRRoK assay with larger set of compounds from MMV Malaria Box (with 
known BRRoK assay data for comparison). 
3. explore the performance of mBRRoK assay in a second genetically modified parasite strain 
(NF54luc). 
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3.2 Results 
3.2.1 Initial proof of concept using known antimalarial drug benchmarks 
In vitro rate of kill data is available for a number of antimalarial drugs (Sanz et al., 2012; Ullah 
et al., 2017; Ullah et al., 2019) and are summarised in Table 3.2. These benchmarks represent 
a range of chemo-types with several modes of action. Using the relative rate of kill (PC1), 
parasite reduction ratio (PRR) and parasite clearance time (PCT) data from these in vitro 
studies, a broad classification of rate of kill can be described. A rate of kill equivalent or better 
than chloroquine (CQ) is defined here as rapid – this is in line with the target candidate profile 
description for a rapid acting compound by the Medicine for Malaria Venture (Burrows et al., 
2013). These rapid acting compounds include the endoperoxides, artemether (ART) and 
dihydroartemsinin (DHA). Compounds Slower than chloroquine, but with a PC1 <0 (as 
reported in Ullah et al., 2017), are described here as having a moderate rate of kill. These 
include the 4-aminoquinolines, amodiaquine (AQ) is included in this group after the initial 
mBRRoK data analysed as no previous data available, and piperaquine (PPQ) as well as the 
aryl alcohols mefloquine (MQ) and quinine (QN). Compounds with a PC1 >0 are defined here 
a slow acting, and include the napthoquinone, atovaquone (ATQ) and the antibiotic doxycycline 
(DOX is included in this group after the initial mBRRoK data analysed as no previous data 
available). 
 The initial proof of concept experiment was designed to explore whether an mBRROK assay 
would provide data that reports the correct relative order for rates of kill for these benchmark 
drugs as well as how the mBRRoK assay data correlates with available BRRoK data (the PC1 
data reported in Ullah et al., 2017). P. falciparum Dd2luc was exposed to these benchmark drug 
at 2µM and 10µM for 6 hours and the residual bioluminescence signal normalized to the mean 
of an untreated control. All experiments were carried out as technical duplicates, with three 
independent biological repeat performed.  
72 
 
The mean and ± standard deviation of n=6 is reported in Figure 3.3A.Taking the mean 
normalized bioluminescence signal after exposure at 2µM and 10µM and plotting them against 
each other provides  a standard representation used in this thesis for mBRRoK data (Figure 
3.3B). Data typically falls on a diagonal from a slope of 1, or above this diagonal i.e. a 
compound does not typically produce a greater kill at the lower 2µM concentration exposure. 
Whilst, the loss of bioluminescence signal is a result of both the intrinsic rate of kill of a 
compound, it will also reflect the fold EC50 achieved at the 2 µM and 10µM - reported in Table 
3.2 where the majority of compounds tested achieve at least a 10-fold EC50 at both 
concentrations tested here.  Fast acting compounds typically fall towards the lower left as there 
is minimal residual bioluminescence after 6hr exposure at either concentration. Slower acting 
compounds (or those with a long lag phase) are towards the top right as they do not report a 
loss of bioluminescence in the 6hr assay done here. For the eight benchmarks tested here – the 
understanding of their relative order of rate of kill is certainly reported in this study where 
artemisinins> quinolines> napthoquinones. Differentiating between 4 amino-quinolines and 
aryl alcohols is not possible at this point. The reduced efficacy of chloroquine in the 
chloroquine-resistant (CQR) strain Dd2 raises the EC50 and consequently reduces the fold-EC50 
that can be achieved. This is certainly compared to those for the other 4 amino-quinolines and 
aryl alcohols, and this may account for this rapid acting compound falling further up the slope. 
There is no available rate of kill data available for amodiaquine and doxycycline from these 
two studies. Amodiaquine shares the same apparent mBRRoK data as other 4-aminoquinolines 
and is termed moderate here. Doxycycline shares the same space as the slow atovaquone. This 
position, however, may also reflect the low EC50-fold achieved at both 2 µM and 10µM (Table 
3.2). 
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To further explore how the mBRRoK assay performs, the mean normalized bioluminescence 
signal at 10µM and 2µM was compared to the PC1 parameter reported in previous 6hr 
bioluminescence assays using this Dd2luc strain (Ullah et al., 2017; Ullah et al., 2019). These 
analyses (Figure 3.3C and D), respectively, report significant levels of good linear correlation 
(R2>0.9). This is expected as the relative order of their rate of kill is maintained in both assay 
systems. Together, these initial findings appear to provide a proof-of-principle that indicates 
that the mBRRoK assay will report loss of bioluminescence based on both the relative rate of 
kill and potency of a compound.  
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Table 3.2: Comparison of in vitro rate of kill data for benchmark antimalarials used in this study 
Name Abbreviation Class EC50 PC1a Log 
PRRb 
PCTb Lag 
phaseb 
Rate of Kill x EC50 at 
      Dd2luc     (hrs)   Classification 2µM 10µM 
Artemether ART Endoperoxide 8.4nM . 8 24 0 Rapid 238 1190 
Dihydroartemisinin DHA Endoperoxide 5nM -97.4 . . . Rapid 400 2000 
Chloroquine 
CQ 
4-
aminoquinoline 
200nM -73.7 4.5 32 0 Rapid 10 50 
Amodiaquine 
AQ 
4-
aminoquinoline 
26nM . . . . Moderate 77 385 
Piperaquine 
PPQ 
4-
aminoquinoline 
43nM -37 . . . Moderate 47 235 
Quinine QN Aryl alcohol 246nM -52 . . . Moderate 8 41 
Mefloquine MQ Aryl alcohol 11nM -42.4 3.7 43 0 Moderate 176 880 
Doxycycline DOX Antibiotic 3µM . . . . Slow 0.7 3 
Atovaquone 
ATQ 
Naphthoqui-
none 
4nM 55.4 2.9 90 48 Slow 500 2500 
a, Ullah et al.,(2017); b, Sanz et al., (2012); ., no data available from these studies 
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 Figure 3.3: Establishing a proof of concept for mBRRoK using benchmark antimalarial       
drugs. 
(A) Bar chart reporting the mean and stdev (n=6) of normalized bioluminescence signal 
after 6 hrs exposure to the indicated compound at 10µM (clear) and 2µM (grey). (B) 
Comparison of the mean normalized bioluminescence signal at 10µM and 2µM to provide 
a standard representation of mBRRoK data in this thesis. The position of benchmark 
antimalarial is shown using a key based on their relative in vitro rate of kill (see Table 3.2). 
Linear regression analyses of mean normalized bioluminescence signal at 10µM (C) and 
2µM (D) against the available BRRoK PC1 parameter for six benchmarks antimalarial 
tested here.  Abbreviations for compounds are reported in Table 3.2. 
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3.2.2  MMV Malaria Box compounds: validation of the mBRRoK assay 
The initial proof of concept was expanded with the pool of compounds tested within the BRRoK 
assay. Ullah et al., (2017) reported the relative rate of kill for 372 compounds in the MMV 
Malaria Box. Here, 100 compounds from the MMV Malaria Box were selected based on a range 
of characteristics, including; predicted rate of kill (rapid, moderate and slow from PC1 data 
reported in Ullah et al., 2017) and groups of compounds related by chemo-type as well as 
predicted mode of action (Ullah et al., 2019). The selection also recognised that samples that 
were running out could not be used as sufficient repeats of data would not be generated for 
analysis. A summary table for these 100 MMV Malaria Box compounds is provided in 
Appendix 1. 
Using the same experimental approach as described above, a comparison of mean normalized 
bioluminescence signal of n=6 (technical duplicates with three independent biological repeats) 
after exposure to 10µM and 2µM is reported in Figure 3.4. Each MMV Malaria box compound 
is shown as a grey filled circle, with the mBRRoK antimalarial benchmarks, colour-coded for 
their rate of kill, overlaid.  
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Figure 3.4: mBRRoK graph for 100 MMV Malaria Box compounds 
Comparison of the mean normalized bioluminescence signal at 10µM and 2µM from mBRRoK 
assay data of 100 MMV Malaria box compounds (grey filled circles). The position of 
benchmark antimalarials is shown using a key based on their relative in vitro rate of kill (see 
Table 3.2 and Figure 3.3B). Each data point represents the mean (n=6).  
 
As expected based on the range of PC1 data available, the MMV Malaria Box compounds are 
distributed over this “mBRRoK graph”. The position of the antimalarial benchmarks provides 
position markers within this dataset to start making predictions of a compounds’ in vitro rate of 
kill. To explore this prediction, the 100 MMV Malaria Box compounds were assigned a rapid, 
moderate or slow rate of kill classification based on the PC1 parameters defined above. Just 
over half were designated moderate (PC1 falls between -73 and 0), with 31 rapid (PC1<-73) 
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and 17slow (PC1>0) (Figure 3.5A). The mBRRoK graph for these data with colour coding was 
plotted (Figure 3.5B).  
 
Figure 3.5: Exploring predictions of rate of kill mBRRoK graph  
(A) Dot plot reporting the PC1 (and thus classification of rate of kill) for the 100 Malaria Box 
compounds used in this study. (B) Replotting the mBRRoK graph from Figure 3.4 with the class 
of rate of kill for each MMV Malaria box compound reported on the graph. Note: the 
antimalarial drug benchmarks have been removed from this representation of Figure 3.4. 
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With the larger set of data, there appear to be some interesting observations; 
1 The slow acting MMV malaria Box compounds are almost exclusively clustered in the 
top right, within the region demarked using the ATQ and DOX benchmarks. 
2 The majority of rapid acting compounds fall in the lower left region, along with the 
artemisinin benchmarks. There are, however, about one third of compounds that are 
position further up the gradient. 
3 Moderately acting compounds occupy most of the gradient, albeit with a focus on the 
centre. These compounds are more likely to overlap with the rapid compounds rather 
than the slow acting compounds. 
4 There are singleton examples of rapid and slow acting compounds that appear in the 
wrong position on this mBRRoK graph based on PC1 data.  
As with the antimalarial drugs, the mean normalized bioluminescence signal at 10µM and 2µM 
was compared to the reported MMV Malaria Box compound PC1 parameter (Ullah et al., 2017; 
Ullah et al., 2019). These analyses (Figure 3.6A and B), respectively, report significant linear 
correlations, although the level of correlation (R2 of 0.5-0.54) are much lower than those for 
the antimalarial benchmarks (Figure 3.3C and D). This likely reflects that the mBRRoK mean 
normalized bioluminescence signals at 10µM and 2µM represent both the rate of kill and 
potency of a compound, whereas the PC1 data is from a BRRoK assay that only explores the 
rate of kill. The generally lower potency of the MMV Malaria Box compounds compared to 
antimalarial drugs means that the 10µM and 2µM concentrations likely do not achieve at least 
a 10-fold EC50 for most of the MMV Malaria Box compounds – and this effect of lower potency 
compounds contributes to the lower correlation with PC1 than achieved using the antimalarial 
benchmarks.  
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Figure 3.6: Correlating mBRRoK and BRRoK data for the MMV Malaria Box compounds  
Linear regression analyses of mean normalized bioluminescence signal at 10µM (A) and 2µM 
(B) against the available BRRoK PC1 parameter for the 100 MMVMalaria Box compounds 
tested in this study.   
 
3.2.3 Determination of the sensitivity and specificity of the mBRRoK assay 
Sensitivity and specificity are two metrics that are employed to ascertain the validity of results 
yielded by a screening test. Sensitivity is typically defined as the ability of a screening test to 
correctly identify true positives, whilst specificity is typically defined as the ability of the assay 
to correctly identify true negatives to a reference standard (Trevethan, 2017). Here, the 
sensitivity and specificity of the mBRRoK assay was determined to provide a rational approach 
in defining the thresholds of the bioluminescence signal that will be used as cut off points later 
in other drug discovery libraries. Sensitivity in the context of this study is defined as a measure 
of the correct identification of a fast rate of kill compound, whilst specificity is a measure of 
the correct elimination of slow compounds.  
The objective here is to define the thresholds of normalized bioluminescence signal after 
exposure to 2 µM and 10µM to enable a plot of box on the mBRRoK graph within which 
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candidates that are considered likely to have a rapid rate of kill will occupy. To complete this 
task the following approach was undertaken; 
1. Using the mean normalized bioluminescence signal at either 2 µM or 10µM, thresholds 
were applied at 10 to 50% at 10% increments. These then defined lists of MMV Malaria 
Box compounds and four benchmark controls that fell on either side of these thresholds. 
Those below the increment threshold were regarded as an mBRRoK prediction as a fast 
acting compound. 
2. Two definitions of the true fast rate of kill compounds were used here to explore 
differences between a high threshold of discovery and a low threshold of discovery. The 
first high threshold criteria is based on the PC1 value for chloroquine (PC1 of -73.7). 
This threshold establishes whether the mBRRoK assay correctly defines a compound 
activity as falling in the TCP1 criteria- i.e. at least as fast as chloroquine. A second, 
lower threshold is based on a PC1 value of -47. This PC1 value encompasses the initial 
rate of kill data for the quinoline drugs (mefloquine, amodiaquine and quinine) included 
in the selected benchmarks and shown to not be clearly resolved from CQ in the initial 
mBRRoK analysis. Of note, is that all of these quinoline drugs are judged as having a 
rapid rate of kill using the 48 hours invasion assay of Linares et al., (2015).  
3. Using the two lists of compounds provided for each 10% increment for both the 2 µM 
or 10µM concentrations, these lists of compounds were then compared against the 
BRRoK PC1 values (high and low threshold). Using these data, the following approach 
was used to determine sensitivity and specificity when compounds were assorted into 
one of four cells; 
 True positive – below the bioluminescence threshold and with PC1 data lower than 
the high (<-73.7) or low (<-43) PC1 threshold 
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 False positive - below the bioluminescence threshold and with PC1 data greater than 
the high (<-73.7) or low (<-43) PC1 threshold 
 True negative - above the bioluminescence threshold and with PC1 data greater than 
the high (<-73.7) or low (<-43) PC1 threshold 
 False negative - above the bioluminescence threshold and with PC1 data lower than 
the high (<-73.7) or low (<-43) PC1 threshold 
The following formulae were used; Sensitivity = [NTP/(NTP + NFN)] *100 and Specificity = 
[NTN/ (NTN + NFP)] *100. The effect of where the cut-off for the normalized bioluminescence 
signals in determining the sensitivity and specificity of the mBRRoK assay are plotted in Figure 
3.7. Figures 3.7A and B use the higher threshold of PC1<-73.7 to define a true fast acting 
compound (with A using the 2µM and B the 10µM bioluminescent data), Figures 3.7C and D 
use the lower threshold of PC1<-47 to define a true fast compound. All graphs report that as 
the remaining bioluminescence signal after 6hr of action is increased, the assay is more likely 
to correctly identify fast acting compounds (increase in sensitivity, filled circles and dotted line) 
but is also likely to include more compounds that are not fast (false positives)and thus the 
specificity of the assay falls (open circles). This is the same whichever threshold of determining 
a true positive is used as well as the concentration of the compound being tested.  
To take the assessment of the mBRRoK assay forward, the bioluminescence signal at which the 
specificity and sensitivity intersected on Figures 3.7A to D were taken to define the regions of 
interest on the mBRRoK graphs (Figure 3.7E). The rationale being that these intercepts reflect 
the position where each quality is optimum compared to the other. Thus, a 20x25 box was 
defined as capturing the mBRRoK fast acting hits based on the higher (chloroquine or better) 
threshold and a 25x45 box defines the mBRRoK fast acting hits based on the low (quinoline or 
better) threshold. Table 3.3 reports the numbers of compounds each box contains, as well as the 
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sensitivity and specificity of those criteria based on the BRRoK PC1 data. In addition, a True 
Discovery Rate was determined (TDR=[NTP/(NTP+NTN)]*100) 
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 Figure 3.7: Exploring the sensitivity and specificity of mBRRoK assay. 
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Using increments of 10% of the normalized bioluminescent signal after exposure to 2µM (A 
and C) and 10µM (B and D) of the 100 MMV Malaria Box compounds and four antimalarial 
benchmark drugs, the sensitivity and specificity of the mBRRoK assay under those conditions 
were plotted. The threshold for a true hit used two definitions; a high threshold based on the 
compounds being at least as fast a CQ in the BRRoK assay (A and B) or a low threshold where 
compounds were at least as fast as the quinolone class of drugs (C and D). Using these 
parameters, boxes that identify regions of interest on a mBRRoK graph (this is an adapted 
version of Figure 3.3) based on these two thresholds. The numbers of compounds identified, 
specificity, sensitivity and true discovery rate for each box is shown in Table 3.3 
 
Table 3.3: mBRRoK assay parameters at high and low threshold cut-offs 
 
 
a, out of 104 compounds; b, see Figure 3.7E 
Therefore, as the “hits” box on the mBRRoK graph is made larger, more compounds are 
identified as potentially being fast acting. The analysis presented in Table 3.3, which uses the 
in vitro rate of kill for CQ or better as the definition of a true hit, suggests that the inclusion of 
the additional hits as the “hits” box gets larger does capture fast-acting compounds and so the 
sensitivity (ability to identify true hits) increases. However, the trade-off is that many of the 
additional compounds are not true hits, thus, the true discovery rate falls off and the specificity 
(ability to discriminate true negatives) declines. 
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3.2.4. Exploring the performance of mBRRoK in a NF54luc transgenic line  
To date, all BRRoK and mBRRoK data were derived using the Dd2luc transgenic line. Another 
PhD student in the Horrocks laboratory has introduced the same luciferase expression cassette 
used in Dd2luc into the NF54 parasite line (Hmoud, 2019 PhD thesis). The pcna 5’ untranslated 
region (UTR)-luciferase-pcna 3’UTR cassette is present in NF54luc as an episomal plasmid, 
using WR99210 antifolate as a selection drug. Of note is that NF54luc is a Chloroquine sensitive 
(CQS) strain yet has the same trophozoite-specific expression of the luciferase reporter as does 
the CQR Dd2luc line. NF54luc was made available to this study to enable a comparison of the 
mBRRoK assay performance in a second genetically-distinct line.  Ullah et al., (2017) have 
previously shown a concentration dependent loss of bioluminescence signal following exposure 
of Dd2luc parasite clone to fold EC50 concentrations of benchmark antimalarials (see figure 3.1). 
To extend this observation to NF54luc (CQS), EC50 data were developed for four benchmark 
antimalarial drugs (dihydroartemisinin, chloroquine, mefloquine and atovaquone) by using 48 
hours MSF assay described in section 2.4. The EC50 values were determined from log dose-
response curves (Figure 3.8). Subsequently, the relative initial cytocidal effect of the four 
antimalarial drugs were determined using BRRoK assay developed by Ullah et al., (2017). 
Here, NF54luc parasites were exposed to a 3-fold serial dilution of 9xEC50 to 0.33xEC50 
concentration series for 6 hours. The mean ± stdev bioluminescence signal was normalized to 
an untreated control and plotted against drug concentrations (Figure 3.9). Comparison of the 
data indicates the expected relative ranking order of dihydroartemisinin > chloroquine > 
mefloquine > atovaquone and agrees with the relative order of rate of kill described for the 
same drugs in vivo and in vitro (White et al., (1997; Pukrittayakamee et al., 2000; Bahamontes-
Rosa et al., 2012; Sanz et al., 2012; Le Manach et al., 2013; Linares et al., 2015; Ullah et al., 
2017). 
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Figure 3.8: Exemplars of log concentration- response curves for the benchmark 
antimalarials, chloroquine and mefloquine against NF54luc parasite clones. 
Each data point represents the mean with standard deviation (from three biological repeats, 
n=9) indicated by error bars. 
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Figure 3.9: BRRoK assay of benchmark antimalarials in NF54luc. 
The mean bioluminescence signal (normalized against an untreated control) remaining after a 
6 hours exposure of P. falciparum NF54luc to the indicated fold-EC50 of each drug is plotted. 
Error bars represent mean ± SDs from three biological replicates. ATQ, atovaquone; CQ, 
chloroquine; DHA, dihydroartemisinin; MQ, mefloquine. 
 
Moving forward, the performance of mBRRoK assay against NF54luc parasite line was 
undertaken. For this comparison, 66 of the 100 compounds from the MMV Malaria Box has 
sufficient materials remaining for this analysis. NF54luc was exposed to two fixed 
concentrations (10µM and 2µM) of the test compounds for 6 hours. The mean and stdev of the 
normalized bioluminescent signals (n=6, technical duplicates and three biological repeats) are 
recorded in appendix 2. The percentage normalised bioluminescence signal at 10µM and 2µM 
concentrations were plotted to produce the standard mBRRoK plot (Figure 3.10A). Here the 66 
MMV Malaria Box compounds (grey circles) with the rate of kill colour-coded antimalarial 
benchmarks are shown. As for Dd2luc, the antimalarial benchmarks are projected into the 
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expected space based on their rate of kill. Interestingly, CQ, in this CQS strain achieves the 
necessary fold EC50 at 10µM and 2µM to move further down to the left and separates from the 
moderate rate of kill aryl alcohols of QN and MQ. Removing the antimalarial benchmarks, and 
colour-coding the MMV Malaria Box compounds for a rate of kill classification based on their 
Dd2luc BRRoK data (PC1 values) allows us to produce Figure 3.10B. Critically, the key features 
of this chart relating to the relative position of fast and slow acting compounds holds. What is 
evident, however, is that there are a number of fast acting compounds, predicted in this 
mBRRoK assay to be slow, and this issue will be picked up in the discussion.  
As expected, there were significant correlation between the screening data for the two parasite 
strains at 10µM (figure 3.10C) and 2µM (figure 3.10D) concentrations. The 10µM data reflect 
a greater discriminating power at excluding the slow-acting compounds. Furthermore, using the 
most stringent sensitivity and specificity threshold of 20% x 25% bioluminescence cut off, 
compounds were divided into four groups (see figure 3.7 for details). A total of 35 compounds 
(more than half) were identified to have initial RoK at least as fast as chloroquine in Dd2luc and 
NF54luc with 31 compounds common to both parasite strains (see appendix 2 for details). This 
results shows that the initial RoK for the MMV Malaria Box compounds appears to be similar 
for the two parasite strains. This concept will be explained further in chapter 5 of this thesis.
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Figure 3.10: Exploring the performance mBRRoK assay in NF54luc parasite line. 
(A) Represent mBRRoK graph for mean (n=6) normalized bioluminescence signal at 10µM and 
2µM for 66 MMV Malaria Box compounds (grey filled circles) against the NF54luc parasite 
clone. Benchmark antimalarial drugs are shown using a key based on their relative in vitro rate 
of kill (see table 3.2 and figure 3.3B). (B) Replotting the mBRRoK graph from (A) with class of 
rate of kill for each MMV Malaria Box compounds reported on the graph (note that the 
benchmark antimalarial drugs have been removed from the plot). Linear regression analyses 
for correlating the mean normalized bioluminescence signal at 10µM (C) and 2µM (D) of 
mBRRoK Dd2luc data against NF54luc data for the 66 MMV Malaria Box compounds tested 
against NF54luc parasite line. 
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3.3 Discussion 
A rapid in vitro screening assay to quickly triage the thousands of antimalarial hits for fast-
acting chemo-types offers an opportunity to triage compound libraries based on both their 
potent and rate of initial cytocidal action. One such assay is the BRRoK assay developed by 
Ullah et al., (2017). The assay can determine the initial cytocidal effect of antimalarial 
compounds after six hours of parasites exposure. One major drawback that limits the scaling of 
the assay for high throughput screening is the need to know the EC50 values of the test 
compounds (48 hours MSF assays) before commencing with the determination of the speed of 
action. To enable scale-up, a modified BRRoK assay that utilizes two fixed concentrations was 
developed here to meet this challenge. The mBRRoK assay explores a compound’s RoK and 
potency together in a format that is much more amenable to a high throughput screening of large 
compound libraries. The principle is that loss of bioluminescence signal following parasites 
exposure to the test compound will be proportional to the rate of kill (greater in fast acting 
compounds) and potency (indicated as reaching at least 10x EC50 in either of the fixed 
concentration).  
An initial proof of concept of this simpler approach was demonstrated by exposing the parasites 
to two fixed concentration of the eight benchmarks antimalarial with available EC50 and RoK 
data. The mBRRoK assay described here was able to rank the drugs’ initial rate of kill in the 
order of endoperoxides > quinolines > naphthoquinone/antibiotics as expected (see Figure 3.3 
B). These findings are in agreement with what has been reported in the literature about the in 
vitro cytocidal action of these antimalarial drugs (Sanz et al., 2012; Ullah et al., 2017; Ullah et 
al., 2019). Interestingly, analysis of this first set of data suggested that bioluminescence signal 
loss for quinine and mefloquine were greater than that of chloroquine at 2µM. This illustrates 
that the mBRRoK assay considers RoK and potency together in the loss of bioluminescence 
(whereas BRRoK compensates for the potency by using equi-potent EC50 concentrations). This 
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suggests that sufficient EC50 folds for the optimum rate of kill for chloroquine (EC50 c. 200nM) 
were not achieved at 2 µM as against that of mefloquine (EC50 of c. 40nM) and this represents 
a limitation in the mBRRoK when attempting to estimate a RoK for a low potency compound. 
Also of note is that whereas Linares et al., (2015) could not differentiate between two fast-
acting compounds (artemisinin and chloroquine) in their flow cytometry based assay, 
mBRRoK, like BRRoK, assay could demonstrate a difference  between these two important 
benchmark drugs. Also, it was shown that whilst doxycycline and atovaquone have a vast 
difference in X EC50 achieved for each drug using the fixed concentrations as atovaquone is 
some 500X more potent than doxycycline, both, as expected have a negligible immediate 
cytocidal effect. Both drugs have lag times and are not initially cytocidal. Ullah et al., (2017) 
observed similar killing profile for atovaquone in which 6 hours window of parasites exposure 
to the drug did not affect loss in bioluminescence signal. Though multiples of EC50 folds 
concentration was achieved for atovaquone, the temporal peak luciferase expression at 
trophozoites stage in Dd2luc parasites (Wong et al., 2011; Hasenkamp et al., 2013), limit the 
possibility of extending the assay readout time. Although, Sanz et al., (2012) in vitro PRR assay 
demonstrated that atovaquone was able to reach its optimum killing rate at a concentration 
corresponding to x10 EC50, however, this was only after 90 hours of exposure. The lag time 
observed with doxycycline likely reflect that the drug is an antibiotic, likely targeting apicoplast 
function, and is used as prophylactic rather than for treatment of an infection. A similar very 
slow killing rate profile was reported for azithromycin (another antibiotic drug used as a malaria 
prophylactic drug) by Linares et al., (2015). 
To further establish this concept, the loss of  bioluminescence signal at 10µM and 2µM 
(modified BRRoK assay) indicated a strong correlation with PC1 values (Ullah et al., 2017) for 
the benchmark antimalarial (Figure3.3 C and D), although there do appear to be some 
limitations in the discrimination between the quinolines; chloroquine, mefloquine and quinine. 
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Overall, this simpler assay appears to work well in discriminating and ranking the benchmark 
antimalarials but provides data distinct to the standard BRRoK or in vitro PRR assays as the 
effect of potency also affects the loss of bioluminescence signal. That said, this modified 
BRRoK assay takes only 6 hours and performed as well as that of Linares et al., (2015) which 
also did not discriminate between quinolines but required 2-4 days to complete. This initial 
proof of concept indicates that the hypothesis of loss of bioluminescence signal directly 
correlates with potency and RoK for the fast-acting antimalarial. The modified BRRoK assay 
based on two fixed concentration is a simpler way to quickly identify the fast-acting compounds 
(TCP1 candidates) based on their initial rate of kill. 
To access the performance of mBRRoK with reference to the standard BRRoK assay, the 
percentage normalized bioluminescence signal at 10µM (A) and 2µM (B) were compared with 
the PC1 (BRRoK) data (Figure 3.6). There was a significant correlation between the two 
parameters, however, this correlation was less than that of benchmark antimalarials reported in 
Figure 3.3. The difference might be due to two reasons. First, the benchmark antimalarial are 
all potent, having EC50 values less than 250nM (except for doxycycline that has an EC50 of 
3µM) and will therefore always be used at a concentration of close to, or greater than, 10x EC50 
at both concentrations tested  and therefore all likely be maximally active in vitro. In the 
BRRoK assays, issues with variations in EC50 are not apparent based on how the concentrations 
are equipotent. Secondly, the BRRoK PC1 values were based on four different concentrations 
of data, covering fold-EC50 concentrations range between 0.33 to 9 x EC50 for all matched 
compounds. This represents a wider range of data over more sampling points as opposed to 
10µM and 2µM data representing only two concentrations and different fold-EC50 for different 
compounds.  
In order to further explore the performance of the modified BRRoK assay in relation to the 
standard BRRoK assay, the PC1 values of the 100 MMV Malaria Box compounds were 
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explored. Compounds were ranked based on a rapid, moderate, slow criteria and then screen in 
mBRRoK and how these compounds distributed within the space specifically explored. 
Importantly, it was confirm that rapid compounds are typically found in the bottom left of the 
distribution. Of a note is that slow compounds almost exclusively are found in the top right and 
the moderate compounds have a wider distribution. Whilst simple to categorise the shift from 
bottom left to top right as just a measure of RoK (fast to slow), this is not straight forward as 
the impact of potency (and thus how many fold EC50 are achieved) will affect this. This is 
perhaps shown best when comparing the red (rapid) and green (slow) compounds. One of the 
16 slow compounds falls at the 50% boundary of the x and y axis, with the remainder all above 
and to the right. Whilst for some compounds, a 10 fold EC50 may not be achieved to reach its 
maximal RoK, the intrinsic RoK is slow anyway and will therefore always fall to the top right 
as minimal loss of bioluminescence is observed. About one third of the rapid (red compounds), 
however, do fall above the same 50%-50% axis split. Here, rapid compounds are likely seen, 
but also less potent compounds – where the mBRRoK output is  less than maximum kill against 
an intrinsic rapid RoK and thus a less than maximal loss of bioluminescence. 
To further explore the correlation between mBRRoK and BRRoK, the sensitivity (ability to 
correctly identify rapid acting compounds) and specificity (ability to disregard slow acting 
compounds) was employed. Two thresholds of “fast acting” were explored – defined as a PC1 
of chloroquine (-73.7) or less or a PC1 of a quinolone (i.e. < 43 based on the PC1 for 
mefloquine). Different mBRRoK parameters were tested and a final future selection criteria 
selected. This criteria defines a 20x25 box on the mBRRoK plot (high stringency box on Figure 
3.7E) that shows high sensitivity (75%) and specificity (82%) and a true discovery rate of 81%. 
Importantly, by reducing the complexity of the BRRoK assay to the mBRRoK assay for a high 
throughput screen, 81% of true fast acting RoK compounds can still be identified in a high 
throughput format. 
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To understand why some 20% were missed, it was considered whether these were likely 
compounds that whilst having a rapid RoK, they were also less potent. Using the same low and 
high threshold parameters from Figure 3.7, compounds were designated to fall either inside (in) 
or outside (out) of the hits box. As expected, and irrespective of the stringency of the threshold 
to define rapid kill, the PC1 of hits inside the box were significantly lower than of those outside 
(Figure 3.11 A and C). The PC1 of compounds outside of the box extend to the full range of 
PC1. Using an hypothesis that compounds that were designated rapid in BRRoK, and not 
discovered in the mBRRoK (red boxes on chart) may not be identified as rapid in mBRRoK as 
they are less potent and therefore do not achieve the fold EC50 to effect the maximal kill effect. 
Interestingly, exploring this with either the low or high threshold for defining rapid action in 
the BRRoK assay, there were no significant differences (ANOVA with Dunnets post-test, all 
p>0.05) between the EC50 of the different groups of compounds (Figure 3.11 B and D).    
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Figure 3.11: Box and whiskers plots showing the distribution of MMV Malaria Box  
Compounds predicted to have chloroquine-like (high threshold) and quinoline-like activities 
(low threshold).The plots A and C show the distribution of PC1 data from BRRoK assay (Ullah 
et al., 2017), using the parameters of mBRRoK assay.   B and D show the comparison of EC50 
values for compounds with chloroquine-like and quinoline-like activities, respectively. Data 
shown in B and D are from compounds marked in the same coloured boxes in A and C, 
respectively – thus a comparison on the relative potency of compounds grouped by their rate 
of kill is shown. 
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Ullah et al., (2019) showed that relative RoK for the MMV Malaria Box compounds provided 
a link to their antimalarial mode of action and information on their core scaffolds. To explore 
how compounds with a shared MoA and structure appear on an mBRRoK plot clusters were 
plotted (Figure 3.12). Predicted MoA for 36 compounds are available across four MoA with 
the known following rank of RoK; PfATP4 > haemoglobin catabolism >DHODH > bc1 (Figure 
3.12A). These clusters fall as anticipated from how we are starting to understand RoK on the 
mBRRoK plot. Importantly the majority of the fast PfATP4 compounds are towards the bottom 
left and the slow DHODH/bc1 targeting molecules are exclusively towards the top right.  
Compounds that share related core scaffold were also clustered based on their mBRRoK data 
(Figure 3.12B). A ranking order of initial RoK for these scaffols has been reported (Ullah et al., 
2019) with iso-Quinolines > Diamino-Glycerol = 2-Phenoxy-Benzylamine > triazolo-
pyrimidine, with the mBRRoK plot recapitulating this known order. The details of the selected 
MMV Malaria Box compounds with their predicted mode of action and core scaffolds are 
reported in appendix 1 of this thesis. 
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Figure 3.12: Correlating mode of action of MMV Malaria Box compounds with mBRRoK 
six hours data. 
(A) Represent normalized bioluminescence signal at 10µM and 2µM for MMV compounds that 
target bc1 complex, DHODH, parasite haemoglobin catabolism and PfATP4. Whilst (B) 
indicates normalised bioluminescence signal at 10µM and 2µM for MMV compounds clustered 
based on their related core scaffolds for Triazolo-Pyrimidine, 2-Phenoxy-Benzylamine, 
Diamino-Glycerol and iso-Quinoline. 
 
Given that the above comparison between BRRoK and mBRRoK assay were done only in 
Dd2luc parasite line, understanding the relationship between intrinsic RoK and MoA in another 
genetically distinct parasite clone was highly desirable. Against this backdrop, MMV 
compounds predicted by mBRRoK assay to be rapid acting for Dd2luc (chloroquine-resistant) 
and NF54luc (chloroquine-sensitive) parasite line were structurally examined to explore 
similarities in RoK based on related core scaffolds. Compounds sharing five core scaffolds were 
identified to have similar initial rapid RoK in both parasite lines. Three compounds from 
Diamino-Glycerol scaffold, two iso-Quinolines, two 2-Phenoxy-Benzylamine, two acridines 
and two quinoxaline (Figure 3.13 for their structures and MMV identifiers)  showed similar 
rapid intrinsic RoK in both parasite lines (Figure 3.14).  
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Figure 3.13: Chemical structures of MMV compounds clusters with related 
initial rapid RoK in Dd2luc and NF54luc parasite lines 
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Figure 3.14: mBRRoK plots illustrating structural related compounds in the Malaria Box 
that share a similar rapid rate of kill in Dd2luc and NF54luc parasite lines. 
(A) Represents Dd2luc, whilst (B) represents NF54luc parasites lines. The key provides 
information on the core scaffolds reported in Figure 3.13. 
 
Interestingly, three compounds from Diamino-Glycerol group were reported by Allman et al., 
(2016) and Ullah et al., (2019) as PfATP4 inhibitors as was one (MMV008455) of the iso-
Quinolines. The second iso-Quinolines was reported by Allman et al., (2016) and Ullah et al., 
(2019) to target parasite haemoglobin catabolism. Also, the two 2-Phenoxy-Benzylamine were 
reported by Allman et al., 2016 and Ullah et al., (2019) as targeting haemoglobin inhibitors. 
Mode of actions are yet to be assigned to the remaining compounds. 
Moving forward, understanding how compounds move across the mBRRoK plot in the two 
parasite strains could provide an insight to potential strain variations – such as the differences 
in drug resistance between these two strains (Hasenkamp et al., 2013). A question here is 
whether compounds that are moving in similar directions in the different mBRRoK plots would 
have structural similarities related to the known drug resistance profilers. To understand this, 
changes (Δ) in percentage normalized bioluminescence signal at 10µM and 2µM was calculated 
for mBRRoK data of the two parasite strains. The data was plotted as scatter plot and overlaid 
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with chemical structures of some MMV Malaria Box compounds (Figure 3.15). Compounds 
indicated in green had a greater killing effect in NF54luc compared with Dd2luc parasite strains 
and they were not structurally related. Whilst, compounds indicted with blue colour has a 
reduced killing effect in NF54luc compared to Dd2luc. Of  note is that MMV000704 and 
MMV666079 (compounds 4 and 5 on Figure 3.15) are quinolines and may be perhaps expected 
to be more potent in NF54luc compared to Dd2luc as they would be able to achieve a greater fold 
EC50 at the tested concentrations. Unfortunately there was some two years between mBRRoK 
testing in NF54luc and Dd2luc and this may account more for any differences than their 
sensitivity to classes of compounds. This effect will be explored again later in this thesis with 
a more contemporary testing of these samples against each other. 
Taking these observations together, the mBRRoK assay is a simpler way of moving the standard 
BRRoK assay forward for scaling up for high throughput screening. Overall, the mBRRoK 
assay would appear to be best placed at the initial screening stage for an antimalarial drug 
discovery campaign to quickly triage compounds with fast cytocidal action and good to 
moderate potency. However, given some apparent limitations around the 81% true discovery 
rate and a need to better understand how the RoK and potency parameters operate, particularly 
outside of the “hit box”   would suggest a moving forward for further validation using an 
additional larger compound library resource for which there was no pre-existing data on their 
initial in vitro RoK action. 
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Figure 3.15: Plot for changes in percentage normalised bioluminescence signal of mBRRoK data for Dd2luc and NF54luc 
parasite stains 
Compounds indicated in figures 1 to 11 are MMV665864, MMV007654, MMV011436, MMV000704, MMV666079, MMV000634, 
MMV665906, MMV000648, MMV000481, MMV665807, MMV396663 respectively. 
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4 CHAPTER 4: The use of the modified BRRoK assay to screen the MMV 
Pathogen Box compound collection 
4.1 Introduction 
The landscape for drug discovery for Neglected Tropical Diseases has been continually 
changing over the last decade with a transition from traditional pharmaceutical industries, with 
their confidential practices, to a more open-access drug discovery process (Duffy et al., 2017). 
Open-access drug discovery has contributed immensely towards the identification and 
optimization of potential chemo-types that have biological activities against a range of 
Neglected Tropical Diseases (Maurer et al., 2004; DeLano, 2005; Munos, 2006; Gunther et al., 
2008; Singh, 2008; Orti et al., 2009; Mazanetz et al., 2012; Ardal and Rottingen., 2012; Davies 
et al., 2015; Reichman and Simpson, 2016). Drug discovery in malaria represents an exemplar 
of this open-access drug discovery approach (Wells et al., 2016; Lucantoni et al., 2013; 
Bowman et al., 2014; Duffy and Avery, 2013; Ruecker et al., 2014; and Hain et al., 2014) but 
has also impacted on other diseases such as tuberculosis (Bhardwaj et al., 2011 and Ballell et 
al., 2013), schistosomiasis (Todd and Coaker, 2015), toxoplasmosis (Boyom et al., 2014), 
cryptosporidiosis (Bessoff et al., 2014) and kinetoplastid diseases (Kaiser et al., 2015). Critical 
to this success was the development and release of open-access compound libraries such as the 
Malaria Box and Pathogen Box by the Medicine for Malaria Venture. These resources are 
distributed to researchers worldwide with the requirement that results generated from such 
libraries will be made publically available to the larger community (Wells et al., 2016). 
Ullah et al., (2017) were one of the over 200 research groups that received the Malaria Box 
(van Voorhis et al., 2016). 236 in vitro screens against different Plasmodium spp. strains as 
well as other cell/pathogen based systems have been reported for the Malaria Box with Meta- 
analyses of these data reported by van Voorhis et al, (2016). The results from these collaborated 
efforts have led to the setting up of some 30 new projects in which the compounds have shown 
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biological activity for diverse disease-causing organisms including cancers (Celik et al., 2015). 
Building on this great achievement of Malaria Box, the MMV has provided a second open-
access drug discovery compound set- termed the Pathogen Box (http://www.pathogenbox.org/). 
This new set comprises of 400 diverse, drug-like compounds that have biological activities 
against a number of Neglected Tropical Diseases (MMV, 2015). One-third of the compound 
set (33%) have activity in malaria screens, followed by tuberculosis with 30%, 18% have 
activity against kinetoplastid pathogens, helminths (8%), cryptosporidiosis (about 3%) and 
toxoplasmosis (about 4%). Dengue has the least number of compounds (about 1%) while about 
7% of the set are reference compounds – compounds that are or have been used in the treatment 
of one or more of these diseases (Figure 4.1) 
 
 
Figure 4.1:  Disease targets for the 400 compounds in the MMV Pathogen Box.  
The bar chest represents the number of compounds with activity demonstrated against the 
indicated disease (Source – www.pathogenbox.org) 
 
The MMV Pathogen Box compound set was triaged from the European Bioinformatics 
Institute’s open-access database (https://www.ebi.ac.uk/chembl/) in collaboration with 
specialists from other disease areas (MMV, 2015). Then, professionals from the medicinal 
chemistry formed a Scientific Selection Committee that reviewed the resulting compounds set. 
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At this point, fresh solid samples were sourced and their biological activity confirmed with 
cytotoxicity tests performed to demonstrate each was 5-fold less toxic against human cell line 
than the indicated pathogen (MMV, 2015). A summary of the selection process is illustrated in 
Figure 4.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Flow chart for the selection of compounds in the MMV Pathogen Box 
The schematic illustrates the major steps that were involved in the filtering process to 
generating the 400 compounds in the Pathogen Box library. (Source: www.mmv.org) 
 
The MMV Pathogen Box also comes with an excel spreadsheet that states the plate layout, 
details of the compounds such as structure, trivial names, salt form, and cLogP. The biological 
activities of the compounds were also included in this supporting information. Some screens 
have been performed on the Pathogen Box to provide the first new leads. The first was the 
identification of Tolfenpyrad (MMV688934), a pyrazole-5-carboxamide based insecticide that 
demonstrated activity against the helminth Barber’s pole worm (Preston et al., 2016). 30 major 
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publications (as at the time of writing up this thesis), from different research groups that have 
exploited the potential of this compounds set against diverse pathogens are available on the 
MMV website (https://www.mmv.org/newsroom/publications). 
The potential of the MMV Pathogen Box as an open-access drug discovery resource to catalyse 
the discovery of drugs against malaria and some neglected diseases have been demonstrated. I 
decided to screen the MMV Pathogen Box using the mBRRoK assay for two purposes; 
(1)To explore the performance of the mBRRoK assay against a larger compound set than had 
previously been tested, but also a compound set for which there was no available in vitro rate 
of kill data. 
(2)To support the utility of the Pathogen Box resource for antimalarial drug discovery by being 
able to provide initial in vitro data on their apparent initial cytocidal action with a view to 
identify those that offer potential as TCP1 candidates. 
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4.1 Results 
4.1.1 Scaling up of the modified-BRRoK assay to screen the MMV Pathogen Box for 
potent and fast-acting antimalarial chemo-types. 
The use of the validated mBRRoK assay to identify fast-acting cytocidal compounds in Dd2luc 
parasites was explored using the MMV Pathogen Box compounds set. P. falciparum Dd2luc 
cultures were exposed to fixed concentrations (10µM and 2µM) of the compound library in a 
96 micro well plate assay for 6 hours and then the residual bioluminescence signal measured 
and normalized to the mean of untreated controls as described in section 2.3. All experiments 
were carried out as technical duplicates with three independent biological replicates performed. 
The mean of n=6 samples was plotted to provide the characteristic mBRRoK plot described in 
the previous chapter (Figure 4.3). Nine benchmark antimalarial drugs: DHA, ART, CQ, AQ, 
PPQ, MQ, QN, ATQ and DOX (EC50 and RoK data available in Table 3.2) were included in 
the plot to act as signposts to mark the activity spaces of the compounds in these mBRRoK 
plots.  
Interestingly, the majority of compounds that appear to have the greatest effect at 10µM and 
2µM (bottom left) are compounds selected from screens for anti-plasmodial activity (Figure 
4.3A). For compounds with other disease indications, there appeared to be none that were as 
active at 10µM and 2µM. Two compounds included in the Pathogen box as reference 
compounds, did appear to have activity at both 10µM and 2µM. The first, mefloquine 
(MMV000016), was expected and its position relative to the mefloquine benchmark control 
included is indicated by two arrows in Figure 4.3B. The other reference compound identified 
was pentamidine (MMV000062). Known to be a potent compound in P. falciparum with EC50 
between 50-130nM (Bell et al., 1990), this is the first indication that its action is also likely to 
be rapid. The entire screening data for the 400 MMV Pathogen Box compounds using mBRRoK 
assay is reported in appendix 3 at the end of this thesis. 
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Figure 4.3: mBRRoK graph for 400 MMV Pathogen Box compounds 
Comparison of the mean normalized bioluminescence signal at 10µM and 2µM from mBRRoK 
assay data of 400 MMV Pathogen box compounds, the keys provides information of each 
disease set. The position of benchmark antimalarial is shown using a key based on their relative 
in vitro rate of kill (see Table 3.2 and Figure 3.3B). Each data point represents the mean (n=6).  
  
To rationally define cut off bioluminescence signals at 10µM and 2µM for the compounds of 
interest whose potency and RoK will be confirmed, the sensitivity and specificity criteria 
described for the Malaria Box compounds in section 3.2.2 were used to rank the compounds’ 
mBRRoK data into a chloroquine (CQ)-like and quinoline-like activity space (Figure 4.4). As 
indicated on the graphs in Figure 3.7E, the meeting points for sensitivity and specificity at 2µM 
and 10µM for chloroquine-like and quinoline-like are 20 by 25 and 25 by 45 respectively. These 
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were used to define boxes for the compounds of interest to be taken forward for potency and 
RoK confirmation. The fast-acting (chloroquine CQ-like) and moderate-acting (quinoline-like) 
are located in the lower left quadrant. These identify 21 and 36 compounds, respectively. 
 
 
Figure 4.4: Prioritising MMV Pathogen Box Compounds from an mBRRoK plot. 
The same mBRRoK plot as Figure 4.3 is shown here, although with variations in the axes to 
highlight the area with greatest loss of bioluminescence signal. Benchmark antimalarial are 
shown in Red and the compounds selected from a malaria screen in blue (as per Figure 4.3). 
Remaining compounds based on disease dataset or reference compounds are all shown in grey. 
Each data point represents the mean (n=6).  
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4.1.2 Confirmation of potency (EC50) and Rate of kill (RoK) of the identified hits from 
MMV Pathogen Box compounds. 
A total of 36 compounds that exert an initial rapid relative rate of kill comparable to quinolines 
(Figure 4.4) were identified for follow up 50% effective concentration (EC50) prior to a BRRoK 
evaluation to confirm a rapid rate of kill independent of the potency of the compound. For these, 
sufficient material from the MMV Pathogen Box provided was available to determine the 
EC50/BRRoK data for ten compounds. Figure 4.5 illustrates how these compounds (shown in 
blue) are positioned compared to the benchmark antimalarials. For comparison, four 
compounds that collocate with the known slow benchmark antimalarials, atovaquone and 
doxycycline (shown in black filled circles on Figure 4.5) were also selected for analysis. 
Using a 48 hours MSF assay described in section 2.4, EC50 data were first developed in Dd2
luc 
parasite line for these compounds (Figure 4.6A). Using this data, BRRoK assays were then 
done using the standard 6 hours experiment (Ullah et al., 2017; Ullah et al., 2019) and their 
plots shown next to their respective concentration-response curve (Figure 4.6B, shown over 
two pages). Table 4.1 reports the MMV identification number, disease targets, EC50 values and 
initial rate of kill of the identified hits (relative to established benchmarks included in the assay). 
Of the ten mBRRoK “hits”, nine were derived from anti-plasmodial screens and one 
(MMV637229) in a trichuriasis screen (https://www.mmv.org/mmv-open/pathogen-
box/pathogen-box-supporting-information). Two of the four predicted slow compounds 
(MMV020537 and MMV024397) were derived from anti-plasmodial screens, with one from a 
kinetoplastid screen (MMV659004) and the last a reference compound (MMV021057- 
Azoxystrobin). 
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Figure 4.5: mBRRoK plot showing selection of MMV Pathogen Box Compounds for follow 
up studies. 
The same mBRRoK plot as Figure 4.4 is shown here, although with variations in the axes to 
highlight the area with greatest loss of bioluminescence signal. Benchmark antimalarial are 
shown in Red and the compounds selected based on predictions they are rapid and potent (i.e. 
“hits “are shown blue with Black identifying compounds predicted to be slow based on their 
colocation with doxycycline and atovaquone.   
 
As expected, all the ten “hit” compounds are potent to moderately potent with EC50 values 
ranging from 48.3nM to 883.7nM (these potency results are in agreement with data from MMV 
Pathogen_Box_Activity_Biological_Data_Smiles at https://www.pathogenbox.org/about-
pathogen-box/composition). From the BRRoK assays, six would likely be compounds of 
interest to meet TCP1 criteria based on their curves position compared to chloroquine or better, 
with the remaining four all within the mefloquine (quinoline –like) control.  
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Figure 4.6: Concentration-response curves and BRROK charts of the MMV Pathogen 
mBRRoK hits (previous two pages). 
Log10 concentration-normalised response graphs (48 hours MSF assay) (A) and standard 
BRRoK (6 hours) fold EC50-normalized response (B) graphs for the indicated compounds 
selected from the MMV Pathogen Box. On A, the curve represents the non-linear regression 
(mean ±stdev n=9) used to estimate the EC50 reported. For B, the BRRoK response for the 
indicated compound is shown using a black line) with the same data reported for four 
benchmark antimalarials (DHA, dihydroartemisinin; CQ, chloroquine; MQ, mefloquine and 
ATQ, atovaquone) shown in gray for comparison. 
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Table 4.1: List of Pathogen Box compounds predicted to be potent and rapid in cytocidal 
action 
 
MMV ID 
 
Indicated 
disease set 
 
EC50(nM) (95% 
Confidence interval) 
 
Relative initial rate of 
kill 
MMV020391 Malaria 883.7 (758.8-916.0) Chloroquine-like 
MMV000858 Malaria 511.3 (483.4-540.8) Chloroquine-like 
MMV006239 Malaria 569.3 (554.3-584.7) Chloroquine-like 
MMV022029 Malaria 622.5 (562.2-689.2) Chloroquine-like 
MMV001059 Malaria 672.3 (527.5-857.0) Chloroquine-like 
MMV634140 Malaria 184 (89.6-377.8) Chloroquine-like 
MMV023183 Malaria 620.9 (560.1-688.2) Mefloquine-like 
MMV020136 Malaria 711.7 (662.0-765.2) Mefloquine-like 
MMV020081 Malaria 48.3 (41.9-55.7) Mefloquine-like 
MMV637229 Trichuriasis 561.2 (467.4-673.9) Mefloquine-like 
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The potency and relative rate of kill of four compounds predicted to be less potent and/or slow-
acting were similarly confirmed using a MSF 48 hours assay and BRRoK assay (Figure 4.7 A 
and B, respectively). The concentration-response curves report that three of the compounds 
(MMV021057, MMV659004 and MMV024397) are within the minimal threshold for potency 
(EC50 below 1µM) but display an initial killing rate comparable to atovaquone. MMV0210537 
appears to be both slow acting and with a low potency.   
Together, these findings provide proof of concept that the mBRRoK assay can be employed 
with a compound set for which no information about their initial cytocidal action is known and 
(i) identify “hits” that show good to moderate potency and initial cytocidal activity as well as 
(ii) apparently exclude slow-acting compounds irrespective of their potency. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Concentration-response curves and BRROK charts of the MMV Pathogen 
mBRRoK compounds that are not identified as hits (following page). 
Log10 concentration-normalised response graphs (A) and standard BRRoK fold EC50-
normalized response (B) graphs for the indicated compounds selected from the MMV Pathogen 
Box. On A, the curve represents the non-linear regression (mean ±stdev n=9) used to estimate 
the EC50 reported. For B, the BRROK response for the indicated compound is shown using a 
black line) with the same data reported for four benchmark antimalarials (DHA, 
dihydroartemisinin; CQ, chloroquine; MQ, mefloquine and ATQ, atovaquone) shown in gray 
for comparison. 
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4.2  Discussion 
The MMV Pathogen Box is a set of 400 structurally diverse compounds that have been 
identified from a number of screens against pathogenic organisms. Of these 400 compounds, 
125 have been identified on the basis of their inhibitory effect on the proliferation of intra 
erythrocytic P.falciparum. Here, this compound library offered the opportunity to evaluate the 
ability of the mBRRoK assay to be used in a fixed-concentration screen to identify potent and 
rapidly acting compounds in a compound library that has not been evaluated for their rate of 
kill activity. The ease of use of mBRRoK assay without the prior determination of EC50 values 
underlines the opportunity for a quick and simple screening tool for antimalarial drug discovery. 
Screening of the MMV Pathogen Box compounds identified 21 compounds to fall within the 
“hit” box defined for this assay in Chapter 3. Figures 4.8 and 4.9 report their structures. 
Analysis of the biophysical properties of these 21 best compounds show there was no 
correlations seen across a range of biophysical properties when compared to compounds that 
were not hits. These key biophysical properties included molecular weight (MW), lipophilicity 
of ionized form (logD), lipophilicity of neutral form (logP), polar surface area (PSA), the 
number of rotatable bonds (RB), and the number of hydrogen bond acceptors (HBA) or donors 
(HBD), basic and acidic pKa. Whilst this may be due to the relatively small number of 
compounds in each disease set, it is apparent that no simple biophysical feature accounts for 
the selection of the predicted 21 Pathogen Box hits.  
Comparing these hits against their predicted mechanism of actions offers an opportunity to 
integrate this mBRRoK data with additional datasets generated by others also investigating the 
Pathogen Box compounds. One such study on the Pathogen Box compounds is a study for 
compounds that disrupt malaria parasite ion and volume homeostasis by Dennis et al., (2018). 
The study identified eleven Pathogen Box compounds that apparently exert their effect through 
direct interaction with PfATP4 protein. This led to the alteration of Na+ export/H+ import 
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function, thereby causing an increase in Na+ influx and cytosolic pH. Of the eleven compounds 
identified by Dennis et al., (2018) as PfATP4 inhibitors, ten (Figure 4.8) were identified as 
“hits” in the mBRRoK assay here. Of note is MMV006239 which shares a structure with the 
spiroindolones KAE609 (cipargamin) and NITD246 which have both been validated as PfATP4 
inhibitors (Rottmann et al., 2010, Spillman and Kirk, 2015). Also of note is MMV085210, the 
only predicted PfATP4 in the Pathogen Box not identified in this screen – with this compound 
being the least potent of the 11 as well as affecting the least change in  Na+ influx in the Dennis 
et al., (2018) study. Of the ten PfATP4 “hits”, six were subsequently investigated using the 
BRRoK assay and had a rapid RoK confirmed independent of their potency (Figure 4.10). Also 
of note is that the potency of these six compounds is similar to that reported in Dennis et al. 
(2018) where they report a range of 110-720nM compares to 48-883nM in this study. 
 
Figure 4.8: Structures and MMV identifiers for MMV Pathogen Box “hit” compounds that 
have predicted action against PfATP4 
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Figure 4.9: Structures and MMV identifiers for MMV Pathogen Box “hit” compounds  
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Table 4.2: Summary of 21 best compounds  from the  MMV Pathogen Box  
 
NA: not available 
 
 
MMV ID Disease set 10µM 2µM Predicted MoA
MMV020391 Malaria 3 5 PfATP4
MMV000858 Malaria 3 6 PfATP4
MMV020136 Malaria 4 5 PfATP4
MMV001059 Malaria 6 9 PfATP4
MMV006239 Malaria 3 6 PfATP4
MMV020081 Malaria 5 6 PfATP4
MMV020623 Malaria 4 8 PfATP4
MMV020710 Malaria 2 3 PfATP4
MMV020520 Malaria 3 4 PfATP4
MMV688980 Malaria 3 8 PfATP4
MMV085071 Malaria 7 7 Digestive vacoule
MMV676380 Malaria 0 4 Digestive vacoule
MMV634140 Malaria 7 7 PfeEF2
MMV667494 Malaria 3 5 PfeEF2
MMV000062 Ref compound 11 13 NA
MMV000016 Ref compound 20 24 Haemozoin synthesis
MMV022029 Malaria 5 22 NA
MMV016136 Malaria 12 21 NA
MMV676442 Malaria 16 18 NA
MMV019721 Malaria 13 15 NA
MMV019993 Malaria 3 7 NA
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Figure 4.10: BRRoK chart of the MMV Pathogen mBRRoK “hits” identified as PfATP4 
inhibitors.  
Standard BRRoK fold EC50-normalized response graphs from Figure 4.6 selecting six 
compounds identified in Dennis et al., (2018) as PfATP4 inhibitors. The BRRoK response 
curves for the PfATP4 inhibitors are shown in red with the same data reported for four 
benchmark antimalarials (DHA, dihydroartemisinin; CQ, chloroquine; MQ, mefloquine and 
ATQ, atovaquone) shown in grey for comparison. 
From Figure 4.9, MMV085071 and MMV676380, whilst structurally unrelated, were reported 
by Tong et al., (2018) as two of three hits in a screen for compounds that permeabilize the 
parasite’s digestive vacuole (DV). The screen was prompted by the work of Ch’Ng et al., (2011) 
who showed that exposure to the sub-micromolar concentration of chloroquine permeabilized 
the DV and led to an efflux of calcium ions that precedes mitochondrial outer membrane 
potential (MOMP) collapse and then DNA degradation. Interestingly, of the ten compounds 
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identified in the Pathogen Box that cause calcium efflux from the DV, MOMP and DNA 
damage, only three did not also inhibit β-haematin formation (which CQ does), with 
MMV085071 and MMV676380 as two of these three compounds. Whilst these compounds 
were not tested in BRRoK here, Tong et al., (2018) reported a rapid in vitro killing rate for 
MMV085071 and moderate to fast cytocidal action for MMV676380 – coincident to the >90% 
loss of bioluminescence even at 2µM shown here.  
MMV634140 and MMV667494 share a structural similarity  to DDD107498, a compound 
originally reported by Baragana et al., (2015) as a novel multi-stage inhibitor of protein 
synthesis through targeting the P. falciparum translation elongation factor 2 (PfeEF2; Jackson 
et al., 2011). MMV634140 was confirmed in this study to have a rapid initial cytocidal action, 
comparable to DHA, as well as a good potency at 184nM (Figure 4.6). These compounds 
potentially represent a new characterisation of the RoK for another target, protein translation, 
which elicits a rapid rate of kill. 
Compound MMV000062 and MMV000016 are reference compounds pentamidine and 
mefloquine, respectively. Pentamidine is used for the treatment of the hemolymphatic stage of 
Human African Trypanosomiasis (HAT) as well as leishmaniasis (Werbovetz, 2006; Kaiser et 
al., 2011). Pentamidine has previously been reported to show activity against P. falciparum, 
but suffers from the setback of not being orally bioavailable as well as serious side effects such 
as renal toxicity and cardiotoxicity (Feddersen and Sack, 1991; Bray et al., 2003; Antoniou and 
Gough, 2005). Duffy et al., (2017) reported an EC50 of 0.01µM for pentamidine against the 
intra erythrocytic stage of 3D7 Plasmodium strain. The rapid killing rate displayed by this drug 
in the 6 hours mBRRoK assay likely resulted from the multiples of fold-EC50 concentrations 
achieved at the two fixed concentrations (1000 x EC50 folds at 10µM and 200 x EC50 folds at 
2µM). MMV000016, mefloquine, a blood schizonticide with some neurological side effects in 
some patients (Nevin and Byrd, 2016). As expected from the use of this compound as a 
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benchmark compound, mefloquine showed a high loss of bioluminescence in the mBRRoK 
assay, a reflection of its previously reported in vitro pharmacodynamics killing rate (Sanz et 
al., 2012; Linares et al., 2015; Ullah et al., 2017) as well as its high potency (Hasenkamp et al, 
2012).  
The remaining five “hits”; MMV022029, MMV016136, MMV676442, MMV019721, and 
MMV019993 have, to date, no reported biological target in P. falciparum. Importantly, these 
compounds, all structurally diverse from one another, may offer some opportunity to the 
malaria drug development community for further hit-to-lead optimization. Of these, however, 
MMV019993 may be the most interesting hit due to its likely rapid parasiticidal effect based 
on the high levels of bioluminescence signal loss in a potent compound (200nM, available for 
Dd2 by MMV). The summary of the predicted fast and potent compounds (with their predicted  
mode of action) from the MMV Pathogen Box compounds is presented in table 4.2. 
Figure 4.11 has been developed here to better explore how compounds with the same MoA can 
be seen to be displayed across the mBRRoK plot. Rapid acting compounds that target PfATP4 
function and haemoglobin catabolism (Ullah et al., 2019), digestive vacuole integrity or PfeEF2 
function (reported here) all are typically clustered towards the bottom left (highest level of 
bioluminescence loss at both concentrations). There are some compounds reported to target 
PfATP4 in the Pathogen Box that do not fall towards the bottom left. This observation in terms 
of the variation in the initial RoK has been reported for predicted PfATP4 inhibitors from the 
MMV Malaria Box (Ullah et al., 2017; Ullah et al., 2019). MMV011229 is an 
imidazopyrimidine selective inhibitor of DHODH (Marwaha et al., 2012) with three additional 
DHODH inhibitors (MMV020591, MMV020537, MMV020289) reported by Ross et al., 
(2018). As expected for DHODH inhibitors (Phillips et al., 2015; Phillips et al., 2016; Ullah et 
al., 2017; Ullah et al., 2019) they cluster towards the upper right (minimal loss of 
bioluminescence at both concentrations).  
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Three compounds; MMV024101, MMV010576 and MMV085499 show a moderately fast 
initial RoK in mBRRoK plot (Figure 4.11). MMV024101 is a 1, 5-naphthyridine identified by 
Kandepedu et al., (2018) as a novel P. falciparum Phosphatidylinositol-4-Kinase (PfPI4K) 
inhibitor from the screening of MMV Pathogen Box compounds. MMV010576 was identified 
by Younis et al., (2013) from a phenotypic screen of the SoftFocus kinase library as a potent 
and selective in vitro inhibitor of P. falciparum. The third compound, MMV085499 was 
reported by Vaele (2019) to share similar structure with UCT943 (2-aminopyrazine). UCT943 
was reported by Brunschwig et al., (2018) to also be a PfPI4K inhibitor with potential to be a 
component in a SERCaP drug for the treatment, prevention and transmission-blocking of 
malaria parasites. Another two compounds; MMV010545 and MMV023985 predicted by Vaele 
(2019) to be PfPI4K inhibitors are clustered together towards the upper left of the mBRRoK 
plot. The prediction was based on their structural similarity with imidazopyridazine compounds 
identified by McNamara et al., (2013) as PfPI4K inhibitors. 
Five compounds, (MMV032967, MMV676260, MMV393144, MMV392832 and 
MMV007920) that show moderate initial RoK in mBRRoK plot were predicted by Vaele 
(2019) to likely target the P. falciparum equilibrative nucleoside transporter type 1 (PfENT1). 
The first three compounds are 2-arylimidazopyridines and the fourth, a pyrrolopyridine that 
closely resemble similar scaffolds reported by Lougiakis et al., (2016) and Gavriil et al., (2018) 
as fungal nucleobase transporter (FcyB) inhibitors and human NK3 tachykinin receptor blockers 
(Geldenhuys et al., 2010). PfENT1 mediate the salvage of purines necessary for parasite 
proliferation from host erythrocyte and offers a potential drug target against P. falciparum 
(Deniskin et al., 2016; Sosa et al., 2020). A group of compounds identified and developed by 
Frame et al., (2015) and Deniskin et al., (2016) as PfENT1 inhibitors closely resemble the fifth 
compound predicted by Vaele (2019) as a putative PfENT1 inhibitor. Details of the predicted 
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mode of action for some of the malaria compounds inside the MMV Pathogen Box compounds 
are presented appendix 4 at the end of this thesis. 
 
Figure 4.11: mBRRoK plot to explore potential MoA information for the MMV Pathogen 
Box compounds 
A standard mBRRoK plot comparing the mean normalized bioluminescence signal at 10µM 
and 2µM.The key reports the colour codes used for the putative MoA. 
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With the mBRRoK data for 400 compounds now plotted, understanding why compounds are 
located in different parts of the plot is important if analyses of MoA and potency are to be of 
use (see Figure 4.12). Compounds in the lower left appear to be rapidly acting and potent as 
hypothesised (Figure 4.12 B red box) and target PfATP4 or DV disruptors that are known rapid 
RoK targets. Compounds in the upper right appear to have compounds within them that are 
slow or have a delayed death phenotype – such as antibiotics, DHODH and bc1 inhibitors 
(Figure 4.12B blue box). The slow acting compounds are arrayed in this space due to the 
apparent absence of initial cytocidal action, irrespective of the potency of the compound. 
Therefore as one moves from lower left to upper right, it can be predicted that the rate of kill is 
getting slower.  
Moving towards the upper left on the mBRRoK plot is less well understood. The plot doesn’t 
go beyond the point where there is a slope of 1 and the slope intercepts the y axis at x=0 and 
y=0 (termed here the minimum line) – this is because a compound should not cause a greater 
loss of bioluminescence at 2µM than at 10µM. Taking the intra erythrocytic potency where 
reported for each of the 400 MMV Pathogen Box compounds (www.mmv.org), these data can 
be plotted (Figure 4.12A) for three different strains of P. falciparum. There appears no obvious 
pattern when a quartile analysis of the potency of the compounds (see key for the 3D7 data) is 
plotted. However, when the most potent (Figure 4.12B) and least potent (Figure 4.12C) are 
plotted and a linear regression done, it is clear that the linear regression for the most potent 
compounds is closer to the minimum line. This would be expected as these more potent 
compounds can better achieve a >10 fold EC50, or at least close to it, at either 2 or 10µM – for 
these compounds, the position of the slope absolutely informs you of their relative rate of kill. 
The regression of the least potent compounds moved towards the upper left and deviates away 
from a slope of 1. For these compounds, the lack of potency suggests they move away from the 
minimum line and for these compounds their position is based on the interaction between the 
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fold EC50 they achieve and the impact this has on them achieving their maximal rate of kill, 
whether this is slow or rapid – and is not simple to predict.   
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Figure 4.12: Exploring the regions of a mBRRoK plot – the impact of potency (previous page) 
(A) Standard mBRRoK plot comparing the mean normalized bioluminescence signal at 10µM 
and 2µM for the 400 MMV Pathogen Box compounds. The three plots show the potency (see 
key on the 3D7plot) in three different P. falciparum strains. Using this data, plots of the most 
potent (B; 0-0.4µM) and least potent (C; 1.3 µM or above) are shown with a linear regression 
plotted for data on graphs B and C. Blue box represents compounds with known slow acting 
MoA and red box compounds with known rapid acting MoA. 
 
Overall, the mBRRoK assay appears to be good at predicting fast-acting compounds and 
excluding slow acting compounds with their initial RoK data appearing to correlate with the 
known or proposed modes of action. Together, these findings appear to validate the utility of 
the mBRRoK assay to rapidly prioritize fast and potent compounds from a library of unknown 
rate of kill  - and even for a resource as reasonably well described as the MMV Pathogen Box, 
new insights around novel hits and information around rates of kill for new potential MoA have 
been achieved. 
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5 Chapter 5 
5.1 Introduction  
The search for new classes of antimalarial has been greatly improved through the application 
of technological innovations such as robotic automation and liquid handling together with 
miniaturization of screening assays to provide ultra-high throughput (HTS) screening of 
massive compound libraries (Lackovic et al., 2014). Moreover, development in the field of 
chemoinformatics for the analysis, filtering and interpretation of the large datasets from such 
ultra-HTS provide an indispensable tool in the field of drug discovery (Duffy et al., 2012). 
These innovations build on two fundamental approaches for screening commonly utilized in 
drug discovery; phenotypic, or “whole-cell” screens, and target-based screens. Phenotypic 
screening allows for the interrogation of all the possible targets of a test compound on the target 
cell (here typically P. falciparum and often the asexual stage within an erythrocyte) within a 
biological context that is “close” to its use as a drug. Whilst target-based screening instead 
involves direct evaluation of the compound effect on a specific target, often the purified protein 
target (Swinney, 2013).  
An advantage of the phenotypic screen is that compounds that do not access the target cell – 
here not penetrate the infected erythrocyte’s multiple membrane layers – can be excluded from 
further characterisation. It is also often considered that the effect of the test compound is 
examined in an unbiased manner in these “whole-cell” assays and that no previous knowledge 
of the target of the compound is required to develop the assay strategy (Swinney, 2013 and 
Katsuno et al., 2016). Compounds that exert synergistic effect or have many targets within the 
same cell are gathered together in this “whole-cell” (Hovlid and Winzeler, 2016). A major 
shortcoming of any phenotypic screen, however, is the difficulty in scaling and optimization of 
the identified hits because some knowledge of the probable target is required (Plouff et al., 
2008). As target-based screens already have defined target, lead optimization and scaling of 
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meaningful screens is a lot easier. Thus, there appears to be some advantage to understanding 
the target for the drug being developed and approaches for resolving targets such as selection 
of resistant mutants and biochemical affinity-based methods may offer some answers (Plouffe 
et al 2008). Although, again, the task of performing these target identification strategies do pose 
difficulties and can be time-consuming (Plouffe et al., 2008). Nevertheless, with automation 
and miniaturization of cellular screens, large amount of data for a particular chemo-type can 
now be rapidly gathered from arrays of different cellular screens (Plouffe et al., 2008; van 
Hooris et al., 2016).  
As compounds which show similar activity against a particular target or pathway will probably 
have the same profile across different screens, this open up the utility of in silico activity 
profiling of antimalarial compounds as demonstrated by Plouffe et al., (2008). Data generated 
from a fluorescence-based screen of 1.7 million compounds yielded some 17,000 compounds 
with potent antimalarial activities following a screen across 131 different cellular and enzymatic 
screens. Plouffe et al., (2008) was able to show the cellular pathway and/ or protein target for 
some of the selected compounds. Since this initial HTS work, several other examples of screens 
against asexual intraerythrocytic stages of P. falciparum using fluorescence-based assays have 
been reported (Banieck et al., 2007; Guiguemde et al., 2010; Avery et al., 2014; Baragana et 
al., 2015). One study reported the screen of nearly 2 million compounds from GlaxoSmithKline 
(GSK) performed by Gamo et al., (2010). All compounds were tested in vitro at a 2µM fixed 
concentration against the P. falciparum 3D7 strain. 19,451 compounds were found to inhibit 
parasite growth by more than 80% over 48hrs. Subsequently, fresh samples of these primary 
hits were re-tested against the multidrug resistant Dd2 parasite strain at 2µM concentration and 
nearly 8000 compounds (80%) inhibited the parasite growth by at least 50%. As expected, 
compounds that were less potent against Dd2 were predominantly quinolines or had structures 
similar to antifolates. This finding agrees with the report of Yuan et al., (2009) that showed a 
132 
 
number of these related chemotypes were less active against the multi-drug resistant Dd2 
parasites. A final selection of 13,533 compounds of confirmed hits in Dd2 and 3D7 is 
collectively termed the Tres Cantos (the GSK research site near Madrid) Antimalarial 
Compound Set (TCAMS) library was based and included compounds that inhibit parasite 
growth by more 80% in at least two of the screening experiments performed. In addition to 
antiplasmodial activity, evidence of cytotoxicity and interference with luciferase reporter assays 
was observed for some 1,982 compounds (15%) when assayed at 10µM against in HepG2 cells 
and were excluded. For many of the compounds within the TCAMS library, when complete 
concentration-response assays have been done, most have thus far been reported to have 
potency within sub-micromolar range (Gamo et al., 2010). For these compounds in TCAMS 
library, a structural analysis of the different chemo-types by molecular framework (Bernis and 
Murcko, 1996) or finger print analysis has been done. These molecular framework and finger 
print clusters describe a core scaffold and minor substituent pattern, respectively (Gamo et al., 
2010). This analysis was reported to provide 416 molecular frameworks, 857 clusters and 1,978 
singletons, with the intention to use these structural data to support discovery of possible 
mechanism of action. This was based on an assumption that compounds clustered together may 
share the same mode of action (Gamo et al., 2010) such as protein kinases and host-pathogen 
interaction related targets suggested for some of these compounds. 
There has been progress in screening the TCAMS library against other parasite stages, where 
screening of P. falciparum gametocytes identified 373 compounds with dual activity against 
both intraerythrocytic and gametocyte stages (Almela et al., 2015). Secondary confirmation and 
cytotoxicity assays of the primary hits resulted in 98 compounds that were progressed for 
further analysis. Filtering these 98 compounds using physicochemical properties resulted in the 
prioritization of 56 compounds for additional follow-up. In a second study, Miguel-Blanco et 
al., (2017) screened the TCAMS library against P. falciparum stage V female gametocytes. 
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More than 400 compounds that showed activities against female gametocytes at 2µM fixed 
concentration were identified. These hits were chemically grouped into 57 clusters and 33 
singletons. Subsequently, four compounds from three different scaffold clusters were selected 
for in vitro transmission-blocking confirmation (Miguel-Blanco et al., 2017). Recently, Delves 
et al., (2019) screened the TCAMS library for transmission-blocking compounds in an ex vivo 
P. berghei ookinete formation assay. 437 compounds were reported to inhibit parasite ookinete 
formation with an IC50 of less than 10µM. Cytotoxicity testing identified 273 compounds that 
showed more than 10-fold parasite selectivity when compared with activity against HepG2 
cells. The remaining hit compounds were classified into 49 chemicals clusters and transmission-
blocking activities were confirmed for six compounds selected from six different scaffold 
clusters (Delves et al., 2019). The TCAMS library has also been used for screening against 
intrahepatic stages of P. falciparum using a forward chemical genetic (Raphemot et al., 2016) 
approach that led to the identification and confirmation of 103 compounds with dual-stage 
malaria parasite inhibitors in liver and erythrocyte host cells.  
GSK has mined the TCAMS library to identify potential compounds that could serve as starting 
points for lead optimization (Calderon et al., 2011).13,533 TCAMS compounds have been 
filtered down to 47 series using an agglomerative structural clustering analysis informed by 
their physicochemical properties. The top 5 important series are indolines, aryl carboxamides, 
alkyl prazoles, thienopyrazoles and 4-aminopiperidines (Calderon et al., 2011). These chemical 
starting points have been presented by GSK for an open innovation in Malaria drug discovery. 
First of these series to be exploited for lead optimization developments were the cyclopropyl 
carboxamides (Rueda et al., 2011; Sanz et al., 2011). This series readily inhibits both drug-
resistant and dug-sensitive P. falciparum strains in vitro and display in vivo oral efficacy in a 
mouse model. However, selection for resistant mutant was relatively easy and this prevented 
their further development (Sanz et al., 2011). The second series to be exploited were the 
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indolines,  but their interaction with serotonin antagonist receptors (Calderon et al., 2012) 
blocked their development. However, a new lead was generated by using a double-divergent 
structural activity relationship analysis (Calderon et al., 2012). The spiroindolone (KAE609) is 
an example of an antimalarial candidate that was identified from the antiplasmodial screening 
of TCAMS library. This molecule is currently undergoing further clinical trials and may 
represent the first new antimalarial chemotype to be introduced in two decades of drug 
discovery research (Flannery et al., 2013).  
Given the development and validation of the mBRRoK assay in the previous two chapters, this 
chapter sets out to demonstrate the optimization of a moderate miniaturization of this mBRRoK 
assay and the application of this assay to screen the TCAMS library for compounds that show 
both potent and fast-acting activity. The TCAMS library being selected based on its provenance 
in antiplasmodial activity and the work already available in terms of structural and cytotoxicity 
data. This work represented an open access collaboration with GSK, who, based on the evidence 
provided to them on the validation of the mBRRoK assay, agreed to provide 12,514 compounds 
from the TCAMS library printed onto 384-well plates sufficient to provide a 10µM or 2µM 
concentration. 
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5.2 Results 
5.2.1 Optimization and miniaturization of the mBRRoK assay to a 384-well plate format 
The TCAMS library was provided on a series of seventy-six 384-well microplates. Of these, 38 
were set up to deliver a 10µM concentration and the remaining 38 (mapped identically to the 
first 19 plates) to deliver a 2µM concentration when solubilised in a 20µL volume of infected 
erythrocyte culture. Thus, each of the 12,514 compounds were provided at two concentrations 
for a n=1 sample count at each concentration. Blank wells were available on all plates to allow 
controls (untreated culture, supralethal kill (10 µM of CQ), and benchmark antimalarials) to be 
included. As all previous assays with BRRoK and mBRRoK used a 2% haematocrit, the same 
haematocrit was used throughout here.  
The first parameter evaluated was to ensure that using 20µL volume of infected erythrocyte 
culture (Dd2luc) would provide for a linear response in loss of parasitaemia (or viable parasites). 
Therefore, in triplicate on a 384-well plate, a 2% trophozoite stage infected erythrocyte culture 
was diluted in a two-fold series with a 2% HCT erythrocyte culture. This reduces the 
parasitaemia but does not affect the overall haematocrit. The samples were processed by the 
addition of 20µL of a 5X passive lysis/luciferase reagent and after mixing the luciferase signals 
measured. The measurements were repeated using three measurement times; 2sec, 1 sec and 
0.5sec. These data are integrated by the bioluminometer and counts/sec are reported – there was 
no difference between the parasitaemia v. bioluminescence – the linear regression of these data 
(Figure 5.1) overlapped exactly and so the data only for 0.5sec of measurement is shown. 
However, using a 0.5sec measurement instead of a 2sec measurement, changed the time to 
measure the signals over a 384-well plate from almost 13 minutes to just over three minutes. 
Data presented in Figure 5.1 also shows a linear response between bioluminescence signal and 
parasitaemia to at least 0.0625% parasitaemis – i.e. over a range that would enable a 96.875% 
kill to be measured over a 6hr assay. This is greater than the estimated maximum performance 
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of the assay – this would assume that a 100% kill is affected immediately and that the luciferase 
½ life is 1.5 hrs (Hasenkamp et al., 2012) – over 6 hrs in these conditions a 93.75% signal loss 
would be achieved. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Exploring the linear correlation between parasitaemia and bioluminescence 
signal on a 384-well microplate   
The bioluminescence signal from the indicated parasitaemia of trophozoite stage Dd2luc was 
plotted (n=3, mean ±stdev) and a linear regression done. The data plotted is from a 
measurement of 0.5sec/well – with data from 1sec and 2sec/well exactly overlapping data 
shown here. 
 
Given the time to record the signal over the whole plate, it was decided to next compare the 
measurement of the effect of compounds when seeded at the top (Rows A to D) or bottom of a 
plate (Rows M to P) that was read over its entirety (wells are measured A1 to A24, then B1 to 
B24 etc.). Ninety compounds were assessed, comprising seven benchmark antimalarials, 16 
Malaria Box compounds and 67 Pathogen Box compounds. These were assessed on different 
plates at either 10µM or 2µM, with three replicates being prepared. Bioluminescence signals 
were measured after 6hrs of exposure and normalized to the mean of six untreated controls 
placed at the top and bottom of each plate. A comparison of the signal (mean, n=3) measured 
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at the top and bottom of the plate reveal a strong linear correlation between the same effects 
measured at the top and bottom of the 384-well plate (Figure 5.2). This would indicate that over 
the time course of measuring a plate that the position of the well would not affect the outcome. 
Of note is the greater killing effect achieved at 10µM providing a greater range of effects to 
enable a greater correlation to be established (Figure 5.2A), whereas the lack of measured kill 
at 2µM for some 50% of the compounds produces a bias in the distribution of data (Figure 
5.2B). 
 
 
Figure 5.2: Exploring the effect of plate positioning on bioluminescence signal on a 384-well 
microplate. 
The plots represent the mean normalized bioluminescence signal (n=3) after exposure to (A) 
10µM or (B) 2µM of 90 compounds positioned either at the top (y-axis) or bottom (x-axis) rows 
on a 384-well plate. The insert text provides the parameters for a linear regression analysis.  
 
 
As a final validation of the adaptation into the 384-well mBRRoK assay, a comparison of the 
384 vs 96 well microplate assays was done. Using the same 90 compounds chosen for the 
analysis of plate-position effect above, the mean of the data developed for both the top and 
138 
 
bottom of the 384-well plates (i.e. n=6 datasets) was compared to available data developed for 
these same compounds as described in chapters 3 (benchmarks and Malaria Box compounds)  
and 4 (Pathogen Box compounds). Thus, for the MMV Compound sets, n=6 datasets at 10µM 
and 2µM were available from a 96-well plate format, with the mean of at least n=9 experiments 
used for the benchmark antimalarials. These data are compared in Figure 5.3. Comparison of 
these signals shows a good correlation (slope close to 1 and r2 of ≥0.76) between the datasets 
developed for the same concentration of each compound. This, and the previous data, indicated 
a position to move forward with the GSK plate screening. 
 
 
Figure 5.3: Comparison of mBRRoK assay performance between 96-well and 384-well 
microplate assay formats. 
The plots represent the mean normalised bioluminescence signal (n≥6) after exposure to (A) 
10µM or (B) 2µM of 90 compounds assayed on 96-well plates (y-axis) or 384-well plates (x-
axis). The insert text provides the parameters for a linear regression analysis. 
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5.2.2 Screening the TCAMS library in a 384-well mBRRoK assay 
As described earlier, each of the 76 plates provided by GSK has empty wells provided for the 
controls to monitor assay performance during the screen. These controls fell into two groups. 
The first was the addition to 25 pairs of plates wells of 1 well with either 10µM or 2µM (based 
on the concentration of the TCAMS library on that plate) of four bechmarks; DHA (rapid), CQ 
(rapid), MQ (moderate) and ATQ (slow). The second control, on all plates, was the addition of 
eight wells with no compound added (the mean of these also acting as the normalization for all 
data on that plate) and eight wells with a 2% erythrocyte haematocrit to act as a negative control 
due to no parasite materials in the culture. These two sets of eight wells allows for each plate 
the following high throughput assay quality parameters (Zhang et al., 1998) to be determined: 
Z’ score, signal/background ratio, coefficient of variation around the maximum (%CVmax) and 
minimum (%CVmin) signals (see section 2.6.5 on how to determine them, and Table 5.1 for a 
report of all values).  
Plotting the 25 pairs of benchmark antimalarial controls (Figure 5.4) provides a “cloud” of data 
points for each of the four compounds in spaces already demonstrated previously in this thesis 
to be occupied by these antimalarial compounds in Dd2luc. The “cloud” illustrates the minimal 
variation in the actual data determined for a series of n=1 measurements, and suggest a 
consistent assay performance, at least for these 25 plates. These data also provide key markers 
on the 384-well mBRRoK plot to provide relative data. 
Plotting the Z’ and S/B ratio across all 76 384-well plates is shown in Figure 5.5. The robustness 
of the assay was demonstrated by high Z’ scores (0.74-0.98) over all plates, with a minimum 
of 0.5 indicated as a good parameter for high throughput screening (Zhang et al., 1998). The 
sensitivity of the assay was maintained, even using the reduced volumes of parasite culture and 
assay reagents, with high S/B ratios (160 to 475) over all plates. As expected for this 
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bioluminescence assay, there is a low maximum coefficient of variation (CVmax, 1% to 9%) 
which illustrates the consistency in maximum signal across all untreated control samples used 
to normalise all other data on the plate. The high minimum coefficient of variation (CVmin, 8% 
to 35%) in bioluminescence assays has previously been described by Hasenkamp et al., (2013) 
due to the very low background (between 50-80 counts) signals obtained, so low that they are 
not used as a background correction in these assays. 
Overall, these assay performance parameters indicate a robust and sensitive assay performed 
across all 76 384-well plates used in this high throughput study. 
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Figure 5.4: Marking benchmark antimalarial data “clouds” on a 384-well mBRRoK 
plot. 
The normalised bioluminescence signal from corresponding pairs of 384-well plates 
(based on the TCAMS compounds arrayed on them – see Table 5.1) for 10µM and 
2µM of benchmark antimalarials are plotted on this mBRRoK plot. Each data point 
represents one of 25 sets of data – producing the data “cloud” for that particular 
antimalarial benchmark. ATQ, atovaquone; CQ, chloroquine; DHA, 
dihydroartemisinin;MQ, mefloquine. Indicated in brackets after each compound is its 
relative in vitro rate of kill effect.  
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Figure 5.5: Monitoring of assay performance parameters for the mBRRoK of TCAMS library  
(A) The Z’ score (ideally above 0.5 for a HTS, Zhang et al., 1998). The first 38 plates represent 
compounds plated at 10µM, with the next 38 plates the same compound plates (in order, see 
Table 5.1) with 2µM of compound plated.  
(B) The mean signal/background (S/B) for the untreated control vs the no-parasite (erythrocyte 
only) control.  
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TCAMS Plates ID Z’ score S/B %CVmax % CVmin TCAMS Plates ID Z’ score S/B %CVmax % CVmin
U004O3V 0.89 267 4 28 U004KV7 0.83 355 6 19
U004O47 0.88 279 4 24 U004KV8 0.9 164 3 21
U004O3S 0.81 297 6 31 U004KVC 0.8 285 7 14
U004FAT 0.75 309 8 23 U004KUN 0.85 247 5 23
U004O3W 0.85 275 5 30 U004KUL 0.86 211 5 19
U00403U 0.88 288 4 32 U004KV1 0.8 278 7 17
U004O3Q 0.84 297 5 35 U004KUW 0.84 333 5 14
U004O40 0.86 188 5 23 U004KUT 0.84 236 5 8
U004O3Z 0.88 160 4 13 U004KUQ 0.9 321 3 14
U004FAS 0.86 268 4 30 U004KV4 0.89 323 4 20
U004O3R 0.9 267 3 30 U004KV9 0.95 332 2 16
U004O41 0.91 204 3 21 U004KUV 0.94 273 2 18
U004O42 0.98 314 1 19 U004KVB 0.96 454 2 22
U004KWJ 0.94 239 2 22 U004KV3 0.93 265 2 20
U004KW7 0.94 348 2 19 U004KUP 0.96 475 1 15
U004KWK 0.92 306 2 25 U004KVA 0.91 331 3 15
U004KWI 0.94 205 2 15 U004KV5 0.9 231 3 32
U004KW4 0.95 259 2 17 U004KUS 0.74 235 9 29
U004KWH 0.88 296 4 35 U004KUZ 0.85 319 5 19
U004KWA 0.95 218 2 23 U004KV6 0.9 210 3 25
U004KVL 0.89 164 4 26 U004KV2 0.95 217 2 22
U004KWE 0.92 242 3 25 U004KUX 0.92 243 3 25
U004O45 0.91 313 3 21 U004KUU 0.94 245 2 10
U004KWB 0.88 308 4 20 U004KUR 0.88 308 4 20
U004KWD 0.88 279 4 16 U004KUY 0.83 356 6 15
U004O44 0.81 265 3 17 U004KVD 0.88 371 4 14
U004KWL 0.94 347 2 13 U004KV0 0.92 386 3 12
U004KWF 0.82 367 6 31 U004KVE 0.88 311 4 18
U004KW9 0.9 264 3 23 U004KVM 0.89 339 4 13
U004O3T 0.91 227 3 23 U004KVK 0.81 261 6 14
U004O46 0.87 291 4 27 U004KVO 0.91 222 3 16
U004O3X 0.93 173 2 17 U004KVI 0.91 169 3 39
U004KW8 0.91 289 3 20 U004KVJ 0.84 269 5 9
U004KW3 0.91 220 3 23 U004KVG 0.91 220 3 23
U004KWG 0.91 330 3 20 U004KVF 0.81 360 6 22
U004O3Y 0.95 302 2 13 U004KUM 0.95 348 2 27
POOLCGS 0.94 335 2 13 U004KVH 0.97 440 1 17
U004O43 0.95 339 2 14 U004KVN 0.92 359 3 14
10µM plate 2µM plate
Table 5.1: mBRRoK assay performance parameters for TCAMS screen. 
Each row reports a pair of plates that contain the same compounds at the indicated concentration. 
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A mBRRoK plot for all the 12,514 TCAMS library compounds is shown in Figure 5.6. A 
complete report of all data against each compound ID is presented in a spreadsheet in appendix 
5 at end of this thesis. In order to define a cut-off for compounds of interest in this screen, the 
sensitivity and specificity thresholds calculated in chapter 3 were applied to the screening data 
(20% for 10µM and 25% for 2µM). A total of 975 compounds were selected in this mBRRoK 
screen of the TCAMS library as compounds likely to be fast-acting and have high potency. This 
primary screen provides a hit rate of 7.8%, a high value that reflects the pre-selection of 
TCMAS library compounds based on their potency. The data was shared with GSK with the 
aim to resupply compounds for the confirmation of potency and rate of kill in a standard 
BRRoK assay. 
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Figure 5.6: mBRRoK plot of 12,514 TCAMS library compounds. 
The normalised bioluminescence signal for 12,514 TCAMS library compounds after 10µM and 
2µM exposure for 6hrs.These are marked in gray (n=1 for each compound). Benchmark 
antimalarials are plotted on this mBRRoK plot. Each data point represents one of 25 sets of 
data. ATQ, atovaquone; CQ, chloroquine; DHA, dihydroartemisinin;MQ, mefloquine. 
Indicated in brackets after each compound is its relative in vitro rate of kill effect. The dashed 
box highlights the region of the chart that contains putative hits in a mBRRoK assay. 
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5.2.3 Re-confirmation of mBRRoK hits 
A total of 165 compounds were resupplied by GSK for the confirmatory assays. Of these, 136 
compounds were selected to fall within the box on the mBRRoK plot predicted to identify 
potent and rapid acting compounds. The remaining 29 compounds fell out of this space and 
thus likely fail one or both of the rapid acting and potency requirements. As the previous assays 
had been done as single measurements, the first step of the confirmation was to repeat the 
mBRRoK assay. For ease of volume handling, these assays were all done in 96-well plates, 
with three independent repeats for 10µM and 2µM fixed concentrations used in all experiments. 
A second step in this confirmation was through the use of a second strain of P. falciparum, 
using the genetically-distinct NF54luc, again with three independent measurements. 
The scatter plots in figure 5.7A reports the distribution of the TCAMS compounds in the 
secondary screening in 96 well plate against Dd2luc parasite strain. The sensitivity and 
specificity criteria for high threshold (20 x 25) in chapter 3 (section 3.2.2) was used to define 
the region on the plot that contain the predicted fast-acting compounds. 110 compounds (81%) 
out of the 136 compounds initially predicted to be potent and fast acting in the HTS of TCAMS 
library were re-confirmed in the secondary screening. Plotting the compounds that were inside 
the box  of  n=1 screen  (Figure 5.7A in red) and outside the box (in blue), highlight that where 
some initial hits were not reconfirmed as being within the predicted rapid acting and potent 
area, no slow/low potency compounds were found to move into the hit box in the subsequent 
screen.  
Using the same experimental approach with the NF54luc strain, a total of 109 compounds 
occupied the hit box (Figure 5.7B). As would perhaps be expected for the majority of the 
compounds, there was good correlation (slope, r2 and significance of the linear relationship) 
between the screening data between the two parasite strains when used at 10µM (Figure 5.7C) 
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or 2µM (Figure 5.7D) concentrations. Interestingly, of the 109 compounds within the NF54luc 
hit box, 97 of these were also found within the Dd2luc hit box, with the remainder (except one) 
just falling outside the box. This suggests that the use of the n=3 mBRRoK assay in the two 
different strains has now taken the compounds of interest from the n=1 screen down from 81% 
based on a n=3 screen of one strain (Dd2luc) down to 72%.   
The initial relative rate of kill data were developed for 58 compounds out of the 165 compounds 
re-supplied by the GSK using the standard BRRoK assay. This would allowed the 
determination of their rate of kill without the issue of the potency of the compound contributing 
to the loss of bioluminescence signal. These 58 compounds were predicted from the mBRRoK 
in 96-well plate as follows: 
Dd2luc screen: 29 compounds in the hit box for speed and potency and 29 outside 
NF54luc screen: 31 compounds in the hit box for speed and potency and 27 outside 
Thus, compounds that appear to have differences in mBRRoK activity in the two genetically 
distinct strains have been identified. 
BRRoK assays require EC50 data to enable the fold-EC50 concentrations to be determined. As 
these could be different in the Dd2luc and NF54luc strains, an initial experiment was determined 
on nine compounds to explore the variation in EC50 in Dd2
luc and NF54luc compared to the 
available data (Gamo et al., 2010) for these compounds prepared in 3D7 (another CQS strain), 
although noting these were only reported in µM and to 1 significant figure. The log 
concentration-normalised response curves used to estimate the EC50 in each strain is shown in 
Figure 5.8 with a comparison of these between the three strains in Table 5.2. Based on the 
similarity of these data between the strains, it was decided to test the activity of all these 
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compounds in both Dd2luc and NF54luc strains using the available 3D7 EC50 data (Gamo et al., 
2010) in  BRRoK assay format. 
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Figure 5.7: Confirmation mBRRoK assay data in Dd2luc and NF54luc strains 
Standard mBRRoK plots of bioluminescence signals in A Dd2luc and B NF54luc for 165 
compounds from the TCAMS library resupplied by GSK. For A, data in red are compounds that 
were initially identified as falling within the hit box for rapid acting and potent compounds in 
the original n=1 screen, with data in blue compounds that fell outside this box in the original 
screen.  C and D report a linear correlation of remaining bioluminescence in Dd2luc(x axis) 
and NF54luc (y-axis) after exposure to 10µM and 2µM, respectively. Each data points represent 
mean of n=6 measurement (three biological repeats as technical repeats).   
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Figure 5.8: Concentration-normalised response curve for selected TCAMS compounds 
Log10 concentration-normalised response graphs for the indicated compounds selected from 
the TCAMS library. Dd2luc and NF54luc EC50 curves are represented in black and red colour 
respectively. The curves represent the non-linear regression (mean ±stdev n=6) used to 
estimate the EC50 reported on each chart (see Table 5.2).   
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Table 5.2: List of selected TCAMS compounds and their EC50 determined in 3D7, Dd2luc and 
NF54luc 
 
1 3D7 EC50 values are from Gamo et al., (2010). 
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The standard BRRoK assay was performed against the two parasite lines for all 58 compounds. 
The standard BRRoK graphs representing the concentration-dependent loss of bioluminescence 
over 6hrs are reported for all the compounds in Figure 5.9. These data were developed in three 
biological repeats, each with three technical repeats (n=9 total). This figure is presented over 
five panels, labelled A to E. In table 5.3 a list of the compound ID, the panel on which the data 
is reported and an interpretation of the curve is shown. The interpretations of the relative rate 
of kill are based on the shape of the curves compared to existing data on available benchmarks 
in Dd2luc and NF54luc (Chapter 3).  Fast highlights compounds that are at least as fast as CQ 
and therefore would meet the minimum in vitro threshold for activity. Moderate highlights those 
compounds that fall around the relative rate of kill activity described for aryl alcohols such as 
mefloquine and quinine – and up to the moderate rate of kill for folate inhibitors such as 
pyrimethamine. Slow represents compounds that are similar to the atovaquone benchmark. 
Different represents compounds that the rate of kill data appears different between Dd2luc and 
NF54luc.  
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Figure 5.9: Confirmation BRRoK plots of 58 selected TCAMS compounds (previous pages) 
Panels A to E each report standard concentration v. bioluminescence signals for 6hr BRRoK assays for 58 selected compounds resupplied from 
the TCAMS library. Solid filled line and broken line represent NF54luc and Dd2luc BRRoK data, respectively. Each data point represents the mean 
±stdev of n=9 data. Information on the interpretation of the rate of kill is reported in Table 5.3. 
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Table 5.3: Mapping of TCAMS compounds to panels on Figure 5.9 and interpretation of 
their relative rate of kills. 
 
Panel TCAMS ID
Relative Rate of 
Kill Panel TCAMS ID
Relative Rate of 
Kill
A TCMDC-124760 Fast D TCMDC-140755 Moderate
A TCMDC-136189 Fast D TCMDC-135335 Moderate
A TCMDC-136088 Fast D TCMDC-140040 Slow
A TCMDC-125071 Fast D TCMDC-133687 Slow
A TCMDC-125016 Fast D TCMDC-135773 Slow
A TCMDC-133478 Fast D TCMDC-140417 Slow
A TCMDC-125424 Fast D TCMDC-137323 Slow
A TCMDC-136607 Fast D TCMDC-135747 Slow
A TCMDC-137603 Fast D TCMDC-136043 Slow
A TCMDC-125139 Fast D TCMDC-136878 Slow
A TCMDC-125361 Fast D TCMDC-135804 Slow
A TCMDC-125253 Fast D TCMDC-135800 Slow
B TCMDC-131436 Fast E TCMDC-140154 Different
B TCMDC-131242 Fast E TCMDC-125321 Different
B TCMDC-124252 Fast E TCMDC-124887 Different
B TCMDC-136792 Fast E TCMDC-124579 Different
B TCMDC-140871 Moderate E TCMDC-140815 Different
B TCMDC-124491 Moderate E TCMDC-140157 Different
B TCMDC-124168 Moderate E TCMDC-142268 Different
B TCMDC-124113 Moderate E TCMDC-136795 Different
B TCMDC-123564 Moderate E TCMDC-142193 Different
B TCMDC-125397 Moderate E TCMDC-138973 Different
B TCMDC-138358 Moderate
B TCMDC-123773 Moderate
C TCMDC-124047 Moderate
C TCMDC-125254 Moderate
C TCMDC-139900 Moderate
C TCMDC-135423 Moderate
C TCMDC-138614 Moderate
C TCMDC-142036 Moderate
C TCMDC-136239 Moderate
C TCMDC-135135 Moderate
C TCMDC-141043 Moderate
C TCMDC-125055 Moderate
C TCMDC-124036 Moderate
C TCMDC-132515 Moderate
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5.3 Discussion 
The development and validation of a modified BRRoK assay in chapters 3 and 4 led to this test 
of the large TCAMS compound library using a 384-well microplate format. The 384-well assay 
was shown to be robust with Z’ scores ranges between 0.74 to 0.98 (with ideal being >0.5) and 
a CVmax from 1% to 9%. The high signal to background ratio from 160 to 475 illustrates the 
sensitivity of the assay at the small assay volumes used. As such, it can be concluded that the 
384-well mBRRoK assay is a reliable and robust assay that offers the opportunity to rapidly 
screen a large compound libraries. Potential future work in adapting to a 1536-well microplate 
format to provide screens of massive compound libraries, in excess of 100,000 compounds, 
may be possible given the sensitivity of the bioluminescence assay used. Comparing these  384-
well assay quality parameters with other in vitro antimalarial HTS assays reported (Che et al., 
2012; Lucantoni et al., 2016; Swann et al., 2016; Baniecki et al., 2007; Plouffe et al., 2016) is 
extremely favourable to the bioluminescence format used here – particularly with respect to the 
high signal to background ratio. 
The screen of the 12,516 TCAMS compounds identified 975 compounds within the “hits” box, 
i.e. compounds that would be predicted to be both potent and rapid acting. The 7.8% hit rate is 
high for a high throughput screen, where typically the top 1-2% of hits would be identified for 
follow up work. The high hit rate here presumably is the result of the TCAMS library containing 
compounds pre-selected for their in vitro antiplasmodial activity. 165 compounds were selected 
for follow up analysis after a resupply of materials from GSK. These contained 136 compounds 
from the hit box. A two-step process was followed – both using a 96-well mBRRoK assay with 
n=3 technical repeats done, but done in two different P. falciparum strains. This approach led 
to 97 of the 136 compounds (71.3%) being a hit in both screens. This suggests that doing a 96-
well mBRRoK assay in both strains does add value to a screening approach – and this will be 
picked up further in the final discussion for the thesis. 
161 
 
The potential to use mBRRoK data generated for Dd2luc and NF54luc parasite lines to explore 
potential strain-specific variation has been discussed earlier in this thesis. Calculating the 
change (Δ) in the percentage normalized bioluminescence signal at 10µM and 2µM between 
the two strains (Dd2luc is used as the zero-point) allowed this concept to be explored with this 
screen of the 165 follow on compounds. In figure 5.10, the variation in bioluminescence signal 
data was plotted and overlaid with chemical structures of 9 compounds that appear to show the 
largest variation between the Dd2luc and NF54luc parasite lines. Four of these compounds; 
TCMDC-142036, TCMDC-138973, TCMDC-142193, and TCMDC-142105) shown in green 
on Figure 5.10, have a greater effect in NF54luc compared to Dd2luc in the mBRRoK assay. 
Interestingly, these four compounds are quinolines and would therefore likely have a higher 
EC50 in Dd2
luc due to its quinoline resistance profile (Hasenkamp et al., 2012), although this 
was not confirmed here due to the lack of material. As the mBRRoK assay uses a fixed 
concentration, the Dd2luc parasites may have been exposed to a reduced fold-EC50 concentration 
of these compounds that affected the killing effect. Looking at the BRRoK data, although noting 
that these were all developed using the 3D7 EC50 data (a CQ-sensitive strain like NF54
luc) in 
Figure 5.9, data for three compounds are available. One, TCAM-142036 has a moderate killing 
effect in both strains – typical for quinolines and aryl alcohols. The most telling data is that of 
TCMDC-138973 and TCMDC-142193 (last two compounds on panel E of Figure 5.9) where 
the killing effect of these compounds was greater in NF54luc than for Dd2luc – strongly 
suggesting that they are less potent in the Dd2luc CQ-resistant strain. Two additional 
structurally-related compounds were picked out in this analysis. Compounds TCMDC-135800 
and TCMDC-135804 appear to be two of four compounds that have a greater killing effect in 
Dd2luc than in NF54luc (identified in blue on Figure 5.10). Currently, the overall RoK for 
TCMDC-135800 and TCMDC-135804 is that they exert a slow killing effect (Figure 5.9) and 
thus any differences in their relative potency would not be readily apparent in a BRRoK plot. 
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However, that this simple comparison approached offer up new data regarding differences in 
activities in different strains, and that at least for some there is a ready explanation, suggests 
that the use of mBRRoK assays extends beyond rapid screening of potent and fast-killing 
compounds – the potential use of this will also be picked up in the final discussion.   
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Figure 5.10: Exploring differences between mBRRoK data developed in Dd2luc and NF54luc parasite strains 
The scatter plot shows the differences between percent normalised bioluminescence signals developed in each strain at 10µM and 2µM (where 
the difference reported is that of NF54luc to Dd2luc). The mean from n=3 measurements in each strain is reported here for 165 compounds.  
Compounds that show an apparent greater killing effect in NF54luc are highlighted in green and are towards the top right quadrant, compounds 
with an apparent greater killing effect in Dd2luc are shown in blue and fall towards the left lower quadrant. All others are shown in red. 
Highlighted structures are shown around the plot.  
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The mBRRoK explores both potency and rate of kill within the apparent killing effects 
observed. To understand the rate of kill of compounds relative to each other, the original 
BRRoK assay is used as it uses the same fold-EC50 concentrations. The move to mBRRoK here 
was in part driven by the fact that the measurement of an EC50 takes longer than the rate of kill 
determination. For the TCAMS compounds, EC50 data is available from measurements done 
using the 3D7 parasite line (Gamo et al., 2010). Data in Figure 5.8 and Table 5.2 showed that 
for the majority of the nine compounds assessed (selected as most of these were made available 
by GSK) that there was little difference in the EC50 for the three strains tested. It was therefore 
decided to use the available 3D7 data to prepare BRRoK plots for 58 compounds for which 
there was sufficient material to enable the three independent assays to be done. A summary of 
the key finding is shown in Table 5.3 and adds new relative rate of kill for discovery antimalarial 
compounds – of note is that there appear to be at least 16 compounds that would meet the TCP1 
criteria of at least as fast as chloroquine and of particular note are compounds TCMDC-124760 
and TCMDC-136189 would readily meet the ideal criteria for at least as fast as artemisinins.  
Using the threshold criteria for each graph that compared the concentration-dependent loss of 
bioluminescent signal compared to antimalarial benchmarks (see chapter 3), the compounds 
were determined as either fast (greater than or around chloroquine), moderate (aryl alcohol to 
pyrimethamine/folate inhibitor) or slow (slower than pyrimethamine/similar to atovaquone). 
Grouping the concentration-dependent loss of bioluminescent signal curves by these categories 
(Figure 5.11) readily shows how they can provide a relative indication of the rates of kills of 
these compounds, with the rapid acting (Figure 5.11A) clearly more distinct in their activities 
at 3x and 9xEC50
 compared to the moderate and slow compounds (Figures 5.11 B and C) – 
supporting the use of the 10xEC50 threshold in the mBRRoK assay to determine the 10µM and 
2µM when screening for the rapid acting compounds. 
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With the large datasets available for the 12,516 compounds screened, the opportunity to better 
understand how the position of a compound on the mBRRoK plot relates to its potency and rate 
of kill was explored again. Previous observations in chapters 3 and 4 highlights that rapid acting 
and potent compounds do fall in the lower left of the mBRRoK plot and slow acting compounds 
fall to the upper right of the plot. Given that most of the benchmark antimalarials show the same 
loss in bioluminescence signal at both 10µM and 2µM, then falling close to this position where 
the slope is 1 and intercept on y-axis is 0 (below which no compound should theoretically lay) 
would perhaps result from their potency as the compounds readily achieve at least a 10-fold 
EC50 at both 10µM and 2µM. It was considered if moving away from this point towards the top 
left of the chart, where compounds have greater activity at 10µM than 2µM, and are thus likely 
to be able to achieve a lower fold EC50 at 2µM than at 10µM that there would be a trend of 
increasing EC50 data as one moves towards the top left. To explore this, five bands of 
compounds moving across the dataset were determined (Figure 5.12A) – with the hypothesis 
that as one moved from band 1 to 5, that there would be an increase in the mean EC50 data as 
we move away from the slope with the intercept on y-axis at 0. The available EC50 data from 
Figure 5.11: Grouping the concentration dependent-loss of bioluminescence curves for 
compounds determined to be (A) rapid, (B) moderate and (C) slow acting in their BRRoK assays 
The BRRoK curves reported here are all adapted from data reported in Figure 5.9 and classified in 
Table 5.3 
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3D7 for the compounds in each band was determined and a box and whisker plot for these data 
in each band prepared (Figure 5.12B). Interestingly, using non-parametric tests for significance 
(ANOVA with Bonferroni post-tests) in the distribution of the data, no significance was seen 
between any of the groups. Any slight variation perceived in the box-and-whisker plot  most 
likely reflects the numbers of compounds within each band (with the most in band 1 and least 
in band 5). This suggests that potency cannot be attributed to a compound based on its position 
on an mBRRoK plot beyond the exiting observation of potent and rapid acting compounds in 
the lower left of the plot.  More work in understanding the impact of the rate of kill, and 
therefore much more data from BRRoK plots are needed. 
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Figure 5.12: Rainbow plot for TCAM library compounds 
Represents the stratification of mBRRoK plot for TCAMS library compounds into five coloured 
bands using their corresponding 3D7 EC50 data. (B) Indicates the box plots for the TCAMS 
EC50 values. 
 
In chapters 3 and 4, compounds with the same MoA were shown to display similar RoK in the 
mBRRoK plot. Using the available data for 195 TCAMS compounds (see appendix 6 for detail), 
mBRRoK plots for inhibitors of PfATP4, haemoglobin catabolism, folate biosynthesis, 
DHODH and bc1 complex were all plotted (Figure 5.13). As expected, compounds that target 
the PfATP4 and haemoglobin catabolism clustered towards the bottom left of the mBRRoK 
plot with  some of the PfATP4 inhibitors displaying moderate to negligible killing effect (an 
observation reported here as well as in Ullah et al., 2017 and 2019). As expected, compounds 
that target DHODH and the bc1 complex clustered towards the upper right, typical of a 
negligible killing effect over 6 hour due to the lag phase. As would be expected for compounds 
that target folate biosynthesis pathway, they display a moderate killing effect on the mBRRoK 
plot. The benchmark for this class of inhibitors would be pyrimethamine which shows a slower 
in vitro rate of kill than aryl alcohols and up to a 24 hour lag period (Sanz et al., 2012). Given 
that the folate inhibitor WR99210 is used as a drug selective marker for the generation of the 
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Dd2luc strain, the action of folates hasn’t been specifically explored in the BRRoK and 
mBRRoK assays – not least as these compounds are not likely to be rapid acting based on the 
Sanz et al., (2012) data and that shown here in Figure 5.13. 
 
Figure 5.13: Correlating mode of action of TCAMS library compounds with mBRRoK six 
hour data. 
Each data point represents normalized bioluminescence signal at 10µM and 2µM for TCAMS 
library compounds that target DHODH, bc1 complex, PfATP4, folate biosynthesis and 
haemoglobin (haem) catabolism. 
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6 Chapter 6: Discussion 
Emergence of resistance to the frontline artemisinin combination therapies underscores the 
urgent demand for alternative antimalarial drugs to treat active malaria cases. Thousands of 
compounds with potent antiplasmodial activity have been identified in whole-cell phenotypic 
screens of compound libraries by GSK (Gamo et al., 2010), Novartis (Plouffe et al., 2008) and 
St. Jude Children’s Hospital (Guiguemde et al., 2010). These hits are available for hits-leads 
optimization and characterization. As part of this process, an in vitro determination of their rate 
of kill would assist in screening for fast-acting compounds as knowing this pharmacodynamic 
property could inform decisions to proceed to in vivo or even clinical studies. The BRRoK assay 
was developed in the Horrocks lab to address issues with other in vitro rate of kill assays 
(Bahamontes-Rosa et al., 2012; Le Manach et al., 2013; Linares et al., 2015; Sanz et al., 2012; 
Ullah et al., 2017), with BRRoK being able to differentiate between compounds that met 
minimal essential and ideal TCP1 criteria using a simple and robust moderate throughput assay. 
However, whilst BRRoK has many strengths as an assay, the need to know the EC50 values of 
the test compounds before performing the assay limits the assay to a medium throughput. To 
enable a scale up in the provision of a robust assay to prioritise the screening for rapidly 
cytocidal antiplasmodial compounds, this thesis addressed the “EC50 bottleneck” through the 
development, validation and use of a modified BRRoK assay, termed the mBRRoK assay. 
Through the “proof-of-concept” using benchmark antimalarials, to a validation using a medium 
throughput screen of the MMV Pathogen Box to the application of the mBRRoK to screen 
12,514 TCAMS library compounds a number of key features have been defined for this assay; 
(i) this 6 hours assay offers a simple, quick, robust and reliable tool for screening 
antimalarial compounds that are both potent and show a rapid initial cyctocidal 
action 
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(ii) the assay performance parameters have been defined and, using the 20x25 “hit box” 
appears to provide a 81% true discovery rate for compounds that are at least as rapid 
acting as chloroquine. 
(iii) the assay also appears particularly effective in excluding compounds that affect a 
slow initial cytocidal action, irrespective of their potency 
(iv) the assay is readily scalable to a 384-well microplate format, retaining its robust 
assay characteristics  
Of particular note is the understanding of how compounds fall on the mBRRoK plot which can 
be used to provide information about their potency and rate of cytocidal action (Figure 6.1). 
These have been well described for rapid and potent compounds as well as for compounds that 
are slow (have a lag phase of > 6hrs) irrespective of their potency. Interestingly, at each stage 
of development of the mBRRoK assay, compounds with known mode of action with well 
understood rates of kill have been able to be plotted to the mBRRoK plot in defined spaces. 
Examples of this include the rapid rates of action for haemoglobin catabolism and for PfATP4 
inhibitors, and slow rates of kill for DHODH and bc1 complex inhibitors (Ullah et al., 2019). 
Compounds with moderate potency and/or moderate rates of cytocidal action, however, do not 
fall on the mBRRoK plot in a predictable manner. Analyses of how EC50 affects the position of 
a compound on the mBRRoK plot have been less successful. One key hypothesis explored is 
that as compounds move towards the top left of the plot they would be less potent. This would 
be exemplified on Figure 6.1 by CQ and MQ – these compounds share a similar rate of kill 
(albeit lying either side of the definition for fast and moderate) with CQ being less potent in 
Dd2 (c 200nM) than MQ (c 40nM). Exploring this hypothesis in this thesis has failed to 
demonstrate any significant difference in compounds as they move towards the upper left 
corner. However, to do this properly a large number of related compounds that target the same 
mode of action would be needed. This would remove the confounder effect of the rate of kill 
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and allow only the effect of potency to be judged. As more data is developed on the modes of 
action, this would be an interesting analysis to complete. 
 
 
 
 
 
 
 
 
 
 
After completing the screening of the first new compound library using the mBRRoK assay on 
the MMV Pathogen Box, the utility of even this small scale screen was highlighted in the 
potential new leads identified. Of particular interest were MMV634140 and MMV66749, both 
structurally related to DD107498 (a novel PfeEF2 inhibitors) and here predicted to elicit a rapid 
relative rate of kill – a novel observation for a new class of molecules. Thus, in terms of a novel 
mode of action that shows a rapid rate of cytocidal action, I would suggest that PfeEF2 
inhibitors would be of interest for further optimization and characterization. Also of note from 
the MMV Pathogen Box screen were five compounds (MMV022029, MMV016136, 
Figure 6.1: Exploring the distribution of compounds on a mBRRoK plot based on their 
potency and initial rate of cytocidal action. 
Figure adapted from Chapter 5. 
 
 
172 
 
MMV676442, MMV019721 and MMV019993) all predicted to show a rapid rate of initial 
cytocidal activity – albeit with no predicted mode of action, and thus potentially of interest as 
they may have a novel mode of action. This work highlights how understanding the rate of kill 
adds a new dimension to existing potency data when reviewing the data from a compound 
library. These data have all been shared with MMV in accordance with the requirements for the 
supply of the materials. There has been no follow up on mBRRoK assays beyond those reported 
here due to the limited amount of material the MMV Pathogen Box provides. However, a 
priority list is available to now discuss with MMV as part of ongoing projects our laboratory is 
providing to this organisation. 
This thesis also first described the use of a second genetic strain in the BRRoK/mBRRoK assay. 
NF54luc was developed using the same Pfpcna-luciferase expression cassette – although here 
the reporter plasmid is likely maintained as an episomal plasmid (Muqdad Hmoud, PhD Thesis 
2019). The initial benchmark RoK data developed for Dd2luc and NF54luc using BRRoK assay 
were essentially the same except for the differences in drug resistance profile for the quinolines 
compound as would be expected. There was a considerable overlap of the number of predicted 
fast-acting compounds against Dd2luc and NF54luc when the hits from the n=1 TCAMS library 
screen were followed up after the resupply of 165 compounds from GSK. Here, I was able to 
repeat all the mBRRoK data with n=3 measurements as well as do BRRoK assays for some 58 
of the compounds in the two genetically distinct lines. 110 and 109 compounds were predicted 
to demonstrate a rapid initial RoK in Dd2luc and NF54luc respectively. There was a great overlap 
between the two parasite strains, with 97 compounds predicted to be fast-acting against Dd2luc 
share the same RoK with NF54luc. In chapter 3 the potential for comparing mBRRoK data from 
two strains was first explored and then used again for the data developed from the 165 TCAMS 
compounds. This comparison plot reveals not only the divergence (Δ % normalised 
bioluminescence) of the data at 10µM and 2µM between the strains, but also a vector for the 
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data that would suggest in which strain the greater inhibitory effect is produced. The potential 
for this comparison information was shown where; 
(i) of the 14 compounds predicted to have a reduced killing effect in Dd2luc compared 
with NF54luc, five of these compounds are quinolines. This observation agrees with 
the report of Gamo et al., (2010) concerning the quinolines in the TCAMS library 
that show less activity against Dd2 parasites. 
(ii) of the 12 compounds predicted to have a greater killing effect against Dd2luc 
compared with NF54luc, two pairs of compounds show similarities in their core 
scaffold (figure 6.2). These are compounds with no designated mode of action 
information.  
These findings appear to support the potential of mBRRoK assay to explore drug resistance 
profiles in genetically distinct parasite strains when used in this assay. For example, the 
mBRRoK assay could perhaps be used in future to study the effect of antimalarial compounds 
against artemisinin-resistant and artemisinin-sensitive parasite strains as the first step in triaging 
compounds that are both potent and rapid – recognising that searching for compounds active 
against artemisinin resistant parasites that will likely dominate the future of antimalarial 
treatment for the next thirty years. 
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Figure 6.2: Chemical structures of two compounds that show greater killing in Dd2luc 
compared with NF54luc  
The compounds show similarities in their core scaffolds. 
 
With the new BRRoK assay data developed here for Dd2luc , a repeat Principle Components 
Analysis (PCA) was carried out in collaboration with Dr Raman Sharma of the Liverpool 
School of Tropical Medicine who completed the analysis with the MMV Malaria Box data 
(Ullah et al., 2017; Ullah et al., 2019). PCA offers the potential to reduce the dimensionality of 
the data into a single parameter (first principle component, PC1) that can easily be included in 
analyses as a measure of the relative rate of kill, where a smaller PC1 – reflecting low 
bioluminescence signals after exposure to compound– reports rapid initial cytocidal activity. A 
new PCA was done using the 6hr BRRoK assay data, this analysis included the previous Dd2luc 
data for benchmark antimalarials and 376 compounds from the MMV Malaria Box – but also 
included here data on 14 compounds from the MMV Pathogen Box in Dd2luc as well as 58 
compounds from the TCAMS library done in Dd2luc and NF54luc. These data are all provided 
in appendix 7. Taking both the potency of compounds (expressed in nM) and the relative rate 
of kill data (expressed as zero-mean PC1 values) a new view of available potency versus rate 
of kill data in the Dd2luc parasite is now available (Figure 6.3). This analysis allows me to 
explore the interplay between the potency and initial cytocidal action of MMV Malaria Box, 
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MMV Pathogen Box and TCAMS library compounds. Compounds that are potent (low EC50) 
and exert an initial rapid RoK occupy the bottom left quadrant of the plot (activity space of 
dihydroartemisinin, DHA). The distribution of the MMV Pathogen Box and TCAM library 
compounds appear to follow similar pattern reported for the MMV Malaria Box by Ullah et al., 
(2017). Using the TCP1 ideal threshold, i.e. compounds that are at least as fast a DHA (PC1<-
85), 11 TCAMS compounds were identified. However, only one compound, TCMDC-124760 
(N-(5-Chloro-2,4-dimethoxyphenyl)-2-(2-methylpropyl)-1-oxo-3-thiophen-2-yl-3,4-
dihydroisoquinoline-4-carboxamide), appears to meet the potency criteria (EC50 <200nM).  
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Figure 6.3: Plot of all available BRRoK (PC1) data against EC50 for the MMV Malaria Box, 
Pathogen Box and TCAMS library compounds against the Dd2luc parasites. 
Malaria Box compounds are indicated as grey circles, Pathogen Box compounds are 
represented by green circles and TCAMS library compounds by blue circles. The 7 benchmark 
antimalarial drugs are indicated with red filled diamonds. The TCP1 ideal and TCP1 minimal 
thresholds are set based on the PC1 values (BRRoK data) for dihydroartemisinin and 
chloroquine, respectively, and are shown as dashed lines. DHA, dihydroartemisinin, CQ, 
chloroquine, MQ, mefloquine, PYN, pyronaridine, PPQ, piperaquine, QN, quinine, ATQ, 
atovaquone. 
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As would perhaps be expected, no compounds from the MMV Pathogen Box appear to meet 
the TCP1 ideal criteria because the compounds were selected for diversity to support drug 
discovery campaign against Neglected Tropical Diseases. However, four compounds do meet 
the minimal threshold of at least as fast as chloroquine. Importantly, new data on a key 
pharmacodynamics property has been shown to be developed quickly and with a process of 
analysis that allows for a ready triage of the most potent and rapid compounds, with additional 
functionality available when comparing two different strains. So, for the first time, the same 
type of plot has been prepared using available potency versus rate of kill data in the NF54luc 
parasite for the 58 TCAMS compounds screened (Figure 6.4). Plotting the TCAMS library 
BRRoK data for NF54luc shows a similar distribution pattern observed in the same plot for 
Dd2luc parasite line. 19 compounds, however, likely meet the TCP1 ideal threshold, with two 
of these (TCMDC-124760 and TCMDC-142268) appearing to look promising for hit-lead 
optimization, although TCMDC-124760 shows the same potency and relative rate of kill in 
Dd2luc parasites. 
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Figure 6.4: Plot of available BRRoK (PC1) data against EC50 for the TCAMS library 
compounds against NF54luc parasites. 
TCAMS library compounds are in indicated in blue circles with TCMDC-124760 shown inside 
a green circle. The seven benchmark antimalarial drugs are indicated with red filled diamonds. 
The TCP1 ideal minimal thresholds are set based on the PC1 values (BRRoK data) for 
dihydroartemisinin and chloroquine, respectively, using broken lines. DHA, 
dihydroartemisinin, CQ, chloroquine, MQ, mefloquine, PYN, pyronaridine, PPQ, piperaquine, 
QN, quinine, ATQ, atovaquone. 
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Taking the best TCAMS hits from both plots, a comparison of the PC1 values shows some 
variation (Table 6.1) between classifications as meeting the minimum or ideal TCP1 threshold. 
That said, the top ranking compounds in both strains align well and show a trend in the TCAMS 
n=1 screen that suggests that they would all have been identified with a more stringent selection 
criteria i.e. a 10x10 hit box (this would reduce the overall number of hits from the 12514 
compounds from 975 to 191). This same criteria would also exclude two compounds that meet 
the ideal TCP1 criteria in both strains and a mixed ideal/minimum TCP1criteria for at least six 
compounds. This would suggest that whilst applying a much more stringent criteria would 
reduce any expected subsequent workflow – the BBRoK data developed in the two strains here 
would suggest that a significant number of compounds (i.e. 50%) of interest would be missed 
out. 
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Table 6.1: Comparison of BRRoK PC1 data against the original TCAMS screening data 
 
 
The validated mBRRoK assay is intended to quickly triage 12,516 TCAMS library for 
compounds that affect rapid relative rate of kill with good potency. The top 100 TCAMS 
compounds (based on their ranking in residual bioluminescence activity) from the n=1 TCAMS 
screen were clustered manually into structural related scaffolds (Figure 6.5). Ullah et al., (2019) 
provided a proof-of-principle that compounds which share similar core scaffolds show the same 
relative rate of kill in the BRRoK assay. Here, the mBRRoK assay data appear to provide 
similar information – as would be expected if an assumption that the related scaffolds affect 
kill through the same rapid mechanism. Of the 100 compounds, 80 fall into one of nine distinct 
core scaffolds;  
 eight 4-aminoquinolines a known rapid acting class of compound 
  four closely related compounds with an isoquinoline core 
High
Compound name EC50  (nM) Dd2
luc
NF54
luc
10µM 2µM threshold
TCMDC-136189 651 -121.2 -116.5 1 1 Yes
TCMDC-124760 46 -121.0 -115.8 6 4 Yes
TCMDC-136088 763 -106.6 -121.4 7 12 No
TCMDC-125071 912 -105.5 -105.5 3 5 Yes
TCMDC-125424 878 -105.3 -119.8 3 9 Yes
TCMDC-125016 971 -105.1 -92.5 2 4 Yes
TCMDC-133478 360 -103.8 -91.8 3 4 Yes
TCMDC-136607 777 -95.8 -88.7 4 9 Yes
TCMDC-125253 899 -95.5 -78.4 4 6 Yes
TCMDC-125139 701 -95.2 -112.3 1 2 Yes
TCMDC-125361 843 -92.8 -110.2 3 8 Yes
TCMDC-137603 497 -87.4 -90.3 17 19 No
TCMDC-140154 967 -85.3 -47.4 17 24 No
TCMDC-131436 804 -83.6 -108.7 14 22 No
TCMDC-131242 1177 -83.4 -82.2 20 22 No
TCMDC-124491 874 -81.4 -67.9 7 9 Yes
TCMDC-123564 844 -76.9 -55.6 3 10 Yes
TCMDC-124252 893 -72.1 -104.7 16 20 No
TCMDC-124168 991 -69.8 -89.8 14 21 No
TCMDC-136792 873 -67.6 -92.5 18 23 No
TCMDC-140815 836 -41.4 -105.1 14 16 No
TCMDC-124887 521 -57.4 -96.1 14 19 No
TCMDC-140871 550 -54.1 -93.2 13 21 No
TCMDC-138973 993 9.5 -91.1 9 90 No
PC1 value TCAMS screen in Dd2 (n=1)
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 Five acridines – a class of compound shown in Ullah et al., (2017) to have a rapid mode 
of action 
 Twelve quinazolines, with three subclusters within this group – no data exists on this 
group of compounds 
 Seven compounds sharing a sulphonamide moiety 
 Ten triazoles, with eight closely related to one another 
 Eight diverse compounds that share a core pyrimidine moiety 
 Eleven diverse compounds that share a core benzamide moiety 
 Fourteen 2-phenyl-benzimidazole compounds, with the same class identified as 
generally having a moderate rate of kill in Ullah et al., (2019). Interestingly, the same 
study reported one of these compounds had a rate of kill that was greater than that of 
DHA. Understanding what substitutions around the 2-phenyl-benzimidazole core would 
be of particular interest.  
Currently, these data are all shared with GSK. The next step in working with this data will be 
to use chemical informatics to prioritise examples of structurally-related compounds that share 
the same rapid rate of kill. BRRoK assays in Dd2luc and NF54luc can then be used to confirm 
this rapid activity. Data from other screens on this compound library would offer the 
opportunity to select classes of molecules that are of particular development interest or are 
novel. 
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Figure 6.5: Chemical structures of the top 100 TCAMS compounds predicted to have initial 
rapid rate of kill in the mBRRoK screen of the TCAMS library  
 
There appear to be two routes forward for development of the mBRRoK assay format. The first 
is the idea of expanding into a 1536-microwell assay format suitable for screening of >100,000 
compound libraries. This could be done using the two strains to provide comparative data that 
would underpin a chemical informatics analysis of the data. This would have the main aim of 
searching for and developing novel classes of compound that are both potent and rapid acting. 
The second opportunity would be to look at changing the nature of the luciferase expression 
cassette. Currently the mBRRoK assay utilizes two genetically modified parasite lines that 
express peak luciferase signal at the trophozoite stage. The performance of mBRRoK assay 
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against other erythrocytic stages (rings and schizont) could be explore by replacing the current 
Pfcna luciferase cassette with one that could constitutively express reporter gene at other stages. 
Data on genes that are constitutively expressed are readily available from studies of 
developmental gene expression and are reported through the PlasmoDB site. As an alternative 
strategy, work is ongoing in the generation of a transgenic parasite that will express reporter 
gene at the ring stage. Regulatory sequences flanking the gene expressing the knob associated 
histidine rich protein (kahrp) (Lanzer et al., 1992) could replace the luciferase expressing 
cassette in the existing base plasmid (MH1 in Figure 6.6). 
 
Figure 6.6: Subcloning strategy for generating Nanoluc-PEST transgenic parasites 
Three sections of the existing plasmid will be replaced: Green fluorescent protein (GFP) 
reporter will be replaced with nanoluc-PEST, CAM5´UTR and Hsp86 3´UTR will be replaced 
with kahrp 5´ and 3´UTR respectively. The restriction sites are indicated with restriction 
enzymes: ApaI, AvrII, XhoI, PstI. Drugs selection (dhfr and AmpR),rep20, DNA repeat 
sequence, AmpR, Ampicillin. 
This approach also envisages reducing the size of the reporter plasmid through the use of a 
nanoluc-PEST transgene – a highly unstable version of the bioluminescence reporter, with work 
done in Leishmania mexicana showing a ½ life measure of some 8 minutes (Berry et al., 2018). 
Comparison of mBRRoK data in rings and trophozoite stages would enable the triage process 
to select compounds that are likely to exert a cytocidal action over  the 48hr life cycle and effect 
a more effective and timely reduction in parasitaemia irrespective of when the treatment is 
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initiated. Clearly, taking the opportunity to develop stage-specific mBRRoK assay to explore 
antimalarial activities of drugs or compounds in artemisinin-resistant (ARTR) and artemisinin-
sensitive (ARTS) strains of P. falciparum offers the opportunity to focus on work with smaller 
compound libraries (e.g. the 975 compounds that have already been highlighted in the screening 
of the TCMAS library) or for libraries of 300-500 compounds synthesised around lead series 
of interest.  
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Appendix 1(Chapter 3) 
This table reports full dataset of the MMV Malaria Box compounds with the predicted mode of action and core scaffolds 
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Appendix 2 (Chapter 3) 
This table reports full mBRRoK screening data of 66 MMV Malaria Box compounds against 
Dd2luc and NF54luc parasite lines (data reported in chapter 3). The compounds are categorised 
as red-initial RoK > CQ in Dd2luc and NF54luc, blue-initial RoK>CQ in only Dd2luc, amber-
initial RoK>CQ NF54luc only, green-initial RoK <CQ in Dd2luc and NF54luc. 
MMV ID 
10µM 
(Dd2luc) 
         2µM  
       (Dd2luc) 
10µM 
(NF54luc) 
2µM 
 (NF54luc) 
MMV306025 8.0 21.0 7 25 
MMV666102 0.0 8.0 4 14 
MMV666021 1.5 7.0 2 10 
MMV396736 15.0 21.0 7 20 
MMV019555 1.5 2.5 6 6 
MMV008455 1.5 17.0 11 24 
MMV006764 5.0 7.0 15 16 
MMV007113 6.0 7.0 14 14 
MMV007224 10.0 13.0 9 25 
MMV007181 19.0 21.0 14 15 
MMV000443 21.0 25.0 15 24 
MMV007275 6.0 8.0 16 17 
MMV396794 16.0 17.0 11 25 
MMV666124 7.0 19.0 11 17 
MMV666116 7.0 25.0 11 24 
MMV019017 19.0 25.0 5 25 
MMV665794 8.0 12.0 10 23 
MMV000442 14.0 18.0 15 15 
MMV019406 18.0 19.0 9 9 
MMV006787 8.5 11.0 9 23 
MMV000848 8.0 22.0 8 23 
MMV006172 10.0 25.0 4 25 
MMV000483 3.0 16.0 9 24 
MMV665949 8.0 25.0 12 20 
MMV009015 11.5 17.0 14 25 
MMV666061 18.0 19.0 10 16 
MMV000839 15.0 20.0 18 65 
MMV000481 12.0 25.0 17 68 
MMV665807 13.0 23.0 19 90 
MMV001049 12.0 16.0 17 41 
MMV396669 5.5 10.0 17 40 
MMV000634 20.0 51.0 8 24 
MMV011795 32.0 48.0 10 25 
MMV665806 18.0 32.0 8 19 
MMV019127 21.0 22.0 11 16 
MMV665890 38.0 58.0 13 20 
MMV007092 22.0 67.5 33 81 
MMV000648 11.0 34.0 18 104 
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MMV009108 37.0 40.0 23 26 
MMV006706 17.0 48.0 33 44 
MMV666604 19.0 68.0 36 104 
MMV007591 28.0 48.0 43 87 
MMV020505 20.0 32.0 44 47 
MMV000704 41.0 56.0 63 78 
MMV006861 62.0 95.0 57 93 
MMV665906 6.0 31.0 13 36 
MMV019780 41.0 55.0 37 45 
MMV020912 26.0 31.0 12 32 
MMV665786 30.0 47.0 34 51 
MMV665882 46.0 66.0 81 101 
MMV665944 25.0 40.0 13 36 
MMV128432 38.0 51.0 48 93 
MMV665864 37.0 60.0 92 109 
MMV019995 32.0 42.0 47 51 
MMV011436 54.0 76.0 97 103 
MMV007654 51.0 67.0 104 103 
MMV666071 16.0 48.0 73 88 
MMV396663 64.0 68.0 97 104 
MMV011259 102.0 112.0 95 100 
MMV666023 64.0 87.0 65 101 
MMV000445 22.0 32.0 98 103 
MMV666079 68.0 82.0 88 104 
MMV666693 103.0 103.0 98 102 
MMV665953 27.0 49.0 13 62 
MMV666025 10.0 45.0 17 47 
MMV665809 17.0 58.0 16 70 
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Appendix 3 (Chapter 4) 
This table reports full mBRRoK screening data for the 400 MMV Pathogen Box compounds 
(data reported in chapter 4). The data indicate the normalized bioluminescence signal against 
the untreated control when the parasites were exposed to 10µM and 2µM concentrations of the 
test compounds. 
Compound ID Disease Set 10µM 2µM 
MMV688854 CRYPTOSPORIDIOSIS 29 83 
MMV689255 CRYPTOSPORIDIOSIS 67 83 
MMV688853 CRYPTOSPORIDIOSIS 74 84 
MMV675994 CRYPTOSPORIDIOSIS 105 108 
MMV676053 CRYPTOSPORIDIOSIS 95 102 
MMV676191 CRYPTOSPORIDIOSIS 101 103 
MMV675993 CRYPTOSPORIDIOSIS 87 90 
MMV676050 CRYPTOSPORIDIOSIS 75 97 
MMV676182 CRYPTOSPORIDIOSIS 84 103 
MMV675968 CRYPTOSPORIDIOSIS 41 92 
MMV676599 CRYPTOSPORIDIOSIS 84 102 
MMV688416 DENGUE 102 106 
MMV688350 DENGUE 93 96 
MMV688921 DENGUE 98 102 
MMV688352 DENGUE 73 96 
MMV688543 DENGUE 99 102 
MMV003270  HOOKWORM 79 100 
MMV688796 KINETOPLASTIDS 101 103 
MMV688776 KINETOPLASTIDS 103 104 
MMV688934 KINETOPLASTIDS 100 104 
MMV690028 KINETOPLASTIDS 100 104 
MMV688943 KINETOPLASTIDS 81 99 
MMV687762 KINETOPLASTIDS 105 99 
MMV688793 KINETOPLASTIDS 106 102 
MMV688942 KINETOPLASTIDS 104 97 
MMV688514 KINETOPLASTIDS 109 109 
MMV688797 KINETOPLASTIDS 98 102 
MMV202553 KINETOPLASTIDS 102 105 
MMV188296 KINETOPLASTIDS 99 101 
MMV688958 KINETOPLASTIDS 99 100 
MMV688360 KINETOPLASTIDS 103 104 
MMV099637 KINETOPLASTIDS 100 102 
MMV688798 KINETOPLASTIDS 95 95 
MMV652003 KINETOPLASTIDS 44 78 
MMV676604 KINETOPLASTIDS 78 105 
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MMV690027 KINETOPLASTIDS 75 101 
MMV676600 KINETOPLASTIDS 67 97 
MMV676602 KINETOPLASTIDS 30 69 
MMV675997 KINETOPLASTIDS 45 66 
MMV595321 KINETOPLASTIDS 94 103 
MMV688547 KINETOPLASTIDS 34 49 
MMV689060 KINETOPLASTIDS 96 103 
MMV689061 KINETOPLASTIDS 101 103 
MMV689028 KINETOPLASTIDS 80 102 
MMV688371 KINETOPLASTIDS 10 72 
MMV688283 KINETOPLASTIDS 47 84 
MMV688361 KINETOPLASTIDS 33 90 
MMV689029 KINETOPLASTIDS 87 106 
MMV688410 KINETOPLASTIDS 31 48 
MMV676048 KINETOPLASTIDS 79 100 
MMV690103 KINETOPLASTIDS 95 102 
MMV676057 KINETOPLASTIDS 62 97 
MMV690102 KINETOPLASTIDS 47 99 
MMV689709 KINETOPLASTIDS 95 101 
MMV688179 KINETOPLASTIDS 33 96 
MMV689437 KINETOPLASTIDS 91 102 
MMV688362 KINETOPLASTIDS 17 51 
MMV687706 KINETOPLASTIDS 66 102 
MMV045105 KINETOPLASTIDS 99 113 
MMV688180 KINETOPLASTIDS 31 93 
MMV676162 KINETOPLASTIDS 99 111 
MMV688467 KINETOPLASTIDS 87 102 
MMV675998 KINETOPLASTIDS 93 101 
MMV659010 KINETOPLASTIDS 98 104 
MMV676008 KINETOPLASTIDS 96 103 
MMV688274 KINETOPLASTIDS 55 91 
MMV688407 KINETOPLASTIDS 20 57 
MMV659004 KINETOPLASTIDS 90 100 
MMV688279 KINETOPLASTIDS 22 23 
MMV688271 KINETOPLASTIDS 30 72 
MMV676186 KINETOPLASTIDS 99 99 
MMV688474 KINETOPLASTIDS 41 81 
MMV688372 KINETOPLASTIDS 76 95 
MMV658993 KINETOPLASTIDS 87 99 
MMV676159 KINETOPLASTIDS 96 103 
MMV004168 KINETOPLASTIDS 59 75 
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MMV676161 KINETOPLASTIDS 94 101 
MMV688795 KINETOPLASTIDS 97 98 
MMV689244 KINETOPLASTIDS 95 98 
MMV689243 KINETOPLASTIDS 73 96 
MMV688754 KINETOPLASTIDS 94 99 
MMV001561 KINETOPLASTIDS 63 74 
MMV658988 KINETOPLASTIDS 81 102 
MMV688415 KINETOPLASTIDS 45 102 
MMV688273 KINETOPLASTIDS 77 98 
MMV1236379 KINETOPLASTIDS 90 104 
MMV688550 KINETOPLASTIDS 55 84 
MMV687776 LYMPHATIC FILARIASIS 77 107 
MMV687775 LYMPHATIC FILARIASIS 67 93 
MMV676492 LYMPHATIC FILARIASIS 104 116 
MMV010764 MALARIA 105 105 
MMV000907 MALARIA 45 84 
MMV084603 MALARIA 35 46 
MMV1028806 MALARIA 101 99 
MMV676350 MALARIA 74 96 
MMV026020 MALARIA 95 102 
MMV006372 MALARIA 57 58 
MMV011903 MALARIA 70 74 
MMV020591 MALARIA 88 97 
MMV020623 MALARIA 4 8 
MMV020512 MALARIA 10 43 
MMV020982 MALARIA 43 82 
MMV020120 MALARIA 68 88 
MMV676605 MALARIA 40 84 
MMV007638 MALARIA 28 46 
MMV021057 MALARIA 85 92 
MMV020136 MALARIA 4 5 
MMV020710 MALARIA 2 3 
MMV020517 MALARIA 70 100 
MMV019721 MALARIA 13 15 
MMV020537 MALARIA 68 91 
MMV019838 MALARIA 37 78 
MMV020520 MALARIA 3 4 
MMV019234 MALARIA 74 96 
MMV016136 MALARIA 12 21 
MMV676442 MALARIA 16 18 
MMV020152 MALARIA 23 77 
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MMV024397 MALARIA 78 87 
MMV019807 MALARIA 92 121 
MMV560185 MALARIA 95 105 
MMV019189 MALARIA 68 91 
MMV020321 MALARIA 76 104 
MMV019087 MALARIA 97 100 
MMV676528 MALARIA 64 77 
MMV020320 MALARIA 84 101 
MMV085210 MALARIA 5 39 
MMV006239 MALARIA 3 6 
MMV000858 MALARIA 3 6 
MMV006741  MALARIA 59 83 
MMV019742 MALARIA 94 116 
MMV009054 MALARIA 104 108 
MMV006901 MALARIA 22 73 
MMV020391 MALARIA 3 5 
MMV676380 MALARIA 0 4 
MMV008439 MALARIA 63 79 
MMV020388 MALARIA 94 105 
MMV022236 MALARIA 79 95 
MMV1030799 MALARIA 95 101 
MMV021375 MALARIA 83 102 
MMV1029203 MALARIA 98 101 
MMV062221 MALARIA 91 102 
MMV1088520 MALARIA 90 115 
MMV023370 MALARIA 102 108 
MMV1019989 MALARIA 97 99 
MMV1037162 MALARIA 99 101 
MMV026468 MALARIA 88 95 
MMV020670 MALARIA 34 77 
MMV023953 MALARIA 27 70 
MMV010576 MALARIA 23 27 
MMV032967 MALARIA 52 92 
MMV031011 MALARIA 22 67 
MMV026356 MALARIA 33 34 
MMV011511 MALARIA 42 77 
MMV007625 MALARIA 50 69 
MMV007471 MALARIA 77 86 
MMV024829 MALARIA 29 90 
MMV022029 MALARIA 5 22 
MMV024035 MALARIA 9 50 
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MMV020291 MALARIA 82 103 
MMV006833 MALARIA 41 51 
MMV026490 MALARIA 65 101 
MMV687246 MALARIA 17 88 
MMV024114 MALARIA 73 99 
MMV676269 MALARIA 62 101 
MMV020081 MALARIA 5 6 
MMV026550 MALARIA 71 87 
MMV023860 MALARIA 24 94 
MMV023949 MALARIA 94 99 
MMV024406 MALARIA 24 54 
MMV023233 MALARIA 22 27 
MMV085230 MALARIA 83 122 
MMV085071 MALARIA 7 7 
MMV676260 MALARIA 41 69 
MMV032995 MALARIA 87 100 
MMV019790 MALARIA 98 101 
MMV009135 MALARIA 92 100 
MMV011765 MALARIA 89 102 
MMV024937 MALARIA 39 77 
MMV085499 MALARIA 29 31 
MMV023985 MALARIA 32 102 
MMV024195 MALARIA 35 83 
MMV007803 MALARIA 109 118 
MMV001059 MALARIA 6 9 
MMV011691 MALARIA 47 66 
MMV676877 MALARIA 36 57 
MMV663250 MALARIA 16 28 
MMV007133 MALARIA 107 114 
MMV022478 MALARIA 2 30 
MMV024101 MALARIA 16 36 
MMV676881 MALARIA 87 104 
MMV024443 MALARIA 31 61 
MMV023388 MALARIA 30 69 
MMV688980 MALARIA 3 8 
MMV011229 MALARIA 103 112 
MMV393144 MALARIA 29 54 
MMV007920  MALARIA 68 89 
MMV019993 MALARIA 3 7 
MMV687794 MALARIA 101 103 
MMV023183 MALARIA 24 36 
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MMV020165 MALARIA 12 48 
MMV667494 MALARIA 3 5 
MMV028694 MALARIA 20 32 
MMV010545 MALARIA 27 96 
MMV023227 MALARIA 73 97 
MMV020289 MALARIA 98 110 
MMV634140 MALARIA 7 7 
MMV030734 MALARIA 68 96 
MMV676358 MALARIA 75 99 
MMV407834 MALARIA 6 30 
MMV019551 MALARIA 91 97 
MMV016838 MALARIA 85 89 
MMV676270 MALARIA 83 108 
MMV026313 MALARIA 91 92 
MMV392832 MALARIA 54 86 
MMV084864 MALARIA 75 101 
MMV676480 ONCHOCERCIASIS 72 102 
MMV001493 ONCHOCERCIASIS 75 104 
MMV002817 ONCHOCERCIASIS 87 100 
MMV668727 ONCHOCERCIASIS 38 105 
MMV676204 ONCHOCERCIASIS 100 110 
MMV675969 ONCHOCERCIASIS 108 114 
MMV676064 ONCHOCERCIASIS 100 111 
MMV675995 ONCHOCERCIASIS 100 100 
MMV676063 ONCHOCERCIASIS 50 92 
MMV675996 ONCHOCERCIASIS 87 96 
MMV671636 ONCHOCERCIASIS 88 100 
MMV689758 REFERENCE COMPOUNDS 86 100 
MMV000062 REFERENCE COMPOUNDS 11 13 
MMV002529 REFERENCE COMPOUNDS 90 104 
MMV687800 REFERENCE COMPOUNDS 38 89 
MMV001625 REFERENCE COMPOUNDS 97 109 
MMV637953 REFERENCE COMPOUNDS 82 87 
MMV000063 REFERENCE COMPOUNDS 48 63 
MMV688773 REFERENCE COMPOUNDS 85 96 
MMV000011 REFERENCE COMPOUNDS 84 104 
MMV688774 REFERENCE COMPOUNDS 16 61 
MMV688991 REFERENCE COMPOUNDS 40 84 
MMV687801 REFERENCE COMPOUNDS 105 103 
MMV689480 REFERENCE COMPOUNDS 68 103 
MMV003152 REFERENCE COMPOUNDS 118 113 
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MMV000023 REFERENCE COMPOUNDS 52 72 
MMV000014 REFERENCE COMPOUNDS 20 24 
MMV687803 REFERENCE COMPOUNDS 72 105 
MMV688994 REFERENCE COMPOUNDS 101 108 
MMV687798 REFERENCE COMPOUNDS 76 103 
MMV688775 REFERENCE COMPOUNDS 33 43 
MMV689000 REFERENCE COMPOUNDS 34 98 
MMV001499 REFERENCE COMPOUNDS 25 28 
MMV002816 REFERENCE COMPOUNDS 100 101 
MMV687796 REFERENCE COMPOUNDS 106 113 
MMV688978 REFERENCE COMPOUNDS 5 73 
MMV688990 REFERENCE COMPOUNDS 99 110 
MMV688761 SCHISTOSOMIASIS 63 104 
MMV676382 SCHISTOSOMIASIS 70 110 
MMV688763 SCHISTOSOMIASIS 46 102 
MMV676536 SCHISTOSOMIASIS 90 100 
MMV688762 SCHISTOSOMIASIS 43 77 
MMV688768 SCHISTOSOMIASIS 98 108 
MMV688313 SCHISTOSOMIASIS 114 118 
MMV1198433 SCHISTOSOMIASIS 89 105 
MMV688178 SCHISTOSOMIASIS 98 105 
MMV688771 SCHISTOSOMIASIS 104 109 
MMV688270 SCHISTOSOMIASIS 101 104 
MMV688766 SCHISTOSOMIASIS 25 34 
MMV688552 SCHISTOSOMIASIS 35 101 
MMV688472 TOXOPLASMOSIS 101 104 
MMV688548 TOXOPLASMOSIS 95 93 
MMV688471 TOXOPLASMOSIS 104 106 
MMV688470 TOXOPLASMOSIS 98 102 
MMV688704 TOXOPLASMOSIS 98 103 
MMV688852 TOXOPLASMOSIS 67 83 
MMV688509 TOXOPLASMOSIS 45 93 
MMV688417 TOXOPLASMOSIS 90 100 
MMV688703 TOXOPLASMOSIS 98 106 
MMV688955 TOXOPLASMOSIS 108 108 
MMV688364 TOXOPLASMOSIS 45 87 
MMV688469 TOXOPLASMOSIS 96 102 
MMV688411 TOXOPLASMOSIS 98 100 
MMV688345 TOXOPLASMOSIS 98 109 
MMV688330 TOXOPLASMOSIS 103 107 
MMV637229 TRICHURIASIS 31 31 
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MMV676526 TUBERCULOSIS 78 112 
MMV688553 TUBERCULOSIS 94 99 
MMV676501 TUBERCULOSIS 90 100 
MMV676449 TUBERCULOSIS 99 102 
MMV676412 TUBERCULOSIS 104 103 
MMV688889 TUBERCULOSIS 98 99 
MMV676389 TUBERCULOSIS 97 102 
MMV676603 TUBERCULOSIS 100 101 
MMV676401 TUBERCULOSIS 61 91 
MMV102872 TUBERCULOSIS 96 98 
MMV676477 TUBERCULOSIS 100 101 
MMV688888 TUBERCULOSIS 90 101 
MMV053220 TUBERCULOSIS 99 103 
MMV676584 TUBERCULOSIS 111 104 
MMV676439 TUBERCULOSIS 102 101 
MMV676395 TUBERCULOSIS 103 103 
MMV676379 TUBERCULOSIS 104 98 
MMV661713 TUBERCULOSIS 61 103 
MMV688554 TUBERCULOSIS 80 103 
MMV676555 TUBERCULOSIS 78 100 
MMV676383 TUBERCULOSIS 68 100 
MMV676444 TUBERCULOSIS 101 102 
MMV676409 TUBERCULOSIS 106 107 
MMV553002 TUBERCULOSIS 104 106 
MMV688756 TUBERCULOSIS 100 102 
MMV090930 TUBERCULOSIS 105 103 
MMV676431 TUBERCULOSIS 100 98 
MMV676571 TUBERCULOSIS 92 97 
MMV676445 TUBERCULOSIS 89 101 
MMV676589 TUBERCULOSIS 99 102 
MMV676388 TUBERCULOSIS 69 94 
MMV688936 TUBERCULOSIS 63 101 
MMV676476 TUBERCULOSIS 100 107 
MMV676377 TUBERCULOSIS 102 105 
MMV676406 TUBERCULOSIS 97 101 
MMV676461 TUBERCULOSIS 98 105 
MMV676509 TUBERCULOSIS 97 101 
MMV063404 TUBERCULOSIS 100 103 
MMV676558 TUBERCULOSIS 101 102 
MMV688555 TUBERCULOSIS 96 101 
MMV676597 TUBERCULOSIS 91 96 
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MMV676588 TUBERCULOSIS 93 98 
MMV676554 TUBERCULOSIS 99 100 
MMV676539 TUBERCULOSIS 96 101 
MMV202458 TUBERCULOSIS 97 100 
MMV676474 TUBERCULOSIS 99 100 
MMV461553 TUBERCULOSIS 98 100 
MMV676520 TUBERCULOSIS 100 109 
MMV676512 TUBERCULOSIS 99 102 
MMV012074 TUBERCULOSIS 112 104 
MMV676386 TUBERCULOSIS 89 98 
MMV069458 TUBERCULOSIS 82 83 
MMV687239 TUBERCULOSIS 96 108 
MMV688122 TUBERCULOSIS 86 102 
MMV687145 TUBERCULOSIS 104 106 
MMV688327 TUBERCULOSIS 98 102 
MMV687747 TUBERCULOSIS 93 103 
MMV688466 TUBERCULOSIS 80 95 
MMV687749 TUBERCULOSIS 25 46 
MMV688846 TUBERCULOSIS 37 86 
MMV054312 TUBERCULOSIS 101 109 
MMV688508 TUBERCULOSIS 104 108 
MMV687243 TUBERCULOSIS 100 114 
MMV687730 TUBERCULOSIS 87 104 
MMV687251 TUBERCULOSIS 100 107 
MMV687254 TUBERCULOSIS 102 103 
MMV687703 TUBERCULOSIS 31 65 
MMV687248 TUBERCULOSIS 45 79 
MMV688125 TUBERCULOSIS 46 64 
MMV687188 TUBERCULOSIS 96 103 
MMV688124 TUBERCULOSIS 39 65 
MMV688845 TUBERCULOSIS 75 96 
MMV687699 TUBERCULOSIS 99 105 
MMV687146 TUBERCULOSIS 98 102 
MMV687696 TUBERCULOSIS 93 101 
MMV687170 TUBERCULOSIS 98 103 
MMV023969  TUBERCULOSIS 21 59 
MMV687138 TUBERCULOSIS 97 106 
MMV688262 TUBERCULOSIS 72 103 
MMV687189 TUBERCULOSIS 103 107 
MMV687807 TUBERCULOSIS 93 106 
MMV676478 TUBERCULOSIS 99 103 
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MMV021660 TUBERCULOSIS 85 91 
MMV687273 TUBERCULOSIS 95 100 
MMV687180 TUBERCULOSIS 95 108 
MMV688891 TUBERCULOSIS 108 104 
MMV687172 TUBERCULOSIS 113 114 
MMV688844 TUBERCULOSIS 101 108 
MMV024311 TUBERCULOSIS 94 101 
MMV688941 TUBERCULOSIS 59 88 
MMV687812 TUBERCULOSIS 3 27 
MMV676411 TUBERCULOSIS 89 101 
MMV676468 TUBERCULOSIS 108 107 
MMV676470 TUBERCULOSIS 96 100 
MMV688938 TUBERCULOSIS 40 59 
MMV047015 TUBERCULOSIS 88 98 
MMV676472 TUBERCULOSIS 74 94 
MMV687765 TUBERCULOSIS 22 54 
MMV676524 TUBERCULOSIS 108 107 
MMV611037 TUBERCULOSIS 112 115 
MMV200748 TUBERCULOSIS 100 103 
MMV687700 TUBERCULOSIS 65 97 
MMV676384 TUBERCULOSIS 112 111 
MMV687729 TUBERCULOSIS 97 99 
MMV687813 TUBERCULOSIS 66 98 
MMV153413 TUBERCULOSIS 93 100 
MMV688755 TUBERCULOSIS 104 104 
MMV228911 TUBERCULOSIS 94 102 
MMV272144 TUBERCULOSIS 33 92 
MMV161996 TUBERCULOSIS 90 104 
MMV146306 TUBERCULOSIS 102 94 
MMV688557 TUBERCULOSIS 87 99 
MMV021013 TUBERCULOSIS 79 86 
MMV688939 TUBERCULOSIS 92 103 
MMV393995 TUBERCULOSIS 100 111 
MMV495543 TUBERCULOSIS 39 90 
MMV1110498 WOLBACHIA LF 100 101 
MMV407539 WOLBACHIA LF 87 106 
MMV676398 WOLBACHIA LF 96 99 
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Appendix 4(Chapter 4) 
This table reports the predicted mode of action and core scaffolds for Malaria compounds in the MMV Pathogen Box 
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Appendix 5(Chapter 5) 
This table reports the mBRRoK screening data of 12,514 TCAMS library compounds 
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Appendix 6: Chapter 5 
This table reports the predicted antimalarial mode of action for 195 compounds of TCAMS library 
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Appendix 7: Chapter 6 
Table A reports the EC50 and PC1 values of selected TCAMS library compounds against the 
Dd2luc and NF54luc , while table B reports the EC50 and PC1 values of selected MMV 
Pathogen Box compounds against Dd2luc. 
(A)   
 
 
Compound name 
EC50  
(nM) 
(PC1) 
Dd2luc 
(PC1) 
NF54luc 
TCMDC-125071 912.2 -105.5 -105.5 
TCMDC-123773 818.7 17.3 7.5 
TCMDC-140154 967.2 -85.3 -47.4 
TCMDC-136189 650.9 -121.2 -116.5 
TCMDC-124113 712.2 -50.6 -87.0 
TCMDC-124047 115.4 7.9 -32.2 
TCMDC-125254 972.0 -26.8 -6.1 
TCMDC-139900 387.2 -31.5 15.5 
TCMDC-135423 125.1 -14.9 -13.5 
TCMDC-138614 295.8 18.2 25.1 
TCMDC-137603 497.0 -87.4 -90.3 
TCMDC-124491 874.4 -81.4 -67.9 
TCMDC-142036 698.4 -8.0 -4.6 
TCMDC-138358 628.5 -49.8 -52.1 
TCMDC-133478 360.3 -103.8 -91.8 
TCMDC-123564 843.6 -76.9 -55.6 
TCMDC-125253 899.0 -95.5 -78.4 
TCMDC-131242 1176.8 -83.4 -82.2 
TCMDC-140040 776.9 -0.6 38.1 
TCMDC-125016 970.7 -105.1 -92.5 
TCMDC-136607 776.7 -95.8 -88.7 
TCMDC-136239 445.6 -2.6 -19.9 
TCMDC-125397 747.0 -63.5 -51.4 
TCMDC-135135 1434.8 -5.3 25.8 
TCMDC-124168 991.0 -69.8 -89.8 
TCMDC-133687 1110.4 31.7 18.5 
TCMDC-125139 701.2 -95.2 -112.3 
TCMDC-136088 763.3 -106.6 -121.4 
TCMDC-135773 80.6 4.4 49.0 
TCMDC-140871 550.1 -54.1 -93.2 
TCMDC-125321 689.0 -10.3 -65.4 
TCMDC-124887 521.4 -57.4 -96.1 
TCMDC-124579 279.4 48.4 -27.5 
TCMDC-141043 247.7 -7.2 -14.8 
TCMDC-125424 878.2 -105.3 -119.8 
TCMDC-125361 843.1 -92.8 -110.2 
TCMDC-131436 804.3 -83.6 -108.7 
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TCMDC-140815 836.0 -41.4 -105.1 
TCMDC-124252 892.8 -72.1 -104.7 
TCMDC-140157 559.4 -53.8 -70.8 
TCMDC-136792 872.6 -67.6 -92.5 
TCMDC-125055 831.4 -18.4 -54.1 
TCMDC-138973 993.0 9.5 -91.1 
TCMDC-124036 530.3 -21.8 -19.8 
TCMDC-132515 757.9 4.8 16.0 
TCMDC-142268 26.3 -38.7 -83.1 
TCMDC-140755 969.2 -2.9 -23.6 
TCMDC-140417 975.5 10.7 5.1 
TCMDC-136878 182.1 47.8 49.0 
TCMDC-135804 37.6 45.9 46.2 
TCMDC-135800 810.0 23.3 33.2 
TCMDC-137323 59.1 3.2 -6.5 
TCMDC-135335 1038.8 -17.6 -20.9 
TCMDC-135747 772.6 8.1 13.1 
TCMDC-136795 122.0 39.3 -16.7 
TCMDC-124760 46.4 -121.0 -115.8 
TCMDC-142193 676.2 19.3 -41.2 
TCMDC-136043 570.9 24.4 -36.8 
 
(B) 
  
 
Compound name 
EC50  
(nM) 
(PC1) 
Dd2luc  
MMV020391 833.7 -64.3 
MMV000858 511.3 -59.5 
MMV020136 711.7 -42.1 
MMV022029 622.5 -56.3 
MMV020081 48.3 -40.7 
MMV001059 672.3 -76.4 
MMV006239 569.3 -66.2 
MMV023183 620.9 -18.8 
MMV637229 561.2 -8.6 
MMV634140 184.0 -79.1 
MMV021057 19.9 16.7 
MMV659004 321.8 39.5 
MMV020537 1980.0 51.8 
MMV024397 843.5 52.1 
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